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Chapter 1
General introduction
Marjolein Meijerink
Part of the introduction is from the review: Epithelial crosstalk at the microbiota-
mucosal interface. Wells JM, Rossi O, Meijerink M, van Baarlen P. Proc Natl Acad 
Sci U S A. 2011 Mar 15;108 Suppl 1:4607-14. Epub 2010 Sep 8 
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1 The gastro-intestinal tract
The largest and most complex immune organ in the body is the gastro-intestinal (GI) 
tract. Its vast surface area can be divided into three major components: the intestinal 
microbiota, the mucosal barrier and the gut-associated lymphoid tissue (GALT). The mi-
crobiota varies considerably in composition and in numbers along the human GI tract. 
Bacterial numbers are the lowest (<103 colony-forming units (CFU) per gram of content) 
in the stomach, because of the low pH and relatively fast transit time but increase to 
around 105 to 106 CFU per gram intestinal content in the terminal ileum. In the colon 
bacterial numbers reach up to 1010 to 1012 CFU per gram content in the colon. The up-
per part of the small intestine supports lower numbers of commensal bacteria due to 
pancreatic enzymes, bile and motility patterns that hamper colonization, while in the 
colon the number of bacteria can be high due to a slower transit time, favorable pH, 
substrate availability and oxygen levels [1]. More than 500 species of predominantly 
anaerobic bacteria are estimated to comprise the human intestinal microbiota and in 
total these outnumber host cells by approximate a factor of ten [2, 3]. The intestinal 
microbes compete with each other for nutrients and adhesion sites and are thus impor-
tant in colonization resistance to pathogens as well as via competition and the produc-
tion of bacteriocins or other inhibitory molecules [4-6]. 
The mucosal barrier consists of physical and chemical components, including epithelial 
cells (ECs) and the mucus layer. The mucus layer is important in limiting bacterial trans-
location (alive and dead) and passage of harmful substances from the gut lumen into 
the body. Host chemical defensins include gastric and pancreatic juices as well as decon-
jugated bile salt and antimicrobial enzymes, peptides and polypeptides (e.g. lysozyme, 
defensins and Reg proteins) that are secreted by Paneth cells and/or enterocytes. 
The GALT comprises all the elements relating to the immune system in the GI tract, 
including organized lymphoid aggregates such as the Peyer’s patches (PP), isolated lym-
phoid follicles (ILFs) containing lymphocytes, dendritic cells (DCs) and macrophages. 
Secretory IgA produced by plasma B cells in the lamina propria (LP) and transported 
across the epithelium into the lumen serves as an important factor to exclude antigens, 
neutralize pathogens or neutralize microbial toxins and viruses [7]. The follicular associ-
ated epithelium (FAE) contains specialized microfold cells (M cells) that transport spe-
cial or particulate antigens to the underlying immune cells to induce mucosal immune 
responses. T and B cell responses induced at one location in the GALT can are dissemi-
nated to other locations in the mucosa via the expression of specific homing integrins 
on mucosal lymphocytes and the circulation via the lymphatics and bloodstream. This 
concept known as the common immune system serves to dissipate protective immune 
responses over our vulnerable mucosal surfaces although recent studies indicate selec-
tivity in the homing of lymphocytes depending on the sites of induction [8]. 
The gut is part of the main route of contact with the external environment and encoun-
ters thousands of different foreign molecules every day. Therefore the mucosal immune 
system is constantly challenged with external stimuli, such as pathogens (bacteria, vi-
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ruses, fungi, protozoa) or toxic substances, as well as harmless food or commensal/ pro-
biotic antigens. The GALT is capable to avoid potentially harmful adverse responses to 
food and commensal microbiota while still retaining a capacity to mount inflammatory 
responses towards invading and harmful pathogens. The typical response to harmless 
antigens that appear in the gut is the induction of local and systemic immunological 
tolerance, known as oral tolerance. Oral tolerance is an effective way to induce periph-
eral tolerance to antigens. Most dietary antigens are degraded, but some can reach 
the small intestine in a partially degraded or even intact form. After absorption these 
molecules are transported into the blood stream and distributed systemically and are 
able to induce tolerance. The underlying mechanism is still not completely resolved 
and suggested to rest on repeated low dose induction of regulatory T-cell populations 
that secrete immunosuppressive cytokines, anergy induction in antigen-specific T-cells 
by presenting the antigens on cells lacking co-stimulatory capacity, and/ or lack of the 
presence of danger signals that stimulate DCs. Dysfunctional regulation of tolerance 
to harmless antigens may be involved in the development of food allergy. The epithe-
lium has developed mechanisms to control bacterial growth, limit direct contact with 
the bacteria, and prevent bacterial dissemination into underlying tissue, to protect the 
body from uncontrolled inflammatory responses. In susceptible individuals a dysfunc-
tional barrier can lead to loss of immune tolerance to the microbiota and an inappropri-
ate inflammatory response, as is thought to occur in the inflammatory bowel diseases 
(IBD) ulcerative colitis and Crohn's disease [9]. 
Mucosal immunity 
Luminal antigens are recognized and taken up by bacterial sampling by DCs or by adhe-
sion to specialized M cells in the PP. In mice and humans, the intestinal DCs are located 
throughout intestinal LP and in the radial muscle layer [10]. They also accumulate in the 
lymphoid tissues of the mucosa, namely PP, ILFs, and mesenteric lymph node (MLNs) 
[11]. DCs are the most important professional antigen presenting cells and express up 
to 100 times more MHCII and are more effective at differentiating naïve T cells than 
other antigen presenting cells (APCs) [12, 13]. In the PP and ILF DCs are considered to be 
primarily responsible for T cell-dependent IgA responses [14]. In the LP, two major sub-
sets of DCs can be discriminated that perform different immune functions. These two 
populations can be discriminated by the differential expression of CD103 (also known 
as integrin aEb7) and the fractalkine receptor CX3CR1 giving rise to the CD103+ CX-
3CR1- and CD103- CX3CR1+ subsets. The LP, CD103+ expressing DCs have recently been 
shown to play a key role in regulating oral tolerance through the induction of regulatory 
Foxp3+ T cells expressing gut-homing receptors in the MLNs (Fig. 1) [15, 16]. 
A subset of LP CD103− cells which share phenotypic traits with both macrophages and 
DCs express the fractalkine receptor (CX3CR1) and bind to the membrane form of frac-
talkine on IEC [17, 18]. The ability of DCs to produce protrusions and sample antigens 
through the epithelium is reported to depend on CX3CR1 expression [19], although this 
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Fig. 1. Mucosal CD103+ dendritic cells (DCs) are conditioned in the peripheral tissues by epithelial 
production of thymic stromal lymphopoietin (TSLP) and transforming growth factor beta (TGF-β), 
which endows DCs with the ability to prime non-inflammatory responses and induce regulatory T 
cells. When they receive an inflammatory or danger signal, they begin to mature, and the expression 
of CCR7 increases, allowing the DCs to enter lymph vessels and migrate to the draining lymph nodes. 
In the T cell areas retinoic acid (RA), plays an important role in the ability of DCs to up-regulate homing 
receptors on lymphocytes. RA is also an important cofactor for the differentiation of Foxp3+ regulatory 
T cells (Treg) and has been shown to inhibit the generation of Th17 cells.
is somewhat controversial, and it is possible that other subsets of DCs can sample anti-
gens in this way [20]. Recently, the CD103− CX3CR1+ subset of LP DCs were shown to 
be derived from a different cell linage than the CD103+ population [21] and seem to 
13
Chapter 1
support
inflammatory immune responses [22, 23]. Taken together these findings suggest that 
the mucosal CD103+ DCs serve classical DC functions and promote T cell responses in 
the draining lymph nodes, whereas the CX3CR1+ DCs are retained in the LP to kill colo-
nizing and invading microorganisms. Several studies have implicated a role for ECs in 
endowing DCs with their ability to prime non-inflammatory responses and induce Tregs 
[15, 24, 25]. DCs that express CCR6, a chemokine receptor that binds the chemokine 
CCL20, are found only in the domes of the PP and acquire antigen solely by M-cell 
mediated transcytosis. The mucosa, in particular the intestinal villi, are inherently fra-
gile structures that can easily be injured by the products (tumor necrosis factor alpha 
(TNF-α) and interferon gamma (IFN-γ)) and actions of cells activated during inflamma-
tion. Potential invaders, including commensal bacteria in the lumen, which do not nor-
mally harm the host must be prevented from penetrating the epithelium, e.g. by the 
constant production of commensal-specific sIgA. The nature of the mucosal DC subsets 
that reside in the dome region of the PP may inherently skew by virtue of their high 
production of IL-10, the differentiation of the Th0 cells that they encounter towards 
regulatory Th3 and Tr1 cells producing transforming growth factor beta (TGF-β) and IL-
10 or Th2 effector cells that produce IL-4, IL-5 and IL-10. This way effective protection is 
provided without overt inflammation.
Conditioning of monocyte-derived DCs with IEC supernatants in vitro abolishes the 
ability of DCs to produce IL-12 and prime naïve T cells toward T helper (Th)1 polariza-
tion in response to microbial stimuli [25]. In contrast, EC-conditioned DCs produce high 
amounts of IL-10 and promote Treg and Th2 cell responses. In vitro the conditioning of 
DCs was shown to depend on epithelial production of thymic stromal lymphopoietin 
(TSLP) (Fig. 1) [25]. Another important immunoregulatory cytokine produced abun-
dantly by IEC and stromal cells in the intestine is TGF-β [24]. This cytokine inhibits NF-
κB dependent gene expression and the production of pro-inflammatory cytokines by 
macrophages and DCs [26, 27]. Additionally, TGF-β acts in concert with TSLP to induce a 
tolerogenic phenotype in monocyte-derived DCs in vitro [28]. DCs purified from the LP 
have also been shown to promote a high level of Tregs conversion relative to lymphoid 
organ derived DCs via a TGF-β and retinoic acid-dependent mechanism. Consistent with 
these findings is the fact that TSLP deletion in mice leads to constitutive overexpression 
of IL-12p40 by intestinal DCs and inability to generate protective regulatory and Th2 
responses against the nematode parasite Trichuris muris [29]. TSLP mRNA is constitu-
tively expressed by ECs and can be up-regulated by NF-κB-dependent pathways [30]. 
Thus, one may expect that recognition of microbiota by epithelial pattern recognition 
receptors (PRRs) would also regulate TSLP production. Support for this idea comes from 
in vitro IEC-DC co-culture studies where it was shown that composition of the micro-
biota exposed to the apical side of the IEC influenced production of TSLP and TGF-β 
and, hence, the function of the underlying DCs [28]. In an in vivo expression profiling 
study where healthy adult humans consumed preparations of viable lactic acid bacte-
ria, a central role was uncovered for the NF-κB signaling cascade in the regulation of 
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1 tolerance in the small intestine [31]. In this study, it was found that NF-κB signaling up-
regulated the expression of downstream effectors such as chemokines but also factors 
that regulate cell survival of B and T cells and DCs as well as regulators that suppress 
inappropriate immune responses. In addition to the epithelial cytokines influencing B 
cell and DCs functions mentioned above, the intestinal epithelium expresses a range 
of metabolic enzymes that can impact on immune cell function. Non-bone marrow-
derived stromal cells located predominantly in the villi of proximal small intestine have 
been shown to constitutively produce cyclooxygenase (COX)-2 and abundantly produce 
the COX-2-dependent arachidonic acid (AA) metabolite, prostaglandin E2 (PGE2) (79). 
Although the production of COX-2 and COX-2-dependent metabolites does not appear 
to be regulated by pro-inflammatory stimuli or the microbiota, its production in the 
epithelium could contribute to the default immunoregulatory tone of the LP [32].
The detection of pathogens by the host is achieved through the families of PRRs that 
recognize conserved molecular structures known as pathogen-associated molecular 
patterns (PAMPs) and induce production of innate effector molecules. Because these 
structures are also found on non-pathogenic microorganisms, the term microbe-as-
sociated molecular patterns (MAMPs) is increasingly used, particularly in the context 
of host–commensal interactions. These signaling receptors can be divided into three 
families: TLR, retinoic acid inducible gene I (RIG-I)-like receptors (RLRs), and nucleotide 
oligomerization domain (NOD)-like receptors (NLRs). The TLR family is the best char-
acterized, and 13 receptors have been reported in mice and humans. For TLR, it has 
been shown that ligand sensing and specificity is achieved through the arrangement 
and sequence variation in the conserved leucine-rich repeat (LRR) domains. TLR-2 can 
form heterodimers with TLR-1 or TLR-6 to detect different but related ligands (Table 1). 
TLR are localized in the cell membrane and/or endosomal membrane components to 
recognize extracellular and endocytosed MAMPs (Table 1). The ubiquitously expressed 
RIG-I-like receptor (RLR) family of RNA helicases are cytoplasmic proteins that recog-
nize viral RNAs and induce innate antiviral responses, including the activation of pro-
inflammatory cytokines and type I interferon (IFN) [33]. The third family, containing >20 
cytoplasmic NLR in humans and mice, is divided into four major groups based on the 
nature of the N-terminal activation domains involved in signal transduction. The NLR 
characterized to date recognize a wide range of bacterial ligands and toxins as well as 
certain damage-associated molecular patterns (DAMPs) of the host cell [34]. NLR pro-
teins can signal through different multicomponent signal complexes to activate alterna-
tive signaling pathways, including caspase activation, cell death, and NF-κB leading to 
cytokine, chemokine, and defensin expression. In the intestine, only the functions of 
NOD1 and NOD2 have been well characterized, and these NLR respond to the synthetic 
peptidoglycan components meso-diaminopimelic acid (DAP) and muramyl dipeptide 
(MDP), respectively (Table 1). 
Recently, several lectin and C-type lectin receptors (CLRs) have been characterized 
that are involved in the recognition and capture of antigens by antigen presenting cells 
(APCs). One such CLR known as DC-specific intracellular adhesion molecule-3 grabbing
15
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Table 1: The PRRs, subcellular localization, and recognized ligands
G (+), Gram-positive; G (−), Gram-negative; dsRNA, double-stranded RNA; ssRNA, single-stranded 
RNA; PGN, peptidoglycan; Meso-DAP, γ-D-glutamyl-meso-diaminopimelic acid; MDP, muramyl di-
peptide NOD1, nucleotide oligomerization domain-like receptor 1; NOD2 nucleotide oligomerization 
domain-like receptor 2. 
non-integrin (DC-SIGN) recognizes high-mannose-containing structures.
Probiotics and their modes of action
Over the last years there has been an increasing awareness of the role played by com-
mensal bacteria in modulating mucosal immune responses which has greatly increased 
interest in the therapeutic potential of probiotics for a range of immune disorders. 
16
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1 Probiotics are defined as living organisms that, when administered in sufficient num-
bers, are beneficial to the host [35] Current evidence indicates that probiotic strains 
mediate their effects by a variety of different mechanisms that are dependent on the 
dose as well as the route and frequency of delivery [36] (Fig. 2). 
Probiotics may act directly on the host or indirectly via modulation of the composition 
and/ or activity of the commensal microbiota, and/ or their stimulation of the immune 
system. By changing the conditions in the gut and improving colonization resistance, 
probiotics make the gut environment more favorable to the growth of genera gener-
ally considered as beneficial (e.g. lactobacilli and bifidobacteria) and less favorable for 
pathogens and other harmful microbes. Some probiotics act in the lumen of the gut by 
producing antibacterial molecules such as bacteriocins; others enhance the mucosal 
barrier by increasing the production of innate immune molecules, including goblet cell–
derived mucins and trefoil factors and defensins produced by intestinal Paneth cells. 
Probiotics may also mediate beneficial effects by promoting adaptive immune respons-
es (secretory IgA, Tregs, IL-10).
In animal models or human studies probiotics have been shown to prevent or treat dis-
orders such as IBD, irritable bowel syndrome, infectious diarrhea, and infection by Sal-
monella or Helicobacter pylori. Probiotics might also be useful in treating or preventing 
allergic diseases, which could be a good alternative to the pharmacological approach 
in patients who experience serious side effects or drug resistance. Currently, allergen-
specific immunotherapy is the only causal treatment of type I allergies (18) and involves 
frequent injections of gradually increasing amounts of an allergen to diminish type I 
sensitivity reactions to the allergen. There is an inherent risk of allergic reactions during 
treatment and the patients compliance is often poor due to the frequency and duration 
of the treatment. 
In addition, probiotics have shown promising results in enhancing immune responses to 
vaccination in young children and in adults. For example, probiotics have been shown 
to increase the antigen specific antibody titers of orally administered vaccines such as 
rotavirus [37], Salmonella [38], polio [39] and cholera [40]. 
 
Commonly used probiotic species of bacteria
Many probiotic strains are lactic acid bacteria (LAB) which are bacteria which produce 
lactic acid as their major fermentation product, and includes species of Lactobacillus, 
Streptococcus, Enterococcus, Lactococcus, Bifidobacterium and Leuconostoc. They are 
widely distributed in the intestinal tract. The largest genus in this order is Lactobacillus 
and are used in fermentation products such as pickle, sauerkraut, beet, wine, juices, 
cheese, yoghurt and sausage [41]. The dietary LAB are generally regarded as safe (GRAS 
status) owing to their long history of use or association with humans and food [42] and 
are therefore often selected as candidate probiotics. Lactobacillus plantarum WCFS1 
was the first Lactobacillus species for which the genome was completely sequenced 
17
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and published [43]. The genome is the largest known among LAB, namely 3.3 Mb, and 
is therefore a good candidate to act as a model organism for other lactobacilli. L. plan-
tarum is found in a variety of niches, including the human GI-tract and can promote 
health and some strains (e.g. 299v and R1012) have been marketed as probiotics. 
 
Fig. 2 Proposed mechanisms of probiotic action: within lumen, mucosal surface, and by stimulation of 
innate and adaptive immunity. The predominant mechanism varies among different probiotic strains 
(Adapted from Rossi et al. [7]).
Probiotics and peanut allergy 
In this thesis a model of sensitization to peanut extract was used to assess the potential 
of selected Lactobacillus strains to prevent allergy. Currently, the prevalence of peanut 
allergic sensitisation varies between 1-2% (US and Canada) to 10% in the UK, of whom 
2% have a clinical peanut allergy [44]. Peanut allergy accounts for the majority of severe 
food-related allergic reactions, and is often associated with anaphylaxis, which can have 
18
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1 a fatal outcome. Most childhood food allergies generally resolve spontaneously with 
age, but peanut allergy resolves in only 20% of cases, resulting in a life-long allergy with 
a high impact on quality of life [45, 46]. Over the past several decades the developed 
countries have seen a steady increase in the proportion of children that develop food 
allergies, but there are reports indicating that this trend has stabilized [47-50]. 
Sensitization and allergic reaction
Peanut allergy occurs in two phases: sensitization and allergic reaction. The develop-
ment of IgE-mediated allergy is always initiated with a sensitization phase to a certain 
allergen. Allergens are taken up by antigen presenting cells, such as DCs, after entering 
the body via the epithelial barrier of the skin, airway, or gut [51]. The allergens are pro-
cessed and the allergen-derived peptides are bound to major histocompatibility com-
plex class II (MHC-II) molecules on the surface of the APCs. The MHC-II-bound peptides 
are presented to the T cell receptor on naïve CD4+ antigen specific T cells which will 
lead to the differentiation into Th1, Th2, Th17 cells or Tregs. In persons predisposed to 
allergic sensitization, this process leads to an exaggerated Th2 response to the allergen 
with an accompanying cytokine profile that includes IL-4, IL-5, IL-10, and IL-13. These 
cytokines drive B cell heavy-chain class-switching to IgE production and secretion of 
peanut-specific IgE. Secreted peanut-specific IgE antibodies are distributed systemically 
and bind to the high affinity receptor FcεRI of mast cells in the tissue or basophils in the 
blood. 
In sensitized individuals re-exposure to peanut elicits an allergic reaction. This is me-
diated by binding of the food antigen to cell bound IgE thereby cross -linking two or 
more FcεR1 receptors on the surface of mast cells or basophils to induce activation and 
release of effectors. The release of inflammatory mediators and cytokines from mast 
cells, and the increase in vascular permeability promotes the subsequent recruitment 
of other effector cells, such as eosinphils, neutrophils, basophils and Th2 lymphocytes 
[52]. In order to induce mast cell and/ or basophil activation, the number and duration 
of cross-links per mast cell or basophils should be at least 100 for at least 100 seconds, 
provoking degranulation and release of mediators such as histamine, leukotrienes, cy-
tokines, platelet-activating factors, and prostaglandin [53]. (Fig. 3)
The release of inflammatory mediators can lead to a variety of cutaneous (urticaria, 
angiodema, eczema), gastrointestinal (nausea, vomiting, abdominal pain, diarrhoea), 
respiratory (cough, wheeze), and systemic (hypotension) symptoms within minutes to 
hours after ingestion of the food. The anaphylactic reactions are life-threatening and 
are the leading cause of anaphylactic reactions treated in emergency departments in 
Westernized countries. In certain persons, the recruitment of effector cells can lead to 
a cell-mediated response, after 6-24h, which is often seen in allergic nasal respiratory 
and skin disease (atopic eczema). If an antigen persists and stimulates allergen-specific 
Th2 cells, this can convert into a chronic inflammatory response, like chronic asthma, 
because of the enhanced IgE production.
The precise combination of factors leading to allergic sensitization in some individu-
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als are complex and not well understood in most cases. There are probably many fac-
tors involved, such as genetic predisposition, type of allergen, allergen concentration in 
the environment, route of exposure and whether allergen exposure is accompanied by 
agents that can enhance or down regulate the initiation phase [54].
Among the several factors involved in the development of IgE-mediated allergic dis-
eases, the most important seems to be genetic predisposition to allergies (atopy) [55]. 
The presence of an atopic phenotype in one or two parents will substantially increase 
the likelihood of an atopic phenotype in the child. However, atopy itself does not deter-
mine if a child will become allergic and to which particular protein an allergic response 
will develop, implicating environmental factors in the outcome of an allergic disease.
These environmental factors may include the age at which an antigen is introduced, the 
composition of the gut microbiota, the infection status of the gastrointestinal tract at 
the time of antigen introduction, the dietary composition, and formula versus breast-
feeding [56]. Food allergies affect only susceptible individuals and are most commonly 
IgE-mediated. 
Potential therapies for peanut allergy
Currently, allergen avoidance is the only way to prevent allergic responses [57] but in 
the case of peanut allergy, accidental ingestion is common due to the trace amount of 
peanut in many food products and cross-contamination during food processing [58]. In 
case of an unintended ingestion, epinephrine injection is used against anaphylaxis [44]. 
At this moment no curative therapy is available for patients that already have an estab-
lished peanut allergy. Recently the potential therapies for peanut allergy were reviewed 
by Stahl et al. [59]. The use of oral immunotherapy, anti-IgE therapy, soy-based immu-
notherapy, Chinese medicine, cellular mediators, engineered allergen immunotherapy, 
plasmid DNA immunotherapy and immunostimulatory sequence and oligodeoxynucle-
otide-based immunotherapy and probiotics were extensively discussed. Most explored 
therapies aim, at least in part, to reverse Th2 predominance towards a Th1 profile. In 
patients that outgrew their peanut allergy, cytokine levels more closely resembled the 
Th1 profile (IFN-γ and TNF-α) of individuals without history of peanut allergy. In contrast 
persons with active peanut allergy have a Th2 profile (IL-4, IL-5, and IL-13). Liposomal 
delivery of IL-12 during and after oral sensitization with peanut allergen enhanced al-
lergen-specific Th1 responses as shown by increased IFN-γ responses in re-stimulated 
splenocytes although the Th2 cytokine responses were unaffected [60]. This strategy 
proved to be effective in both prevention and treatment of allergy. 
Given the potential for probiotics to modulate host immune responses there is ongo-
ing interest in their application in the treatment and prevention of allergy including 
food allergy. A review of the literature on probiotics and allergy is beyond the scope of 
this introduction but this has been recently reviewed in relation to human studies [61]. 
Most success has been obtained in primary prevention of atopic eczema. However after 
almost a decade of research on this topic it is clear that more research is needed to un-
derstand probiotic mechanisms in humans [62]. There have been some clear successes 
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Fig. 3 Sensitization and elicitation phase of the allergic reaction (based on [51]).
but also negative results and the field would benefit from more comparative studies
using different strains that have been extensively characterized in vitro using immune 
assays and animal models. 
Peanut sensitization model
Due to ethical considerations for testing directly in vivo in humans, animal models of 
food allergy have been used to study the mechanisms involved in the development of 
hyper-sensitization reactions to food proteins as well as the immunologic mechanisms 
of the adverse reactions to allergen re-exposure [63, 64]. The use of mucosal adjuvants 
and manipulation of the epithelial barrier has been frequently been used to break oral 
tolerance in animal models [65]. Cholera toxin (CT) is the most common adjuvant used 
for oral sensitization in rodent models of food allergy [64, 65]. CT is composed of an A 
subunit with ADP ribosyltransferase activity and a pentameric B subunit. The B subunit 
mediates the binding to the cell membrane through a high-affinity receptor, the ganglio-
side GM-I [66]. After internalization of the CT by the cells, the A subunit ADP-ribosylates 
the α subunit of Gs protein and causes intracellular increase of cAMP. The mechanisms 
of the adjuvanticity are believed to be a complex multistep phenomenon resulting from 
the interaction of CT with different cell types. The binding of CT to mucosal ECs [67] and 
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the increase of the mucosal barrier permeability [68] might be critical, as this allow the 
CT and the co-delivered antigen to cross the mucosal barrier and to come in contact 
with the cells of the immune system. The induction of allergic sensitization by CT is ac-
companied by the up-regulation of MHC-II and co-stimulatory molecules on monocyte 
and bone-marrow derived DCs, resulting in DCs that preferably prime naïve CD4+ T cells 
to a Th2 phenotype [69]. Furthermore, the matured DCs express functional chemokine 
receptors CCR7 and CXR4, which are involved in the migration of DCs from the intestine 
to the MLNs, and the migration from the sub-epithelial dome to T cell areas of the PP 
[70-72].
In this thesis a peanut sensitization model was used to determine the immunomodu-
latory effects of different strains of lactobacilli. C3H/HeOuJ mice were sensitized with 
peanut extract (PE) in combination with CT for three consecutive days, following weekly 
sensitizations for a further three weeks with an oral challenge of PE alone on the fifth 
week. This model has been used succesfully for different studies showing that an oral 
challenge in C3H/HeOuJ mice resulted in measureable mast cell degranulation but not 
in clinical signs of anaphylaxis (unpublished data, TNO). This hypersensitivity model has 
been proven very suitable to study the mechanisms of oral sensitization, including chal-
lenge responses (such as mast cell activity). 
Probiotics as adjuvants for vaccination 
In this thesis intranasal vaccination with the Influvac 2010/2011 influenza vaccine was 
used as a model to investigate the potential adjuvant effects of different selected lac-
tobacilli. Influenza is an interesting model because it could reveal beneficial effects of 
a probiotic in healthy subjects. Furthermore influenza is a relevant vaccine target given 
its global importance as a respiratory pathogen and the high degree of morbidity and 
mortality associated with influenza infections each year. Both mucosal and systemic 
immunity contributes to resistance to influenza infection and disease. Antibodies se-
creted locally in the upper respiratory tract are a major factor in resistance to natural 
infection. Secretory IgA (SIgA) is involved in protection of the upper respiratory tract 
and serum IgG in the protection of the lower respiratory tract by the production of 
neutralizing antibodies directed against important viral proteins. The humoral immune 
system, both mucosal and systemic, plays a major role in immunity to influenza infec-
tion, and the cell-mediated immune response is particularly effective in the clearing of 
virus-infected cells. The cytotoxic T-cell response is mainly directed against nucleopro-
tein (NP) proteins [73, 74], which are more conserved than the surface hemagglutinin 
and neuraminidase glycoproteins [74-76]. This response is important for the clearance 
of virus and recovery from illness, but does not confer protection against infection. The 
influenza vaccine has to be reformulated almost every year because the virus is continu-
ously undergoing antigenic drift and shift to escape the host’s acquired immunity. The 
efficacy of influenza vaccine varies each year depending on the match between vaccine 
subtypes and circulating viral strains, patient’s age and pre-existing immunity. In young 
healthy adults, the influenza vaccine provides a protective clinical efficacy in 70-90% 
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1 of cases, which is reduced to only 17-53% in elderly individuals. In addition to the in-
activated vaccine, a live attenuated influenza vaccine (LAIV) has been licensed by the 
Food and Drug Administration (FDA) since 2003. The LAIV contains live but attenuated 
(weakened) influenza viruses, and is sprayed into the nostrils rather than injected into 
the muscle. Since 2007 the FDA approved use of the LAIV in healthy children and adults 
from 2-49 years of age allowing it to be used to control pandemic outbreaks. To improve 
the efficacy of vaccines several approaches have been investigated such as increasing 
the dose of antibody in the vaccine (Centers for Disease Control and Prevention, 2010), 
using alternative routes of administration such as intradermal injection [77] and us-
ing immune adjuvants. In general, new strategies are needed for mucosal adjuvants to 
increase the efficacy of oral vaccines such as polio, rotavirus and influenza. Probiotics 
have shown to enhance specific immune responses to vaccination in young children and 
in adults. They increased the immunogenicity of orally administered vaccines such as 
rotavirus [37], Salmonella [38], polio [39] and cholera [40]. Furthermore a recent study 
on LGG as an immune adjuvant for LAIV in healthy adults showed significantly improved 
protective serum responses to one of the three viruses present in the vaccine [78]. This 
has important implications for the use of probiotics to stimulate immunity to respira-
tory pathogens and enhance responses to intranasally delivered vaccines.
IFN-γ and IL-12, which are produced by Th1 cells, play crucial parts in the stimulation of 
natural-killer-cell activity and maturation of cytotoxic lymphocytes, and thus in protec-
tion against infectious diseases and vaccination. Systemic administration of IL-12 has 
pleiotropic effects on T and B cells and is a key regulator of Th1 differentiation. As our 
understanding of the immunomodulatory properties of different LAB increases, it might 
be possible to select potential probiotic that influence the balance between Th1- and 
Th2-cytokine production and by that enhance the vaccine specific immune response.
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Table 2. Frequently measured immune parameters in this thesis
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1 Research aim and thesis outline
The research aim of this thesis is to better understand the molecular mechanisms of 
host responses to probiotics. As mentioned above probiotics can be used to stimulate 
or regulate immune responses in epithelial and immune cells of the intestinal mucosa 
and generate beneficial effects on the immune system. Carefully selected probiotics 
should be able to steer the activity of the immune response in a predetermined manner 
by increasing or decreasing the activity of different aspects of the immune system (e.g. 
T helper subsets). Beneficial effects of strains of probiotics have been established in the 
treatment and prevention of various intestinal disorders, including allergic diseases and 
diarrhea. However the precise molecular mechanisms and the strain dependent factors 
involved are poorly understood. Here in vitro molecular studies and in vivo mechanistic 
studies were combined in different mouse models to generate new insights into the 
beneficial mechanisms of selected lactobacilli and identify novel bacterial genes influ-
encing the immune response. A further aim was to investigate the predictive value of in 
vitro immune assays for the effects of probiotics in vivo. 
Given the importance of DCs in mucosal tolerance and immunity and their use in im-
mune assays with probiotics, the current knowledge and understanding of the immu-
nomodulatory effects of different probiotic species and strains on DCs and the adaptive 
immune system is reviewed in chapter 2. The relevance and the implications of the in 
vitro studies for clinical trials or mechanistic research in animal models are also dis-
cussed.
Chapter 3 and chapter 4 present new insights gained from research on the strain-de-
pendent factors involved in probiotic immune modulation. These chapters describe 
the extensive variation in immune responses among a collection of 42 L. plantarum 
strains and the identification of genetic loci in the model organism L. plantarum WCFS1 
that modulate the host cell immune response using gene-trait matching. In chapter 3 
we used more specialized antigen presenting cells, namely DCs and in chapter 4 we 
used peripheral mononuclear cells (PBMCs). The amounts of cytokines secreted by the 
immune cells after stimulation (see Table 2 for immune parameters measured in this 
thesis) with 42 individual L. plantarum strains were measured and correlated with the 
strain-specific genomic composition using comparative genome hybridization and the 
Random Forest algorithm. This in silico “gene-trait matching” approach led to the iden-
tification of several candidate genes in the L. plantarum genome that might modulate 
the immune cytokine response to L. plantarum. Selective gene deletions mutants were 
constructed for the candidate genes in L. plantarum WCFS1 and compared to the wild-
type strain in immune assays with PBMCs and DCs. 
In vitro assays for pre-screening of candidate probiotics would benefit from standard-
ized methods and cryopreservation techniques for immature DCs or precursor mono-
cytes. Literature on the effects of cryopreservation and thawing of monocytes or mono-
cyte-derived iDCs suggested that this strategy might be useful although bacteria had 
not been used as a stimulus. Thus in chapter 5 we investigated the effects of cryopreser-
25
Chapter 1
vation and thawing of precursor monocytes and immature DCs on the maturation and 
immune response of DCs to potential probiotic strains and bacterial TLR agonists. 
As there are only a few studies comparing potential probiotics strains in vitro and in 
vivo, strains of Lactobacillus and Bifidobacterium were isolated from different commer-
cially available products and were screened for their immunomodulatory properties 
in a co-culture assay with human PBMCs (chapter 6). Three of these strains were se-
lected on the basis of their induced cytokine profiles and predicted immune modula-
tory mechanisms and tested for their potential to attenuate allergic sensitization in vivo. 
In chapter 7 we selected strains based on the results of chapter 3 and chapter 4 that 
might modulate systemic immune responses in a mouse influenza vaccination model. 
First we established an intranasal influenza vaccination model in young female Balb/c 
mice. As the administration of different L. plantarum strains could potentially lead to 
either down-regulation or up-regulation of the immune responses, conditions had to 
be selected in such a way that both types of modulation could be detected. Therefore, 
the vaccine dose was titrated in an initial experiment to induce a sub-maximal immune 
response. Modulation of cellular immune responses to vaccination by the L. plantarum 
strains was studied by delayed type hypersensitivity (DTH) responses, as a parameter 
for cellular Th1 dependent immunity, and by ex vivo ConA and vaccine-induced MLN 
response as a parameter for T-cell activation. Modulation of the humoral immune re-
sponse to vaccination was measured by vaccine-specific serum antibody. In addition, 
mRNA levels of different cytokines, chemokines and receptors were measured in naïve 
MLNs (see Table 2 for immune parameters measured in this thesis). In this way we were 
able to compare different L. plantarum strains in a standardized and well characterized 
study.
Chapter 8 completes this thesis with a general discussion on the results and conclusions 
of the different chapters. It discusses the future perspectives for probiotic research with 
respect to strain characterization in vitro and in vivo, microbiota, peanut allergy, and 
influenza vaccination.
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Abstract
Over the past decade it has become clear that probiotic and commensal interactions 
with mucosal dendritic cells in the lamina propria or epithelial cells lining the mucosa 
can modulate specific functions of the mucosal immune system. Innate pattern-recog-
nition receptors such as Toll-like receptors (TLRs), NOD-like receptors (NLRs) and C-type 
lectin receptors (CLRs) play a crucial role in the host recognition of probiotics and other 
microorganism. Signalling via these receptors directly influences the chemokine and 
cytokine response of dendritic cells as well as the crosstalk between the epithelium and 
the immune cells in the lamina propria. This can influence the population of effector 
and regulatory T cell subsets in the mucosa. Immune assays with probiotics have shown 
that the in vitro immune response is both species and strain-specific. Such assays may 
be useful for the selection of probiotic strains that have beneficial effects on the regu-
lation of intestinal inflammation but more comparative studies are needed to confirm 
recent findings. A better understanding of the molecular mechanisms of probiotics, the 
effect of dose, and frequency of administration on microbial sampling by mucosal anti-
gen presenting cells (APCs) will also help to clarify the value of immune assays as selec-
tion criteria for probiotics.
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Mucosal dendritic cell and antigen sampling 
The surface area of the intestinal epithelium is estimated to be around 400 m2 and the 
major portal for the entry of pathogenic viruses and bacteria. The intestinal tract is also 
home to a myriad of commensal bacteria which are largely mutualistic and symbiotic 
in nature. Several host adaptations appear to have evolved to avoid potentially damag-
ing inflammatory immune reactions to harmless food and commensal antigens while 
retaining the capacity to detect and protect against pathogens. It would be incorrect 
however, to consider the epithelium as impermeable to microbes even in the absence 
of inflammation. Antigen sampling occurs at mucosal sites associated with isolated lym-
phoid follicles (ILFs) in the large intestine and Peyer’s patches (PP) in the small intestine 
which contain large aggregates of lymphoid follicles (LFs). Specialized antigen sampling 
cells, called M cells are present in the epithelium overlaying the mucosal lymphoid tis-
sue and actively transport antigens to the underlying immune cells. In addition epithe-
lial cells can transport antigens to the lamina propria (LP) albeit much less efficiently 
than M cells [1]. 
Dendritic cells (DCs) are present throughout the intestine in PP, ILFs and LP and play a 
key role in regulating tolerance and immunity [2]. DCs are the most important profes-
sional antigen-presenting cells and express up to 100x more MHC-class II and are more 
effective at differentiating naïve T cells than other antigen presenting cells (APCs) [3, 4]. 
DCs in the PP and ILFs are considered to be primarily responsible for T–cell dependent 
IgA responses [5]. The LP of both the small and large intestine is populated by two major 
DC subsets which perform different immune functions. These two populations can be 
discriminated by the differential expression of CD103 (also known as integrin aEb7) and 
the fractalkine receptor CX3CR1 giving rise to the CD103+ CX3CR1- and CD103- CX3CR1+ 
subsets. The CD103+ subset of DCs are derived from a common DC progenitor that gives 
rise to DCs in the lymphoid organs but not monocytes [6]. CD103+ DCs traffic from the 
mucosal tissues to the draining lymph nodes (LN) where they present luminal antigens 
including those derived from microorganisms to T–lymphocytes [7, 8]. The CD103+ 
DCs are primarily involved the induction of CD4+ Foxp3+ T regulatory cells (Tregs) via a 
transforming growth factor beta (TGF-b) and retinoic acid dependent mechanism [9]. 
In contrast the CD103- CX3CR1+ cells are longer lived but poor T cell stimulators [10]. 
Furthermore this cell population expresses the macrophage markers CD11b, F4/80 but 
also variable levels of CD11c, and CD14 suggesting that this population consists of sev-
eral different cell subsets [10]. The CX3CR1+ cell population were recently reported to 
comprise both CD68+ and CD68- cells indicating the presence of both macrophage and 
DC cell types. CX3CR1+ ‘DC’ cells have been shown to extend protrusions through the 
paracellular space between epithelial cells to sample luminal antigens. However, the 
dependency of this mechanism on expression of CX3CR1 is somewhat controversial and 
it is possible that other LP cells can sample antigens in this way [11]. CX3CR1+ CD68- 
DCs are associated with inflammatory responses and IL-17/ IFN-g responses [12, 13] 
and thus are considered as effector T cell inducing cells. 
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Microbial recognition by dendritic cells 
DCs play a key role in mucosal immunity and tolerance, and, not surprisingly, have been 
implicated as key players in the interaction between probiotics and the immune system. 
Several studies have implicated a role for epithelial cells in endowing DCs with their 
ability to prime non-inflammatory responses and induce Tregs [14-17]. Conditioning 
of monocyte-derived DCs (MoDCs) with intestinal epithelial cell (EC) supernatants in 
vitro abolishes the ability of DCs to produce interleukin (IL)-12 and prime naïve T cells 
for T helper (Th) 1 cell polarization in response to microbial stimuli [16]. Consequently 
the EC conditioned DCs produce high amounts of IL-10 and promote Tregs and Th2 cell 
responses. In vitro this was shown to be dependent on epithelial production of thymic 
stromal lymphopoietin (TSLP) which acts in concert with epithelial produced transform-
ing growth factor beta (TGF-b) to induce a tolerogenic phenotype in MoDCs in vitro [14, 
18]. TSLP mRNA is constitutively expressed by epithelial cells, but is upregulated by NF-
kB dependent pathways [19]. Thus one may expect that recognition of microbiota by 
epithelial pattern recognition receptors would also modulate TSLP production. Support 
for this comes from in vitro EC-DC co-culture studies where it was shown that compo-
sition of the microbiota exposed to the apical side of the EC influenced production of 
TSLP and TGF-b and hence the function of the underlying DCs [18]. Microbial stimula-
tion of DCs in the LP and PP is mediated via the binding of microbe-associated mo-
lecular patterns (MAMPs) to pattern recognition receptors (PRRs) expressed by mucosal 
dendritic cells and intestinal epithelial cells. One such family of PRRs comprises the 
Toll-like receptors (TLRs) which are expressed by a variety of cells of the innate immune 
system including immature DCs. Each TLR family member is endowed with the ability to 
recognize a distinct class of conserved MAMPs. With respect to microbial recognition, 
TLR 1, 2, 4, 5, 6, and 9 signal via binding to common bacterial structures whereas TLR 3, 
7 and 8 are aimed at primarily at viral detection. In DCs TLRs 2, 4, 1, 5, and 6 participate 
in innate signalling on the cell surface and TLR 9, 7, 8 and 3 in endosomes. 
A different set of receptors known as the nucleotide binding and oligomerization do-
main-like receptors (NLRs) of which there are more than 20 family members recognize 
intracellular ligands. NOD1 and NOD2 have been shown to detect the synthetic mimics 
of peptidoglycan (PGN) meso-DAP and muramyl dipeptide respectively, whereas the 
specificities of most of the other NLRs remains uncharacterized. 
Activation of TLRs and NLRs can trigger the release of cytokines and the differentiation 
of immature to mature dendritic cells, making a link to the adaptive arm of the immune 
system. During maturation DCs up-regulate expression of MHC and co-stimulatory mol-
ecules required for antigen presentation and activation of T cells [20]. The cytokines 
produced by activated DCs are also influenced by the nature of the TLR and NLR stimu-
lus which has important consequences for the induction of different T cell subsets (Fig. 
1). The activation of Th1 responses by DCs has often been associated with the pro-
duction of IL-12 and elicits IFN-g production by T cells and by NK cells [21]. IL-10 is an 
anti-inflammatory cytokine that suppresses IL-12 production and consequently IFN-g 
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production, thus favouring a Th2 or Treg response. Furthermore, IL-10 down-regulates 
antigen (Ag) presentation by blocking translocation of Ag-MHC class II complex [22] and 
acts on macrophages to prevent their activation and elaboration of pro-inflammatory 
molecules and chemokines, thus inhibiting T cell recruitment into the intestine. 
TLR2 is important for the innate recognition of bacterial MAMPs and can form heter-
odimers with TLR-1 or TLR-6 to detect different but related ligands. TLR-2/1 recognizes 
tri-acyl lipoproteins found predominantly in Gram-negative bacteria and TLR-2/6 the 
diacyl groups on lipoteichoic acid and lipoproteins of Gram-positive bacteria. Signal-
ling through these different receptors can have important functional consequences as 
shown in a recent study where TLR-2/6 agonists induced high amounts of IL-10 and low 
amounts of IL-12 whereas TLR-2/1 agonists have the opposite effect [23]. Several stud-
ies report that preparations of macromolecular PGN (PGNpolymer) can activate NF-κB 
through human Toll-like receptors 2 (TLR-2). However, a recent study showed that pu-
rified PGN isolated from S. aureus mutant lacking prolipoprotein diacylglyceryl trans-
ferase (Lgt), which couples the diacyl groups to lipoproteins in Gram-positive bacteria,
fails to stimulate TLR-2 signalling [24]. This demonstrates that lipoproteins within the 
macromolecular structures of PGNpolymer, but not PGN itself, activate TLR-2. HPLC-
purified monomeric PGN (PGNmonomer) lacked TLR-2 activity but acted as a potent 
co-stimulator of the innate immune system exclusively in the presence of TLR signals 
[24]. This synergistic effect was lost in NOD2(-/-) DCs demonstrating that NOD2 is the 
natural ligand for PGNmonomer [24]. 
Recently, several lectin and C-type lectin receptors (CLRs) have been characterized that 
are involved in the recognition and capture of antigens by APCs. One such CLR known 
as DC-specific intracellular adhesion molecule-3 grabbing non-integrin (DC-SIGN) rec-
ognizes high-mannose-containing structures. Some viral pathogens such as HIV-1, and 
non-viral pathogens, such as Mycobacterium tuberculosis, subvert DC functions to es-
cape immune surveillance by targeting the C-type lectin DC-SIGN. For example, the in-
teraction of the abundant mannose containing cell wall component of M. tuberculosis 
to DC-SIGN inhibits DC maturation and increases expression of IL-10, thereby prevent-
ing the induction of cell-mediated responses against the pathogen. DC-SIGN binding 
activity has also been reported for certain strains of Lactobacillus species and shown to 
have an immunomodulatory effect on DC cytokine responses and T cell priming in vitro 
[25, 26]. Other polysaccharides expressed on commensals may also influence mucosal 
immunity as demonstrated for the PSA polysaccharide of a non-toxin producing Bacte-
roides fragilis strain. Colonization of germ-free mice with the polysaccharide producing 
strain leads to the induction of Tregs and IL-10 production [27]. 
Given the complex array of PRRs involved in microbial recognition and the possibili-
ties for crosstalk between the different signalling pathways there are conceivably many 
ways in which interaction of DCs with a microbe could lead to different outcomes. Here 
we aim to specifically review our knowledge and understanding of the immunomodula-
tory effects of different probiotic species and strains on dendritic cells and the adaptive 
immune system and discuss the relevance and implications of the in vitro studies for 
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clinical trials or mechanistic research in animal models.
Immunomodulation by probiotic strains
It is clear that some intestinal bacteria such as lactobacilli and bifidobacteria, frequently 
used as probiotics, can play a beneficial role on the health of the host. Probiotics have 
been shown to enhance barrier function, alter epithelial signaling, compete with patho-
gens for mucosal colonisation, and directly modify the activity of immune cells [28-30] 
(Fig. 1). The positive effects of probiotics on inflammatory diseases seem to be largely 
mediated by an increase in the population of Foxp3+ Tregs as well as the induction of 
other lymphocytes producing regulatory cytokines. For example, treatment of colitic 
mice with VSL#3 cocktail of probiotics increases the number of TGF-b and IL-10 produ-
cing T cells [31]. Administration of VSL#3 in patients with ileal pouch-anal anastomosis 
due to ulcerative colitis was associated with a significant increase of Tregs and an in-
creased expression of Foxp3 mRNA in mucosal biopsies [32]. Bifidobacterium infantis 
induced Tregs were also shown to protect against pathogen induced inflammation [33]. 
Such effects are likely to be mediated by interactions with mucosal DCs [34] although 
interactions with other immune cells may also play a role. A recent study demonstrated 
that probiotics selected on the ability to induce high IL-10/IL-12 ratios and enhanced 
Foxp3 expression in MLNs, modulated CD103+ DCs to induce Tregs in vivo [35]. 
Probiotics and even fragments of dead or lysed bacteria can influence the immune sys-
tem with their cell wall components, metabolites and their DNA (Fig. 1). Several in vitro 
studies have been conducted on the effect of probiotic bacteria on immune function 
using different types of immune cells, such as human MoDCs, human peripheral blood 
mononuclear cells (PBMCs) and mouse bone marrow derived DCs. Different Lactobacil-
lus species and even strains of the same species have been shown to differ strikingly 
in their capacity to induce the cytokines IL-10, IL-12p70 and TNF-a in co-culture with 
DCs [36, 37]. Many studies on the co-culture of bacteria with immune cells measured 
cytokine production only after one particular time point of stimulation despite the fact 
that the kinetics of production are cytokine-specific [38]. To determine the optimal time 
point for cytokine measurement several studies have been published. For example, 
Lammers et al. found a time-dependent effect for L. casei and Bifidobacterium breve by 
exposing PBMCs for 24, 48 and 72 h to 20 mg/mL probiotic DNA. IL-1β, IL-6 and IL-10 
secretion reached maximum levels after 24h incubation and thereafter remained at this 
level [39]. Chen et al. investigated the kinetics of IL-10 and TNF-a secretion by PBMCs 
co-cultured with cell wall fragments isolated from Eubacterium aerofaciens and Strep-
tococcus pyogenes. IL-10 peaked at about 24h incubation, while TNF-a reached the 
highest level already after 6h [38]. Latvala et al. showed the kinetics of bacteria-induced 
cytokine mRNA expression and cytokine secretion by DCs co-cultured with S. thermo-
philus THS, B. breve Bb99, and L. lactis subsp. cremoris ARH7. The expression of CCL20 
and TNF-α mRNAs, CCL20, TNF-α, and IL-6 production was detected 8h after stimulation 
with these three probiotic bacteria. While IL-10, IL-12 and IFN-γ were produced 24h 
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after stimulation with S. thermophilus and the probiotic strains [40]. In general most 
cytokines accumulate in the culture supernatant after stimulation of the immune cells, 
therefore 24h or 48h incubations are typically used and represent a good time point 
for immune screening. Quantitative PCR (qPCR) is a more sensitive method to measure 
cytokine expression, and can be used to measure induction after only a few hours but 
may not reflect the amount of cytokines that is actually secreted. Additionally feedback 
signalling of secreted cytokines on immune cells will be missed by this method, while 
ELISA will measure the accumulation after a certain time.
Probiotics are defined as viable microorganisms which when supplied in sufficient quan-
tities confer a health benefit on the host, but in vitro immune assays often utilize dead 
bacteria and bacterial DNA. According to Rachmilewitz et al., γ-irradiated non-viable 
bacteria and live bacteria showed similar effects in PBMC co-culture assays [41]. Heat-
killed bacteria have been shown to reduce IL-4 and IL-5 production by staphylococcal 
enterotoxin A stimulated PBMCs [42]. UV-killed bacteria are also often used in studies 
to investigate the immunomodulatory effects of bacteria [43, 44], but the results do not 
always correlate with those obtained with live bacteria. Purified bacterial DNA has been 
shown to induce the same immune responses as live bacteria [41, 45] by the binding 
of non-methylated CpG motifs in bacterial DNA to TLR-9. The study of Rachmilewitz 
showed that DNA isolated from VSL#3, a probiotic mixture, but not DNAse-treated pro-
biotics and E. coli genomic DNA ameliorated the severity of colitis in DSS-induced and 
TNBS-induced colitis models as well as spontaneous colitis in IL-10 knockout mice. Ghad-
imi et al. showed that live probiotic bacteria as well as their genomic DNA inhibited IL-4 
and IL-5 and increased the IFN-γ production by PBMCs in healthy donors. The bacterial 
DNA appears to contribute to about 50% of the immunomodulatory effects of these 
probiotics [45]. Bifidobacterium genomic DNA decreased IL-1β secretion and induced 
the secretion of IL-10 by PBMCs from healthy donors, suggesting that purified bacterial 
DNA can have immunomodulatory effects [39]. In contrast Medina et al. showed that 
some B. longum strains and their genomic DNA increased IL-12 and IFN-γ production 
by PBMCs [46]. In TLR9-/- mice the Treg frequencies are dramatically increased suggest-
ing that commensal DNA constrains the generation of Tregs [47]. However this is not 
comparable to studies with individual probiotic DNA samples and may also involve the 
effects of TLR-9 signalling on other cell types such as the epithelium. Furthermore, it is 
unlikely that the purified DNA of bacteria will be presented in the same way in vivo and 
in the context of whole bacteria the induced cytokines could be quite different due to 
the synergistic or inhibitory effects of other MAMPs. Most immune co-culture assays 
with bacteria employ antibiotics to prevent overgrowth and acidification of the culture, 
and therefore the probiotic strains will be killed, or arrested in growth during the incu-
bation period [36, 37, 45, 48]. Mileti et al. used an elegant method by which the live 
bacteria are in co-culture with DCs and after 1h incubation, the cells are washed and the 
medium is replaced by an antibiotic containing medium [49]. The bacteria to cell ratios 
(BCR) used in probiotic co-culture experiments differs a lot between in vitro 
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Figure 1. Microbe associated molecular patterns derived from bacteria (including probiotics) are 
recognised by pattern recognition receptors (PRRs), such as Toll like receptors and NOD like receptors. 
Initiation of dendritic cell maturation starts after ligation of PRRs. The integration of different 
signaling via PRRs determines the selective priming of DCs for production of Th1, Th2 or Tregs 
polarizing cytokines.
39
Chapter 2
matured DCs, expressing high levels of CD86 [25], other groups used BCR of 1:1 or 10:1 
studies. Whereas Konstantinov et al. matured MoDCs with BCR 100:1 and obtained fully
to maturate DCs or stimulate their immune cells [26, 36, 37, 48, 50]. In vivo it is likely 
that DCs will only be in contact with low numbers of bacteria (or fragments) that are 
either actively sampled by M cells or intra- and transepithelial DCs [5]. Therefore BCR of 
1:1 or 10:1 seem to be more relevant to the in vivo situation.
The phase of growth also can influence the immunomodulating capacity of the bac-
teria. Strikingly a recent study showed that exponential phase and stationary phase L. 
plantarum WCFS1 cells elicited distinct human duodenal transcript profiles. This ap-
peared to result from differential modulation of canonical NF-kB-dependent signalling 
pathways associated with mucosal immune tolerance in epithelial tissue biopsies [51]. 
Hemert et al. showed in vitro that PBMC cytokine responses were also differently in-
duced by exponential- and stationary-phase grown bacteria [48]. Commercial probiotic 
products are typically in stationary growth phase and thus are used as such in immune 
assays. However, it cannot be ruled out that some probiotics persist in the intestine and 
will therefore be sampled in different growth phases by the mucosal immune system. 
Both species-specific and strain-specific effects of different lactobacilli and bifidobacte-
ria on PBMCs and DCs have been described in several studies [36, 37, 40, 46, 48, 50, 52-
56]. For example, Christensen et al. showed that different species of Lactobacillus exert 
very different and even opposing effects on DC activation [52]. Similarly, co-culture of 
DCs with different strains of B. longum led to variable cytokine responses and co-culture 
with PBMCs led to the secretion of either pro-inflammatory or regulatory cytokines 
[46]. Foligne et al. demonstrated large strain-specific variations in cytokine production 
by PBMCs co-cultured with 13 different bacterial strains and strain-specific differences 
in their protective capacity in a mouse TNBS-induced model of colitis. Taken together 
these findings suggest probiotics intended for modulation of immune responses should 
be selected on a strain by strain basis in a comparative study [36, 48, 50]. This does not 
take into account the possibility that different probiotic species and even strains may 
also differ in their fate in vivo. Probiotic sampling may occur at several places along the 
GI tract but the efficiency is likely to vary substantially within the entire small intestine 
due to the anatomical differences in the epithelium and lymphoid tissue. Competition 
for binding and adhesion of probiotic organisms will also be influenced by competing 
microorganisms which reach more than a million fold higher numbers in the colon than 
in the small intestine. Bacterial translocation or sampling of probiotic strains, could be 
very different in healthy individuals compared to individuals with colitis or intestinal 
damage thereby leading to different effects on the host immune system.
Linking results from in vitro and in vivo studies
Although studies on the in vitro immunomodulatory properties of probiotics usually 
precede their application in animals or humans, there is a dearth of systematic com-
parative studies linking in vitro data to in vivo data for different strains. 
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Animal models
The ability of different lactobacilli to induce a high ratio of IL-10/ IL-12 or IL-10/ TNF-a 
in immune cells correlates with their capacity to provide significant protection in TNBS 
induced colitis in mice and rats [37, 57, 58]. Foligne et al. showed that the ranking of 
strains obtained on the basis of an in vitro IL-10/IL-12 cytokine induction ratio closely 
correlates with the ranking of the in vivo ability of the strains to attenuate experimental 
colitis. However, this study did not include strains exhibiting a moderate or low IL-10/
IL-12 profile in the in vivo study, which might have validated the proposed screening 
strategy. In contrast Mileti et al., demonstrated that L. paracasei and LGG induced a 
similar cytokine ratio in DCs, but did not show comparable protective effects in vivo in 
the mouse DSS model of colitis. Mice receiving L. paracasei showed a delay in colitis de-
velopment and a reduced severity of disease whereas LGG exacerbated colitis [49]. The 
protection of L. paracasei could work via another mechanism than the induction of an 
anti-inflammatory response, which might explain the contradictory results. Additionally 
the probiotics used could also have different colonization patterns. Two different strains 
of Lactobacillus with similar in vitro growth, survival and adherence properties showed 
distinct differences in colonization patterns, resulting in distinct host immune responses 
at both the mucosal as well as systemic level [59]. The study by Mastrangeli et al. inves-
tigated the immunomodulatory effects of VSL#3 on bone marrow derived dendritic cells 
and spleen cells from naïve and allergen-sensitized mice and tested the ability of VSL#3 
to prevent in vivo development of allergen-specific sensitization in a mouse model. Co-
culture of DCs with VSL#3 induced maturation of DCs and production of IL-10 and IL-12. 
IL-10 and IFN-γ secretion by spleen cells from both naïve and Parietaria judaica-sensi-
tized mice was increased by co-culture with VSL#3. In vivo prophylactic treatment with 
VSL#3 induced IgG1 levels in serum, and in the lung IL-13 and IL-4 mRNA expression 
were remarkably decreased, while IL-10 expression was increased [60].
Kwon et al. demonstrated that probiotics induce regulatory DCs that expand the Treg 
population in the MLNs [35]. Tregs are important in immunological tolerance by the 
suppression of effector T cells at inflammatory sites. This study underlines the impor-
tant role of DCs in the induction of Tregs and how in vitro assays can be used for the 
selection of probiotic strains and species that have therapeutic effects in models of 
inflammatory bowel disease, atopic dermatitis and rheumatoid arthritis. Nevertheless 
the human gastrointestinal tract is a complex and variable environment and other host 
factors such as TGF-b and TSLP produced by epithelial cells can influence the mucosal 
immune functions [30]. DCs conditioned with EC supernatants in vitro are blocked to 
produce IL-12 and to prime naïve T cells for Th1 polarization in response to bacteria. 
The conditioned DCs secrete more IL-10 and promote Treg and Th2 responses, which 
was shown to be dependent on TSLP production [16]. 
Although there is evidence that in vitro data can be used to predict in vivo action, speci-
fic probiotic strains need to be investigated in vitro and in vivo using more than one mu-
rine disease model to select suitable strains, as the activity of certain strains depends 
on the type of colitis model. For example Shibolet et al. showed variable responses to 
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VSL#3 and LGG in two models of experimental colitis in rats, where the two probiotis 
significantly ameliorated the severity of the colitis induced by sulfhydryl-blocker iodac-
tamide but had no effect on the immune mediated DNBS-induced colitis. Sulfhydryl 
plays an important role in maintaining the mucosal integrity, blocking sulfhydryl com-
pounds will therefore induce colitis, while DNBS induces severe transmural necrosis. 
Thus the differences in (severity of) colitis induction might explain the differences in 
protection [61]. Contrasting results have also been obtained for the same probiotic mix-
ture VSL#3 in the DSS-induced colitis model. Whereas Rachmilewitz et al. showed that 
the protective effect of VSL#3 was due to interaction of bacterial CpG DNA with TLR-9, 
Gaudier et al. reported no protective efficacy. The two study designs look similar with 
respect to daily dose and the colitis-inducing agent, but the start of VSL#3 administra-
tion differed between the studies and thus could be an explanation for the conflicting 
results [41, 62]. Differences between studies with the same probiotic could also poten-
tially be affected by the method of culturing the bacteria or the schedule of probiotic 
administration. Furthermore, the techniques used for cytokine quantification (RT-PCR, 
immunohistochemical analysis, ELISA or cytometric bead arrays) differ a lot between 
published studies, sometimes making data comparison difficult. 
Human trials
A few studies have been performed to directly compare the in vitro properties of pro-
biotics with the in vivo response in humans. Flinterman et al. studied both the in vitro 
immunological effects of a mixture of bacterial strains and the ex vivo immunological 
effects after oral administration of a probiotic mixture in children with food allergy [63]. 
This showed that the probiotics had a different potential to modulate the immune re-
sponse in vitro and ex vivo. Co-culture of PBMCs isolated from the food allergic children 
resulted in an increased T-cell proliferation with enhanced production of IFN-γ, IL-10, 
TNF-a and to a lesser extent IL-6. After oral treatment for three months, proliferation 
of the T-cells was increased, whereas in vitro IgE production decreased in the probiotic 
treatment group compared to the base line. The cytokine production of IL-10, TNF-a, 
and IL-6 tended to decrease, but other Th1 and Th2 cytokines were not altered. The 
study by Kopp et al. investigated the protective effect of LGG on the development of 
atopic dermatitis in neonates with a family history of atopy [64]. They showed that LGG 
co-cultured with mononuclear cells enhanced IL-10 production and decreased IFN-g 
release, but supplementation with LGG during pregnancy did not alter the prolifera-
tion capacity or cytokine pattern in their recipients. Taken together these studies reveal 
discrepancies between the data obtained in vitro with PBMCs and the clinical effects of 
probiotics. 
In vitro VSL#3 induced IL-10 and down regulated IL-12p40 production in colonic DCs 
and this correlated well with the results of an in vivo study in ulcerative colitis (UC) pa-
tients [65]. The VSL#3 treated group showed improved intestinal function, an increase 
in regulatory cytokines and lowered pro-inflammatory cytokines and TLR expression 
compared to placebo, which might have contributed to the therapeutic benefit [65, 
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66]. In UC patients the effect of VSL#3 was similar to treatment with corticosteroids 
which also modulated cytokine production in colonic DC. Taken together these results 
suggest that this probiotic mixture mediates a positive effect in acute UC via modulation 
of colonic DC. 
In one study where immune assays were not used as selection criteria there was an 
unfavourable outcome in the treatment of irritable bowel syndrom [67]. L. plantarum 
strain MF1298 was found to have the best in vitro probiotic properties of 22 strains of 
lactobacilli isolated from fermented food products. The selection was based on adher-
ence to the human colon adenoma cell line CaCo2, increased epithelial barrier func-
tion, antimicrobial activity against potential pathogens, and good survival during pas-
sage through the human gastrointestinal tract. Nevertheless unfavourable effect on IBS 
symptoms was observed in subjects after intake of L. plantarum MF1298 compared to 
placebo. 
Conclusions
Certain strains of probiotics have been shown to confer health benefits in clinical trials 
and experimental animal models but there have also been a number of inconclusive, 
negative and even contrasting outcomes from in vivo studies. It is becoming clear that 
the effects of probiotics are highly dependent on the strain properties and the study 
population or animal model. Furthermore, our lack of knowledge concerning the pre-
cise mechanisms of different probiotics is hampering the rational selection of strains 
and the correlation of in vitro data with the outcomes in vivo. 
Many of the positive results obtained with probiotics in vivo are linked to effects on the 
immune system but comparison of in vitro data with efficacy in vivo is confounded by 
the lack of standardized assay methods and comparative studies. Despite these limi-
tations there is evidence that the immune profile obtained in co-culture assays with 
bacteria and immune cells (especially for IL-10 and IL-12) can be predictive for their in 
vivo immunomodulatory activities [35, 37, 57]. This will depend on the assays and the 
strains used but also on the type of DCs or immune assays. Immune assays for screen-
ing the immunomodulatory effects of probiotics would benefit from using appropriate 
ratios of live bacteria to cells which most likely reflect the in vivo situation. Additionally, 
methods that use live whole bacteria, even if for short incubations with immune cells, 
are likely to be more predictable than the use of heat killed bacteria or bacterial frac-
tions such as purified DNA. It should be taken in account that dead probiotic organisms 
may not have the same properties as live probiotics and further studies are needed to 
fully understand the effects of bacterial metabolites and secreted proteins on immune 
cells. 
Results from mouse models provide growing evidence that the induction of Tregs by 
probiotics is mediated by interactions with LP DCs, but supporting data is lacking from 
human studies mainly due to the difficulty in obtaining cells from different compart-
ments of the mucosal immune system. Other probiotic mechanisms are likely to in-
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clude modulation of the T effector subsets and the CX3CR1+ LP cells that can sample 
bacteria through the epithelium. Further research is needed to identify host and bacte-
rial target genes and molecules, which are involved in the effect of probiotics on the 
immune system. Additional interactions with dietary components could influence the 
efficiency of probiotic strains. Furthermore it is important to understand the effects of 
dose in humans and resolve how best to formulate probiotics. More understanding of 
the molecular mechanism of probiotics in vivo will help us to identify and select the 
right probiotics for prevention or treatment of certain inflammatory mediated diseases. 
Probiotics should be selected on strain by strain basis in comparative studies, because 
their effects on the immune system and other properties can vary considerably even 
within a species. Different probiotic species and even strains may also differ in their fate 
in vivo, and further research is needed to increase our knowledge about the effect of 
dose, and frequency of administration on sampling of different strains and species of 
probiotics by DCs and other APCs.
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Abstract
Background
Probiotics can be used to stimulate or regulate epithelial and immune cells of the intes-
tinal mucosa and generate beneficial mucosal immunomodulatory effects. Beneficial 
effects of specific strains of probiotics have been established in the treatment and pre-
vention of various intestinal disorders, including allergic diseases and diarrhea. How-
ever, the precise molecular mechanisms and the strain-dependent factors involved are 
poorly understood.
Methodology/Principal Findings
In this study, we aimed to identify gene loci in the model probiotic organism Lactobacil-
lus plantarum WCFS1 that modulate the immune response of host dendritic cells. The 
amounts of IL-10 and IL-12 secreted by dendritic cells (DCs) after stimulation with 42 
individual L. plantarum strains were measured and correlated with the strain-specific 
genomic composition using comparative genome hybridisation and the Random Fo-
rest algorithm. This in silico “gene-trait matching” approach led to the identification of 
eight candidate genes in the L. plantarum genome that might modulate the DC cytokine 
response to L. plantarum. Six of these genes were involved in bacteriocin production 
or secretion, one encoded a bile salt hydrolase and one encoded a transcription regu-
lator of which the exact function is unknown. Subsequently, gene deletions mutants 
were constructed in L. plantarum WCFS1 and compared to the wild-type strain in DC 
stimulation assays. All three bacteriocin mutants as well as the transcription regula-
tor (lp_2991) had the predicted effect on cytokine production confirming their immu-
nomodulatory effect on the DC response to L. plantarum. Transcriptome analysis and 
qPCR data showed that the transcript level of gtcA3, which is predicted to be involved 
in glycosylation of cell wall teichoic acids, was substantially increased in the lp_2991 
deletion mutant (44 and 29 fold respectively).
Conclusion
Comparative genome hybridization led to the identification of gene loci in L. plantarum 
WCFS1 that modulate the immune response of DCs.
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Introduction
Several species of Lactobacillus are naturally present in the human intestinal tract and 
several species and strains have been evaluated for their probiotic activity. Oral ad-
ministration of certain probiotic strains has shown significant and promising results 
in human clinical trials and experimental animal models of inflammatory bowel dis-
ease, irritable bowel syndrome and allergy [1-8]. Conclusive evidence for the mecha-
nisms underlying the beneficial properties of probiotics is lacking but results obtained 
from in vitro studies and animal intervention models indicate a strong role for immu-
nomodulation and enhancement of the epithelial barrier functions [9, 10]. Proposed 
immunomodulatory mechanisms include down-regulation of inflammatory responses 
through the modulation of dendritic cell (DC) function and subsequent expansion or 
induction of regulatory T cells producing the anti-inflammatory cytokines transforming 
growth factor (TGF)-b and interleuking (IL)-10 [11, 12]. The capacity of lactobacilli to 
stimulate pro-inflammatory or anti-inflammatory cytokines in co-culture with DCs or 
peripheral blood mononuclear cells (PBMCs) indicates that different strains of Lacto-
bacillus plantarum may differentially stimulate immune cells and could therefore exert 
opposite immunomodulatory effects.
Dendritic cells play a key role in mucosal immunity and tolerance and not surprisingly 
have been implicated as key players in the interaction between probiotics and the im-
mune system. In the small intestine DCs are known to sample microbes that enter the 
Peyer's Patches via M-cells [13] but also directly across the epithelium by opening tight 
junctions and sending dendrites to the luminal side [14]. In the mucosa DCs are the 
main activators of naive T cells and their T cell polarising properties are largely gov-
erned by the nature of the microbial products encountered at mucosal sites. Addition-
ally cellular cytokines such as thymic stromal lymphopoietin (TSLP) and TGF-b which 
are produced by epithelial cells can also modulate the function of resident DCs [15, 16]. 
Previous studies have shown that the DC responses to different probiotic bacteria are 
strain-specific and that this can have different outcomes on T cell polarisation [17, 18], 
[19], [20], [21]. Immature DCs are characterized by a high capacity for antigen uptake 
and following antigen capture in the presence of appropriate stimuli, they migrate to 
secondary lymphoid organs and mature. During maturation the major histocompatibil-
ity complex (MHC) molecules for antigen presentation and co-stimulatory molecules, 
such as CD40, CD54, CD83 and B7.1 and B7.2 (CD80 and CD86) are up regulated for an 
effective T-cell stimulation [22]. T helper(h) 1 immune responses critically depend on 
the ability of DCs to produce interleukin (IL)-12 and are characterized by the production 
of interferon (IFN)-g and IL-2, which induce cell-mediated immunity. Th2 immune re-
sponses involve IL-4, IL-5, IL-6, and IL-13 and induce humoral immunity. IL-10 is a critical 
regulatory T cell cytokine which suppresses IL-12 production and consequently other 
Th1 cytokines such as IFN-g and tumor necrosis factor alpha (TNF-a). It also prevents 
activation of antigen-presenting cells, inhibits the maturity of DCs, limits T-cell prolifera-
tion, and can induce a state of antigen-specific tolerance. In the gut, IL-10 is a key 
52
Ch
ap
te
r 
3
molecule for the induction of regulatory T cells and prevention of mouse colitis [23-
25]. The suppression of IL-12 in the gut by IL-10 prevents an inflammatory cascade 
of Th1 cytokines and cellular migration. The ability of different lactobacilli to induce a 
high ratio of IL-10/IL-12 production in human PBMCs has been shown to correlate with 
their capacity to provide significant protection from 2,4,6-trinitrobenzene sulfonic acid 
(TNBS) induced colitis in mice [26].
Lactobacilli have been shown to differ substantially in their ability to modulate DC re-
sponses and subsequent T cell induction but the factors responsible for these differen-
ces remain largely unknown. Comparative genomic analysis is one approach to identify 
genetic loci linked to certain phenotypes and has been applied to Lactobacillus spp. to 
identify genes involved in persistence in the intestine [27], mannose binding [28], and 
pilli formation [29]. Several innate pattern recognition receptors (PRR) recognizing evo-
lutionary conserved microbe-associated molecular patterns (MAMPS) are potentially 
involved in immunomodulation by lactobacilli. The most well characterised family of 
innate receptors are the Toll-like receptors (TLR) of which TLR-2 is known to recognise 
bacterial cell wall components such as peptidoglycan (PG), and when present as a he-
terodimer with TLR-6 it can also recognize the fatty acid chains present on lipoteichoic 
acid (LTA) [30, 31]. There are considerable differences between the LTA molecules of dif-
ferent Lactobacillus species and strains, which may influence their immune stimulating 
activities, including variation of the quantity of LTA produced per cell, its chain length, 
and its degree of substitution with D-alanine and/or glucose [32-34]. For example, a 
D-alanyl transfer protein B (dltB) deletion mutant of L. plantarum induced higher levels 
of the anti-inflammatory cytokine IL-10 in PBMC co-culture experiments than the wild 
type strain thereby increasing its protective effect in a TNBS mouse model of intestinal 
colitis [30]. DltB is a putative transmembrane protein predicted to be involved in the 
passage of the activated D-alanyl-Dcp complex across the glycerol phosphate backbone 
of LTA. Thus, the altered phenotype of the dltB mutant was attributed to the loss of D-
alanyl substitution in LTA although an increase in glucose substitution on LTA was also 
observed. In L. rhamnosus the DltD membrane protein facilitates the binding of Dcp for 
ligation with D-Ala and additionally has thioesterase activity for removing mischarged 
D-alanyl carrier proteins. In contrast to L. plantarum, deletion of the D-alanyl transfer 
protein in L. rhamnosus had no effect on cytokine production in co-culture with PBMCs 
[35]. These findings suggest the involvement of multiple interacting bacterial molecules 
in the observed phenomena. TLR-2 in combination with TLR-1 or TLR-6 can also re-
cognise the fatty acid chains present on lipidated lipoproteins of bacteria although for 
Lactobacillus this topic remains relatively unexplored.
Extracellular polysaccharides (EPS) are potentially important probiotic effector mole-
cules and they show a high level of diversity and complexity among different strains and 
species. EPS could have a shielding effect on the recognition of LTA by host receptors 
or a direct effect on immunomodulation by binding to specific lectin receptors such 
as the dendritic-specific intercellular adhesion molecule 3-grabbing non intergrin (DC-
SIGN) [36]. Yasuda and colleagues have shown that in Lactobacillus casei the cell wall 
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associated polysaccharide PS-1 functions as a modulator that suppresses the immune 
response of macrophages and monocytes [37].
The NOD-like receptors NOD1 and NOD2 are intracellular receptors for muropeptides of 
the PG in the bacterial cell wall. NOD2 recognises muramyl dipeptide which is present 
in lactobacilli but for these peptides to be released PG would have to be hydrolysed by 
PG-hydrolases of either bacterial or host origin (lysozyme). An immune evasion strategy 
established by some pathogens involves the action of cell wall modifying enzymes to 
prevent cell wall degradation by lysozyme and thus the release of immunostimulatory 
muropeptides [38, 39].
The aim of this study was to identify genetic loci that encode, modify or regulate im-
munomodulating factors in L. plantarum by measurement of cytokine responses to 42 
different L. plantarum strains and a comparative genome hybridization approach based 
on the genome sequence of L. plantarum WCFS1 and comparative genome hybridiza-
tion datasets of different L. plantarum strains [40]. WCFS1 is a single colony isolate of 
strain NCIMB8826, which was originally isolated from human saliva and known to sur-
vive gastrointestinal passage after oral administration in healthy volunteers [41]. Host 
responses to L. plantarum WCFS1 were recently demonstrated in healthy human volun-
teers by transcriptome analyses of duodenal tissue samples [42, 43]. Mutation analysis 
of several of these candidate genes in L. plantarum WCFS1 allowed us to evaluate their 
immunomodulatory properties and had the predicted effect on cytokine production 
confirming their immunomodulatory effect on the DC response to L. plantarum.
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Material and methods
Bacterial strains
42 different L. plantarum strains isolated from humans and different food resources 
were used for immunoassays and comparative genome hybridization studies (CGH) (Ta-
ble S1). Genomic composition of the strains has been previously described [44, 45]. 
L. plantarum strains were grown overnight to stationary phase at 37°C in  deMan, Ro-
gosa Sharpe (MRS) broth (Merck, Darmstadt, Germany). The bacteria were recovered 
by centrifugation and washed twice in phosphate buffered saline (PBS, pH = 7.4) and 
resuspended at 2×108 CFU/ml in PBS containing 20% glycerol and stored at −80°C prior 
to use in the immunoassays. Colony forming units (CFU) were determined by plating 
serial dilutions of the cultures on MRS agar.
Blood donors
The study was approved by Wageningen University Ethical Committee and was per-
formed according to the principles of the Declaration of Helsinki. Buffy coats from blood 
donors were obtained from the Sanquin Blood bank in Nijmegen (The Netherlands). A 
written informed consent was obtained before the sample collection.
Differentiation and maturation of dendritic cells
Human monocytes were isolated from blood using a combination of Ficoll density cen-
trifugation and cell separation using CD14-specific antibody coated magnetic micro-
beads (Miltentyi Biotec, Bergisch Gladbach, Germany). The purity of isolated CD14+ 
cell fraction was greater than 90% in all experiments. To generate immature DC (iDCs), 
the purified CD14+ cells were cultured for 6 days in the presence of IL-4 (R&D systems) 
and GM-CSF (R&D systems) to differentiate then into myeloid dendritic cells. At day 6 
the cells were left unstimulated (iDCs) or were stimulated with LPS (1 µg/mL) or with 
different L. plantarum strains or WCFS1 deletion mutants (1:1 bacteria to DC ratio) for 
48 hours. As anticipated, as a consequence of the application of antibiotics, no bacterial 
growth was observed during this period.
Analysis of cell surface markers and measurement of cell death by flow cytometry
During the 8 day culture period of the CD14+ cells, cells were stained on days 3, 6 and 
8 with fluorescence-conjugated monoclonal antibodies specific for CD83, CD86 or their 
isotype-matched controls (BD biosciences, San Diego, USA) and analyzed by flow cyto-
metry (FACSCanto II, BD, San Diego, USA). To check the activation status of the cells (data 
from day 3 and 6 not shown), the CD86 expression on the cells were measured. CD83 
was not expressed on immature dendritic cells (d3 and 6) but was highly expressed on 
DCs after activation with known maturation factors (e.g. LPS)[46]. Live, apoptotic and 
necrotic cells were discriminated by staining with Annexin V and propidium iodide (PI) 
on days 3, 6 and 8 according to the manufacturer's protocol. The cells were analyzed 
by flow cytometry. Cells that were negative for both Annexin V and PI are not apoptotic 
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or necrotic as translocation of the membrane phospholipid phosphatidylserine has not 
occurred and the plasma membrane is still intact. Therefore, Annexin V and PI double 
negative cells were considered as viable cells, whereas both single and double positive 
cells were regarded as non-viable [47]. The flow cytometry data was analyzed using the 
BD FACSDiva software. On days 3 to 8 the viability of the cells was between 50–80%.
Cytokine analysis
Supernatants from the DC stimulation assays were collected after stimulation for 48 
hours and analyzed for the presence of cytokines (TNF-a, IL-12p70 and IL-10) using 
a cytometric bead-based immunoassay that enables multiplex measurements of solu-
ble cytokines in the same sample [48], according to the manufacturer's protocol (BD 
biosciences). The limits of sensitivity for detection were as follows: TNF-a 0.7 pg/mL; 
IL-12p70 0.6 pg/mL and IL-10 0.13 pg/mL. The antibody used to measure IL-12 spe-
cifically recognizes the dimeric cytokine designated IL-12p70 whereas some antibodies 
recognize the p40 subunit which is also present in IL-23. The flow cytometry data were 
analysed using the BD FCAP software.
Identification of candidate genes involved in cytokine secretion by gene-trait matching
Candidate L. plantarum genes, that were potentially involved in modulation of the DC 
responses were identified by in silico gene-trait matching [28] using genotype informa-
tion referenced from the L. plantarum WCFS1 genome [40, 44]. The significance of the 
gene-trait co-occurrence was assessed by assuming a discrete probability distribution 
of genes and traits in the context of a null hypothesis that co-occurrence is caused 
by a random process [49]. All L. plantarum genes were tested for their significant co-
occurrence with each cytokine concentration or cytokine concentration ratio (i.e. IL-10/
IL-12). L. plantarum WCFS1 genes with the highest variable importance measures as 
returned by the Random Forest method were selected for further characterization us-
ing a gene deletion approach in combination with immunoassays.
Construction of knock-out mutants
A previously described L. plantarum lp_3536 deletion mutant was used in this study 
[50]. Gene deletion mutants of lp_0419-0422 and lp_0423-30 were constructed for 
a different study involving immune cytokine profiling of lactobacilli with PBMCs (van 
Hemert et al., personal communication) (Fig. 1). Construction of the L. plantarum gene 
deletion mutants for lp_0423 and lp_2991 was performed as previously described with 
several modifications [51]. The upstream and downstream flanking regions of the target 
genes, as well as the lox-cat-lox region of pNZ5319 were amplified by PCR. The resul-
ting amplicons were used as templates in a SOEing PCR reaction [52] linking the flanking 
regions and lox-cat-lox together by means of complementary 5′ regions in the prim-
ers (Table 1). Subsequently, PCR products were cloned into the non-replicating integra-
tion vector pNZ5319 [51] digested with SwaI and Ecl136II. Plasmids were transformed 
into competent cells of E. coli JM109 by electroporation as described by the manufac-
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turer (Invitrogen, Groningen, The Netherlands). This resulted in a plasmid containing 
the complete gene replacement cassette. Plasmid DNA was isolated from E. coli by us-
ing Jetstar columns, following the manufacturer's instructions (Genomed GmbH, Bad 
Oeynhausen, Germany). The sequence of the cloned DNA was confirmed by sequence 
analysis (BaseClear, Leiden, The Netherlands).
A double cross-over gene replacement strategy was used to substitute the target gene(s) 
with a chloramphenicol gene (cat). The mutagenesis plasmids were transformed to L. 
plantarum WCFS1 and integrants were selected on MRS plates containing 10 µg/mL 
chloramphenicol. After growth at 37°C for 2 to 4 days, full-grown colonies were replica-
plated to MRS with or without 30 µg/mL erythromycin. Colonies displaying an erythro-
mycin sensitive phenotype represent candidate cat-gene replacements resulting from 
a simultaneous double cross-over event in both the 5′- and 3′-flanking regions of the 
target gene. The anticipated cat-replacement genotype was confirmed by PCR using 
primers flanking the sites of recombination (Table 1). One integrant displaying the an-
ticipated phenotype and genotype was selected for all mutants and was utilized in the 
remainder of the study.
Figure 1. Schematic representation of the genetic loci targeted by mutagenesis in L. plantarum WCFS1.
RNA isolation
Bacteria (WCFS1 and delta-lp_2991) were grown in MRS to OD600 nm of 1 and then 40 
mL of quenching buffer (66.7 mM HEPES (pH 6.5) 60% methanol, −40°C) was added to 
10 mL of bacterial suspension to quench cellular processes. Cells were harvested by 
centrifugation at 15500 g for 10 min at −20°C and then resuspended in 400 µL of ice-
cold MRS. The cell suspensions were transferred to ice-cold tubes containing 0.5 g of 
glass beads, 400 µL of phenol, 100 µL chloroform, 30 µL 10% sodium dodecyl sulfate 
and 30 µL 3 M sodium acetate (pH 5.2). Cells were disrupted with three 40-s treat-
ments in a Fastprep (Obiogene Inc., Illkirch, France) separated by 1 min intervals on ice. 
After centrifugation the aqueous phase was used for RNA isolation with a High Pure kit 
(Roche diagnostics, Mannheim, Germany). The RNA concentration was measured at 
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an OD of 260 nm with the ND-1000 spectrophotometer (NanoDrop Technologies Inc., 
Wilmington, USA). The A260/A280 ratio was measured to check purity of the RNA. Qual-
ity of the RNA obtained was analyzed with the 2100 Bioanalyser (Agilent Technologies, 
Amstelveen, The Netherlands). Samples whereby the 23S/16S RNA ratio was superior 
or equal to 1.6 were taken for further labeling.
Table 1. Primers used for deletion mutants in L. plantarum WCFS1 and RT-PCR.
cDNA synthesis and quantitative reverse transcription-PCR
cDNA was synthesized from 1 µg of total purified bacterial RNA and random oligonu-
cleotide hexamers using Superscript III reverse transcriptase (Invitrogen). Reverse tran-
scription was performed at 55°C for 60 min, after which the reverse transcriptase was 
inactivated at 85°C for 5 min. Primers were designed using Oligo Program version 6 
(MedProbe, Oslo, Norway) to have melting temperatures between 60 and 62°C and an 
amplicon size of approximately 400 bp (Table 1). Quantitative PCR was performed with 
the synthesized cDNAs by using Absolute SYBR Green QPCR (Westburg, Leusden, The 
Netherlands). Each reaction mixture contained 1x SYBR Green master mix, 70 nM of 
each primer and 5 ng of reverse-transcribed RNA. After activation of Thermoprime Plus 
DNA polymerase at 95°C for 15 minutes, PCR was carried out for 40 cycles of 95°C for 
15 s, 55°C for 30 s and 72°C for 30 s. The identities of the amplicons resulting from the 
reactions were checked after amplification by melting curve analysis and 1.5% agarose 
gel electrophoresis. Reaction mixtures containing no template were included in each 
real-time PCR experiment to control for contamination. Relative transcript levels were 
calculated by using the comparative ΔΔCt method described by Pfaffl [53]. The average 
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Ct values observed for the target gene transcripts (lp_2991, mntH2 and gtcA3) were 
normalized to the average Ct values obtained for the reference gene recA from the 
same RNA sample. Two replicates of all samples and primer pairs were included and the 
experiment was performed in duplicate. 
Transcriptome analysis
A two-color microarray-based gene expression analysis was performed on a custom-
made 60-mer oligonucleotide array (Agilent Biotechnologies, submitted in GEO under 
platform GPL9359) to determine the global gene transcription levels of WCFS1 and the 
lp_2991 deletion mutant. Cy3- and Cy5-labeled cDNAs were prepared using a Cyscribe 
post labeling kit (GE Healthcare, Bucks, United Kingdom). Slides were prehybridized for 
45 min at 42°C in 20 ml prehybridization solution (1% bovine serum albumin, 5× SSC, 
0.1% sodium dodecyl sulfate; filtered) (1× SSC is 0.15 NaCl plus 0.015 M sodium citrate), 
washed in filtered deionized water, and dried. Co-hybridization with Cy5- and Cy3-la-
beled cDNA probes was performed overnight at 42°C for 16 h in Slidehyb#1 (Ambion, 
Austin, TX). The slides were then washed twice in 1× SSC-0.1% sodium dodecyl sulfate 
and twice in 1× SSC before they were scanned. The experiment was repeated with Cy5/
Cy3 dye swaps.
Slides were scanned with a ScanArray Express 4000 scanner (Perkin Elmer, Wellesley, 
USA), and image analysis and processing were performed using the ImaGene Version 7.5 
software (BioDiscovery Inc., Marina Del Rey, CA, USA). The microarrays were scanned at 
different intensities. For each of the individual microarrays the best scan was selected 
on the basis of signal distribution (combination of a low number of saturated spots and 
a low number of low signal spots). The data were normalized using Lowess normaliza-
tion as available in MicroPrep [54]. The data were corrected for inter-slide differences 
on the basis of total signal intensity per slide using Postprep [54]. The median intensity 
of the different probes per gene was selected as the gene expression intensity. CyberT 
was used to compare the different transcriptomes, taking into account the duplicates 
(dye swaps) of each of the conditions [55]. This analysis resulted in a gene expression 
ratio and false discovery rate (FDR) for each gene. Genes with FDR values <0.05 were 
considered to be statistically significant. All microarray data is MIAME compliant and 
are available in GEO.
Statistical analysis
Mixed general linear model using restricted maximum likelihood (REML) was used to 
determine the statistical differences within donors between cytokines produced by DCs 
stimulated with the constructed deletion mutants compared to the wild type L. plan-
tarum WCFS1. A two-sided p-value of 0.05 or lower was considered to be significant. 
The statistical analysis was performed by using SAS software (version 9.1, SAS Institute 
Inc., Cary, NC, USA).
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Results
DC cytokine responses to different L. plantarum strains
Monocyte derived immature dendritic cells were cultured in the presence of 42 dif-
ferent L. plantarum strains. Based on the variation in CD83 and CD86 expression and 
cytokine secretion, 20 strains were selected to repeat the culturing with monocyte de-
rived DCs from 5 different donors. The strains differed considerably in their ability to 
modulate DC responses (Fig. S1 and Fig. 2). For example, the amounts of IL-10 induced 
by the strains ranged from 28 pg/mL to 1095 pg/mL (39 fold) and for IL-12 the values 
ranged from 20 to 11996 pg/mL (600 fold). For TNF-a some strains induced very low 
amounts (close to the detection limit of 0.7 pg/mL) whereas others induced 8.4 to 12 
ng/mL (Fig. 2 and Table 2). The large variation in strain immune profiles suggested that 
there could be some underlying strain-dependent genetic differences influencing the 
innate response to L. plantarum.
Some strains such as NIZO2766, NIZO2801 and NIZO2897 were clearly strong inducers 
of pro-inflammatory cytokines IL-12 and TNF-a while others were considerably less po-
tent (e.g. strains NIZO1839, NIZO2494 and NIZO2831; Fig. 2 and Table 2). 
Figure 2. Cytokine secretion by DCs. IL-10, TNF-a and IL-12p70 production by monocyte-derived den-
dritic cells derived from blood of five different donors after stimulation with 20 different L. plantarum 
strains. Each symbol represents a different L. plantarum strain.
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Similarly, the strains showed strikingly different capacities to induce the anti-inflam-
matory cytokine IL-10. From a comparison of IL-12 to IL-10 ratios it is clear that these 
cytokines can vary independently of each other allowing the possibility for strains with 
distinct pro-inflammatory (e.g. strain NIZO1840 and NIZO2257) and anti-inflammatory 
profiles (e.g. strain CIP104448). As expected levels of cytokines induced by L. plantarum 
strains differed between donors but the ranking of the strains was highly consistent for 
each cytokine showing that the strain immunoprofiles were reproducible (Fig. 2).
Table 2. Ranges of DC cytokine induction by L. plantarum strains.
Identification of candidate gene loci by in silico gene trait matching
L. plantarum genes potentially involved in the production of pro- and anti-inflammatory 
cytokines were identified by in silico gene-trait matching by correlating measurements 
of cytokines induced by the different strains with their genotypic information based 
on comparative hybridisation to a whole genome microarray [44-45]. Seven genes dis-
played a match with lower levels of IL-10 concentration in the co-culture system. One of 
these genes, lp_2991 is annotated as a transcription regulator (Table 3) which is present 
in 90% of the strains tested. The other six genes (lp_0422, lp_0423, lp_0424a, lp_0424, 
lp_0425 and lp_0429) lie within the plantaricin locus (lp_0403 to lp_0431) involved in 
plantaricin biosynthesis and secretion. The plnEFI operon (lp_0419 to lp_0422) is en-
coding two bacteriocin-like peptides and a bacteriocin immunity protein. Homologues 
of the gene loci in this operon are present in 81-85% of the tested strains. Lp_0423 is 
distal to lp_0422 and located in another operon and encodes an ABC transporter in-
volved in the transport of bacteriocins [56, 57]. Lp_0423 (plnG) is present in 88% of the 
tested strains [58].
Three genes (lp_2991, lp_0422 and lp_3536) had a gene-trait match with a lower con-
centration of TNF-a produced in the supernatant of L. plantarum DC co-culture (Table 
61
Chapter 3
3). There was a co-occurrence of low TNF-a secretion and the presence of lp_2991 and 
lp_3536. Lp_3536 is predicted to encode a bile salt hydrolase capable of removing the 
amino acid moiety from the steroid nucleus of conjugate bile salts by hydrolysis and is 
present in 81% of the tested strains.
Table 3. Candidate genes identified by gene trait matching.
Validation of the role of the candidate genes in cytokine secretion
To further investigate the role of the genes identified by gene-trait matching in modu-
lating DC cytokine secretion, specific gene-replacement mutants of genes lp_2991 and 
lp_0423 were constructed in L. plantarum strain WCFS1, to yield strains lp_2991::cat 
and plnG::cat. Construction of the bsh1::lox72, plnGHSTUVWX::lox72 and plnEFI:lox72 
mutant is described in the Material and Methods section above. The capacity of the 
deletion mutants to induce IL-10, IL-12p70 and TNF-a production by DCs was higher 
than compared to the wild-type strain L. plantarum WCFS1. As predicted on basis of 
the gene-trait correlation, deletion mutants lacking genes involved in plantaricin se-
cretion and immunity induced significantly higher amounts of IL-10 in DC co-culture 
compared to the wild type strain WCFS1 (Fig. 3 and Table 4). For mutant plnEFI::lox72 
in which the two bacteriocin-like peptides and a bacteriocin immunity protein were 
deleted, IL-10 was significantly increased 3.3 fold (p<0.05). Deletion of the pheromone 
and bacteriocin transport operon (plnGHSTUVWX), in strain plnGHSTUVWX::lox72 also 
significantly increased IL-10 3.1-fold (p<0.05) compared to the wild type strain WCFS1. 
Similar increases (3.2 –fold; p<0.05) were also observed for plnG::cat (Fig. 3 and Table 
4). In the plnEFI, plnGHSTUVWX and plnG mutants TNF-a secretion was significantly 
increased by 4.2-fold (p<0.05), 4.1-fold (p<0.05) and 7.4 fold (p<0.05) respectively. In 
all plantaricin associated mutants IL-12p70 secretion was also significantly (p<0.05) in-
creased between 1.9 and 2.4 fold.
The presence of the lp_2991 gene in strains was associated with induction of lower 
amounts of IL-10 and TNF-a secretion compared to strains lacking this gene. As pre-
dicted by gene-trait correlation analysis, deletion of this gene in wild type strain WCFS1 
significantly increased IL-10 and TNF-a secretion compared to the wild type strain. IL-10 
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secretion was increased 6.3-fold (p<0.05) and TNF-a secretion was increased 17.2-fold 
(p<0.05). Additionally, IL-12p70 secretion was induced 3.2-fold (p<0.05) (Fig. 3 and Ta-
ble 4). Deletion of lp_3536 (strain lp_3536::loxp72) had no significant effect on cytokine 
production compared to the wt strain (Fig. 3 and Table 4). In conclusion four of the five 
deletion mutants showed the predicted effect on DC immune responses.
Table 4. Validation of the candidate genes knock out mutants.
Transcriptome analysis
Transcriptomes of the WCFS1 and lp_2991 deletion mutant were compared to obtain 
an expression ratio for each gene. Genes with FDR values <0.05 were considered signifi-
cant. Of the 3100 genes present on the microarray 33 genes were significantly upregu-
lated in the lp_2991 deletion mutant and 25 genes were significantly downregulated 
(Table S2).
In the lp_2991 deletion mutant, the gene lp_2991 signal was not significantly differ-
ent to the wild type due to the very low expression (signal) level. In the mutant the 
most highly increased transcript (44.7-fold) was the gtcA3 gene which is predicted to 
be involved in glycosylation of cell wall teichoic acids including LTA which is an agonist 
of TLR-2. Another gene associated with cell envelope structures that showed increased 
expression in the mutant was tagO (4.4-fold), encoding an enzyme involved teichoic 
acid synthesis. A group of 6 genes involved in nucleoside and nucleotide synthesis were 
4.1 to 17 fold higher in the mutant as was the purR1 pyrimidine operon regulator (2.6 
fold). The reasons for this are not clear but these genes are regulated by several factors 
and are often differentially expressed in microarray experiments (unpublished results 
Michiel Kleerebezem). Transcript levels of several genes encoding hypothetical proteins 
and transporters were either increased or decreased in the mutant compared to the 
wild type. In the mutant, the largest decrease in expression was for lp_2531 which is 
predicted to be a PTS transporter for N-acetylglucosamine and glucose.
RT-PCR results
Quantitative reverse transcription-PCR (RT-PCR) was performed to validate the results 
of the transcriptome analysis for mntH2 and gctA3 using RNA isolated from the WCFS1 
and delta-lp_2991 strains. The specificity of the PCR products was confirmed by
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Figure 3. Validation of the candidate genes in different deletion mutants of L. plantarum WCFS1. IL-10, 
IL-12p70, and TNF-a secretion by monocyte derived dendritic cells after stimulation with different L. 
plantarum deletion mutants and the wild type strain WCFS1. Data are presented as the mean +/− 
standard error of the mean from five donors of duplicate wells. Differences between wild-type and 
mutant were calculated according mixed general linear model using REML. A two-sided p-value of 0.05 
or lower was considered to be significant, indicated by *.
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a combination of melting curve analysis and 1.5% agarose gel electrophoresis (data not 
shown). The gtcA3 gene which lies directly downstream of lp_2991 was indeed strongly 
up-regulated (29.6 fold) in the mutant strain suggesting that it is normally repressed by 
lp_2991 under these growth conditions (Fig. 4). In contrast transcript levels of mntH2, 
which is orientated in the opposite direction to lp_2991 were only modestly altered in 
the deletion mutant (1.8 fold) suggesting that this gene is not directly regulated by the 
putative transcription regulator. The lp_2991 gene was expressed in strain WCFS1 but 
no specific PCR product was amplified for in the lp_2991 deletion mutant as expected.
Figure 4. Relative gene expression levels determined by quantitative RT-PCR. RNA prepared from the 
wild type WCFS1 strain and lp-2991 deletion mutant was used for quantitative RT-PCR. The average Ct 
values observed for the target gene transcripts (lp_2991, mntH2 and gtcA3) were normalized to the 
average Ct values obtained for the reference gene recA from the same RNA sample. Two replicates 
of all samples and primer pairs were included and the experiment was performed in duplicate. Fold 
changes in transcript level were calculated by using the comparative ΔΔCt method described by Pfaffl  
[53].
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Discussion
In this study we aimed to determine whether 42 different strains of L. plantarum, sever-
al strains of which are currently marketed as probiotics, possess different immunomo-
dulatory properties in co-culture with DCs. Additionally, we aimed to identify genetic 
loci of L. plantarum WCFS1, that influence the immune response using comparative ge-
nome hybridization data and a gene-trait matching approach. The L. plantarum strains 
differed considerably in their ability to induce pro- and anti-inflammatory cytokines. Im-
mune responses to strain NIZO1839 were strikingly lower than for all other strains sug-
gesting that it might directly attenuate immune responses, possess non-typical MAMPs 
or produce a capsule-polysaccharides that interferes with innate recognition [59]. The 
amounts of IL-10 induced by the 42 strains ranged from 28 pg/mL to 1095 pg/mL (39 
fold) and IL-12 measurements ranged from 20 to 11996 pg/mL (600 fold). The amounts 
of TNF-a induced by the strains ranged from very low (close to the detection limit of 
0.7 pg/mL) to more than 8.4 ng/mL. These ranges are higher than those reported for 
different Bifidobacterium longum strains (8-fold) [60] and for multiple Lactobacillus and 
Bifidobacterium species in PBMC co-culture assays (10–15 fold) [26], [60-63]. The high-
est IL-10 secreting cells in PBMCs are the monocytes which typically represent about 
8% of the total leucocytes. This could explain why a larger range of IL-10 measurements 
were obtained in our experiments using a pure dendritic cell population. The strain 
differences observed in our experiments were not due to variation in CFU of bacteria 
as the samples used in the assays were checked twice by plating on solid medium and 
measurements of optical density (OD600 nm).
Probiotics might affect the immune system by the induction of regulatory T cells [64, 
65]. Recently a study was published suggesting that probiotics may not directly gener-
ate regulatory T cells but induce regulatory DCs via the differentiation of naïve T cells 
into regulatory T cells in the mesenteric lymph nodes [12]. Regulatory T cells are impor-
tant in immunological tolerance by the suppression of effector T cells at inflammatory 
sites. The study by Kwon et al. [12] underlines the important role of dendritic cells in the 
induction of regulatory T cells and how in vitro assays (as described in this study) can 
be used for the selection of probiotic strains and species that have therapeutic effects 
in models of inflammatory bowel disease, atopic dermatitis and rheumatoid arthritis.
The large variation in strain immune profiles suggested that there could be some under-
lying strain-dependent genetic differences influencing the innate response to L. plan-
tarum. Therefore results from the cytokine secretion by the DCs or concentration ratios 
were correlated with the gene presence/absence patterns in the L. plantarum strains by 
regression using the Random Forest algorithm. The output of the algorithm is a model 
(forest) consisting of many different decision trees. As an output of the algorithm im-
portance measures for each individual gene of the L. plantarum WCFS1 genome are 
given. Genes that score with high importance show a high correlation with the tested 
immune response and are therefore the most likely candidates to cause the change in 
immune response. The Random Forest Algorithm model has been used for many appli-
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cations in bioinformatics, for example to identify single nucleotide polymorphisms pre-
dictive of a certain phenotype [66], and to select disease marker genes from microarray 
gene expression datasets relevant for the prediction of a certain disease [67].
This approach allowed us to identify eight variable L. plantarum genes which influence 
the immune response of DCs to L. plantarum. Other genes influencing the immune re-
sponse of DC may also exist but were not picked up in this screen because a natural mu-
tant was not present in the strain collection. For example, this would include essential 
genes involved in the production of MAMPs such as peptidoglycan and LTA that form 
key structural elements of the bacterial the cell wall. Nevertheless, differences in these 
structures are known to occur due to modifying enzymes which can affect recognition 
by innate receptors. Point mutations or small deletions that alter bacterial gene expres-
sion or protein activity could also modulate the immune response but these would not 
be detected using this approach. As the genome comparison is based on strain WCFS1, 
genes present in the other strains but not in WCFS1 may also be involved in immu-
nomodulation. Six of the identified genes were located in operons linked to bacteriocin 
production or secretion, the other two encode a bile salt hydrolase and a predicted 
transcriptional regulator of which the exact function is unknown. Deletion mutants of 
the candidate genes were constructed in the WCFS1 strain in order to validate their an-
ticipated effect on cytokine induction and all but one (the bile salt hydrolase) affected 
the immune response as predicted by the direction of the correlation. The identifica-
tion of false positive candidate genes has been reported previously, e.g. only one of the 
two candidate mannose-specific adhesin genes identified by gene trait matching was 
shown to be correct [28]. As far as we know this is the first time a comparative genome 
hybridization approach has been used to identify bacterial gene loci that modulate host 
immune responses.
Most of the candidate genes influencing the immune response were involved in bac-
teriocin production and secretion. Bacteriocins are antimicrobial peptides secreted by 
bacteria that inhibit the growth of closely related micro-organisms. Bacteriocins pro-
duced by lactic acid bacteria have received special attention due to their potential use 
as food preservatives [68]. For example, the bacteriocin called nisin A and nisin-produc-
ing strains of Lactococcus lactis are used commercially worldwide in dairy products, as 
a bio-preservative [69, 70]. Among the different bacteriocins described in L. plantarum 
strains [56, 71-73], the complex pln regulon is the best known. This system is organized 
into five operons (see Fig. 1). The regulatory operon (plnABCD) encodes an inducing 
bacteriocin-like peptide (plnA), a histidine protein kinase (HPK) (plnB), and two cyto-
plasmic response regulators (RR) (plnC and plnD). Another operon (plnGHSTUVWX) is 
associated with plantaricin transport and the operons (plnJKLR, plnMNOP, plnEFI) are 
related to plantaricin production and immunity [56, 74]. Genes plnW, plnX and plnY 
are related to membrane integral proteins and other plantaricin biosynthesis proteins. 
Deletion mutants were constructed for plnG and the operons plnEFI and plnGHSTU-
VWX. All the deletion mutants of these gene loci induced significantly increased levels 
of IL-10 secretion (3.3-fold), IL-12p70 (2.4-fold) and TNF-a (7.4 fold) compared to the 
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wild-type strain WCFS1. It is possible that the bacteriocin secreted by L.plantarum af-
fects the DC immune response because some human antimicrobial peptides have also 
been shown to activate Toll-like receptors and modulate immune functions [56, 75, 76]. 
Three independent approaches, namely (in vivo expression technology (R-IVET, [77]), 
qRT-PCR [78] and transcriptomics [79] showed that the expression of the L. plantarum 
plantaricin immunity protein PlnI is induced in the mouse intestine, suggesting that it 
may be important in vivo.
Lp_2991 was one of the candidate genes identified during the in silico gene-trait match-
ing. DC stimulation with the deletion mutant of lp_2991 led to a significantly higher se-
cretion of IL-10, IL-12p70 and TNF-a compared to the wild-type control (Table 4 and Fig. 
3). Lp_2991 encodes for a predicted transcriptional regulator gene upstream of gtcA3, a 
putative teichoic acid glycosylation protein. Upstream of lp_2991 is a manganese trans-
port gene mntH2 which is orientated in the opposite direction.
Transcriptome analysis and qPCR data showed that transcript level of gtcA3 was sub-
stantially increased in the lp_2991 deletion mutant (44 and 29 fold respectively). This 
supports the idea that lp_2991 is a repressor of gtcA3 transcription and points to this 
enzyme as being a prime candidate for the altered immune response. GtcA3 is pre-
dicted to glycosylate teichoic acid including lipoteichoic acid (LTA) which is a known 
TLR-2 agonist capable of modulating immune cell responses. Modification of LTA e.g. by 
substitution can have striking effects on the immune response as shown by Grangette 
et al., using a mutant in which dltB was deleted [30]. DltB is a putative transmembrane 
protein predicted to be involved in the passage of the activated D-alanyl-Dcp complex 
across the glycerol phosphate backbone of LTA. The dltB mutant of L. plantarum in-
creased IL-10 secretion and dramatically raised the IL-10/IL-12 ratio in PBMC co-culture 
assays. In our experiments the lp_2991 deletion mutant also led to an increased IL-10 
secretion in immune assays (6.3 fold) compared to wild type strain but the IL-10/IL-12 
ratio was only slightly elevated due a corresponding increase in the induced levels of 
IL-12 (3.2-fold).
As the transcript levels of gtcA3 were increased 44 fold in the lp_2991 deletion mutant 
and this enzyme is predicted to glycosylate TA or LTA we consider it most likely to be 
responsible for the altered immune response. However, we cannot rule out possible 
effects due to changes in mntH2 gene expression which was modestly affected in the 
mutant (1.8 and 2.4 fold increase by qPCR and transcriptome analysis respectively). 
Manganese is an important element involved in the protection of L. plantarum against 
oxidative stress [80]. One uptake mechanism described is the Mn (2+) and Cd (2+)-spe-
cific P-type ATPase MntA. Besides mntA, WCFS1 encodes an ABC transporter system 
(mtsCBA) and three genes encoding Nramp transporters (mntH1, mntH2 and mntH3)
[80]. Studies conducted in pathogenic bacteria have shown that Nramp transporter mu-
tants are less virulent [81] due to the role of Nramp in sequestering of Mn(2+) which is a 
cofactor for enzymes that protect against host oxidative killing mechanisms. The muta-
tion of lp_2991 may increase manganese transport and therefore enhance survival of 
lactobacilli in the phagolysosome. This may alter the kinetics and magnitude of the im-
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mune response due to altered release of ligands for host pattern recognition receptors.
This study emphasizes the usefulness of in silico gene-trait matching in assessing the 
role of specific bacterial genes in the interaction with the host immune system, an ap-
proach that is fully supported by the recent availability of full genome sequences for 
some lactobacilli. Screening with another L. plantarum than WCFS1 may also lead to 
the identification of other genes influencing the immune response. In the future this 
knowledge may be useful to select probiotic strains with anti-inflammatory or immune 
stimulatory properties. Future work is aimed at understanding the role of the genes we 
have identified in modulating the immune response to L. plantarum.
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Figure S1. CD83 and CD86 expression by monocyte-derived dendritic cells derived from blood of five 
different donors after stimulation with 20 different L. plantarum strains. Each symbol represents a dif-
ferent L. plantarum strain.
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Table S1. Origin of bacterial strains used in this study.
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Table S2 Transcriptome analysis of WCFS1 and lp_2991 deletion mutant.
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Abstract
Background
Modulation of the immune system is one of the most plausible mechanisms underly-
ing the beneficial effects of probiotic bacteria on human health. Presently, the specific 
probiotic cell products responsible for immunomodulation are largely unknown. In this 
study, the genetic and phenotypic diversity of strains of the Lactobacillus plantarum 
species were investigated to identify genes of L. plantarum with the potential to influ-
ence the amounts of cytokines interleukin 10 (IL-10) and IL-12 and the ratio of IL-10/
IL-12 produced by peripheral blood mononuclear cells (PBMCs).
Results
A total of 42 Lactobacillus plantarum strains isolated from diverse environmental and 
human sources were evaluated for their capacity to stimulate cytokine production in 
PBMCs. The L. plantarum strains induced the secretion of the anti-inflammatory cy-
tokine IL-10 over an average 14-fold range and secretion of the pro-inflammatory cy-
tokine IL-12 over an average 16-fold range. Comparisons of the strain-specific cytokine 
responses of PBMCs to comparative genome hybridization profiles obtained with L. 
plantarum WCFS1 DNA microarrays (also termed gene-trait matching) resulted in the 
identification of 6 candidate genetic loci with immunomodulatory capacities. These loci 
included genes encoding an N-acetyl-glucosamine/galactosamine phosphotransferase 
system, the LamBDCA quorum sensing system, and components of the plantaricin (bac-
teriocin) biosynthesis and transport pathway. Deletion of these genes in L. plantarum 
WCFS1 resulted in growth phase-dependent changes in the PBMC IL-10 and IL-12 cy-
tokine profiles compared with wild-type cells.
Conclusions
The altered PBMC cytokine profiles obtained with the L. plantarum WCFS1 mutants 
were in good agreement with the predictions made by gene-trait matching for the 42 L. 
plantarum strains. This study therefore resulted in the identification of genes present in 
certain strains of L. plantarum which might be responsible for the stimulation of anti- or 
pro-inflammatory immune responses in the gut.
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Introduction
Metagenomics and host-microbe molecular interaction studies are rapidly expanding 
our understanding of the indigenous gut microbiota and the contributions of microbes 
to human health [1,2]. These efforts are complementary to the numerous reports de-
scribing health benefits associated with the ingestion of probiotic bacteria [3,4]. Pro-
biotics are living microorganisms which confer health effects on the host when admin-
istered in sufficient amounts [5]. Strains of Lactobacillus and Bifidobacterium are the 
most commonly applied probiotics in food products. Members of these genera are resi-
dents of the human intestine and have a long history of safe use in foods and beverages. 
Health benefits conferred by probiotics can be specific to the gastrointestinal tract (e.g. 
protection against intestinal inflammation or enteric pathogens) or occur at peripheral 
mucosal sites in the human body (e.g. prevention of allergy or dermatitis) [6].
There is substantial evidence that an important mechanism by which probiotics pro-
vide health benefits is through modulation of immune functions [7-11]. Differences 
among probiotic strains to stimulate immune cells towards pro- and anti-inflammato-
ry responses have been shown in studies measuring cytokine production in vitro [7-
11]. These comparisons have resulted in the identification of strains inducing similar 
responses in vivo. For example, ratios of IL-10 to IL-12 produced by peripheral blood 
mononuclear cells (PBMCs) in response to different probiotics in vitro were correlated 
to their protective capacity in a mouse model of colitis [10]. Similarly, recent studies on 
the mechanisms of probiotics highlight their effects on epithelial barrier function via 
Toll-like receptor 2 signaling and the generation of regulatory dendritic cells and regula-
tory CD4+Foxp3+ T cells in peripheral tissues [12,13]. The latter mechanism is linked to 
the administration of a collection of five strains which induced a high IL-10/IL-12 ratio 
in co-culture with immune cells [12]. Administration of these strains was shown to have 
a therapeutic effect in experimental mouse models of inflammatory bowel disease, at-
opic dermatitis, and rheumatoid arthritis and was associated with enrichment of CD4+ 
Foxp3+ Tregs in the inflamed regions [12].
The cell products of probiotics that are responsible for modulation of cytokine induc-
tion are largely unknown but might involve modifications of some of the known mi-
crobe associated molecular patterns (MAMPs) such lipoteichoic acids (LTA) [14-16] and 
(lipo)proteins localized on the bacterial cell surface [17] which interact with Toll-like 
receptors. Additionally cell-surface associated bacterial glycosylated proteins or exopo-
lysaccharides [18] may interact with other host pattern recognition receptors including 
the C-type lectins and scavenger receptors found on antigen presenting cells [19]. These 
extracellular and secreted products produced by probiotic cells are the likely targets for 
strain-dependent interactions with host cells and have been the focus of several recent 
reviews [6,20,21].
Certain strains of Lactobacillus plantarum are marketed as probiotics and reported to 
confer various health effects including immunomodulation [22]. The genome sequence 
of L. plantarum strain WCFS1 is known [23] and extensive bioinformatics tools [24,25], 
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molecular models [26], and a database of genome hybridization profiles [27,28] are 
available for this organism. It is a single colony isolate of strain NCIMB8826, which was 
shown to survive gastrointestinal passage after oral administration to healthy volun-
teers [29]. Global gene expression profiling of L. plantarum WCFS1 in the intestinal con-
tents of the human gut and conventionally-raised and germ-free mice has shown that 
this organism adapts for growth in vivo by modification of its cell-surface composition 
and metabolism in a diet-dependent manner [30-34]. Human duodenal transcriptio-
nal response profiles have also been obtained in response to ingestion of L. plantarum 
WCFS1 [35,36]. Notably, exponential phase and stationary phase L. plantarum WCFS1 
cells elicited distinct human duodenal transcript profiles which appeared to mainly 
result from differential modulation of canonical NF-κB-dependent signaling pathways 
associated with immune tolerance [35]. The aim of the present study was to identify 
genes involved in immunomodulation by L. plantarum WCFS1. The IL-10 and IL-12 cy-
tokine levels elicited by PBMCs upon stimulation with L. plantarum WCFS1 and 41 other 
Lactobacillus plantarum strains were determined. We compared the IL-10 and IL-12 
stimulating phenotypes of each strain to its genome composition determined by com-
parative genome hybridization (CGH) to identify candidate L. plantarum genes with the 
capacity to affect cytokine production in PBMCs. The immunomodulatory potential of 
these gene products was confirmed for L. plantarum WCFS1 gene deletion mutants and 
found to be dependent on the growth-phase of the L. plantarum cultures.
Results
Immunomodulation of PBMCs is a variable phenotype in L. plantarum
A total of 42 L. plantarum strains from distinct (fermented) food, environmental, and 
gastrointestinal sources (Table 1 and [27,28]) were investigated for their capacities to 
stimulate PBMCs to produce the cytokines IL-10 and IL-12. Comparisons of cytokine 
amounts induced among different donors in response to the L. plantarum strains 
showed that the L. plantarum cultures induced a similar range of IL-10 but up to 10-
fold different levels of IL-12 (Figure 1). This result is in agreement with previous studies 
showing that PBMCs respond differently depending on the donor from which the cells 
were isolated [37]. However, the capacity of individual L. plantarum strains to induce 
cytokines production in PBMCs was similar among the different donors relative to the 
other strains tested. For example, L. plantarum KOG18 consistently induced the highest 
amounts of IL-12 whereas strain CIP104448 induced the highest ratios of IL-10 to IL-12. 
Collectively, the 42 L. plantarum strains induced, on average, IL-10 and IL-12 in PBMCs 
over a 14- and 16 - fold range, respectively, and IL-10/IL-12 ratios over a 13.5 - fold range 
(Figure 1). Strain WCFS1 induced relatively low IL-10 amounts (between 440 and 780 
pg/ml), moderate amounts of IL-12 (between 20 and 260 pg/ml), and consequently a 
moderate to low IL-10/IL-12 ratio (bottom quartiles) compared with the other strains 
(Figure 1).
83
Chapter 4
Table 1. L. plantarum strains selected for genotyping and screening for immunomodulatory capacity.
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Figure 1. Cytokine secretion by PBMCs after 24 h co-culture with L. plantarum strains. IL-10 (A) and IL-
12 (B) production and the IL-10/IL-12 ratio (C) by peripheral blood mononuclear cells (PBMCs) derived 
from blood of 3 different healthy donors after stimulation with 42 different L. plantarum strains har-
vested in stationary-phase. The L. plantarum strains grown and prepared on separate days constitute 
set 1 and set 2. PBMCs isolated from donor A were inoculated with L. plantarum culture set 1 (A-1) and 
PBMCs from donor B were inoculated with the L. plantarum replicate set 2 (B-2). PBMCs from Donor C 
received both sets of cultures and the mean of the IL-10 and IL-12 amounts induced by these cultures 
is shown. Each symbol represents a different L. plantarum strain or the PBS or LPS controls.
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Identification of candidate genes involved in immunomodulation
To identify candidate L. plantarum genes involved in the modulation of the immune 
response, Random Forest models [38] were used to compare L. plantarum CGH profiles 
with the relative amounts of IL-10 and IL-12 and IL-10/IL-12 ratios induced by the strains 
in co-culture with PBMCs (Figure 1). PBMCs from different donors incubated with rep-
licate L. plantarum cultures were used for these models to take into account the levels 
of variation in cytokine production. Comparisons of L. plantarum strain genotype to the 
IL-10-stimulating capacities resulted in the identification of 6 different chromosomal 
loci and a total of 13 genes that might influence IL-10 production or hte IL-10/IL-12 ratio 
(Table 2). In comparison, concise correlations between L. plantarum CGH profiles and 
IL-12 amounts were not found. One of the genes correlated with IL-10 amounts was 
L. plantarum WCFS1 lp_1953. L. plantarum strains harboring this gene stimulated the 
production of IL-10 in 1.6-fold higher amounts, on average, compared to L. plantarum 
strains for which this gene was absent. Lp_1953 encodes a hypothetical intracellular 
protein of unknown function [25]. The remaining five genes with putative roles in IL-
10 modulation comprise a putative 5 gene operon (lp_2647 to lp_2651) encoding Pt-
s19ADCBR, an N-acetyl-galactosamine/glucosamine phosphotransferase system (PTS). 
Strains harboring these genes were associated with induction of lower amounts of IL-10 
by PBMCs.
Table 2. L. plantarum genes with putative roles in modulating PBMC cytokine production.
a Gene number on the L. plantarum WCFS1 chromosome [23].
b Percentage of L. plantarum strains containing the gene according to CGH [27,28].
c Gene-trait matching importance measures (in parentheses) and predicted effects of the gene(s) on the variable 
and average magnitude and direction (higher or
lower) of IL-10 and IL-10/IL-12 amounts.
Comparisons between L. plantarum strain-specific CGH profiles and IL-10/IL-12 ratios 
from PBMCs resulted in the identification of four L. plantarum WCFS1 loci which cor-
related with IL-10/IL-12 values (Table 2). L. plantarum WCFS1 plnEFI and plnG (lp_419-
423) and lamB (lp_3582) were most commonly present in strains stimulating low IL-10/
IL-12 ratios. These genes are under the control of the auto-inducing peptide (AIP)-based 
quorum sensing (QS) two-component regulatory systems (QS-TCSs) found in L. planta-
rum [39,40]. The genes plnEFI and plnG encode two bacteriocin peptides, a bacteriocin 
 
Gene(s)  Gene number 
a
Product
Percent of 
strains with the 
gene(s) b
Gene-dependent contribution to 
cytokine stimulation c
  lp_1953 lp_1953 Hypothetical protein 48    IL-10 (0.29)               1.6-fold  
  pts19ADCBR lp_2647-2651                                          N-galactosamine PTS, EIIADCB and 
transcription regulator, GntR family
33    IL-10 (0.16)               1.7-fold 
  plnEFI lp_0419-0422 Immunity protein plnI 81-85    IL-10 / IL-12 (0.35)    1.7-fold
Bacteriocin like peptide plnF
Bacteriocin like peptide pln E
  plnG lp_0423 ABC transporter 88    IL-10 / IL-12 (0.13)    1.8-fold  
  lamB lp_3582 Accessory gene regulator protein 43    IL-10 / IL-12 (0.14)    1.3-fold 
  Prophage P2b 1 and 21 lp_2460 Prophage P2b protein 21 38    IL-10 / IL-12 (0.17)    1.5-fold  
lp_2480 Prophage P2b protein 1, integrase
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immunity protein, and an ATP - Binding Cassette (ABC) transporter [23,41]. The lamB is 
the first gene in the L. plantarum lamBDCA operon and shows 30% amino acid identity 
to the S. aureus AgrD-processing protein AgrB required for AIP modification and ex-
port [39]. The other L. plantarum genes associated with specific IL-10/IL-12 ratios are 
lp_2460 and lp_2480 coding for prophage R-Lp3 remnant proteins P2b protein 21 and 
1, respectively [23]. These genes are conserved among L. plantarum strains stimulating 
high IL-10/IL-12 ratios in PBMCs. The functions of prophage R-Lp3 and other complete 
prophages in the L. plantarum WCFS1 genome are not known [42]. Because the differ-
ent prophages found in L. plantarum WCFS1 share high levels of sequence homology 
and potential functional redundancy [42], these genes were not examined further.
Verification of the roles of the candidate genes in immunomodulation
To validate the influence of the candidate L. plantarum genes on PBMC cytokine re-
sponses, lp_1953, pts19ADCBR, plnEFI, and plnG deletion mutants were constructed 
for L. plantarum WCFS1. A previously constructed L. plantarum WCFS1 lamA (lp_3580)
lamR (lp_3087) double mutant was used to examine the potential roles of the lamB-
CDA QS-TCS on PBMCs. This strain was selected because lamA and lamR encode the 
response regulators of the 2 TCS (lamBCDA and lamKR) regulating the expression of the 
LamD AIP in L. plantarum WCFS1 [40]. In the ΔlamA ΔlamR mutant, expression levels 
of lamB and the other genes in this operon were at 5% of the levels found in wild-type 
cells [40].
Wild-type and mutant L. plantarum WCFS1 cells harvested in the stationary- and ex-
ponential phases of growth were examined for their capacity to stimulate IL-10 and 
IL-12 in PBMCs. Overall, among the donors examined, IL-10 and IL-12 were produced 
in response to L. plantarum at levels between 500 to 4500 pg/ml and 3 to 68 pg/ml, 
respectively (shown as log2 values in Figure 2 and 3). Notably, exponential cultures of 
wild-type L. plantarum WCFS1 and most mutant strains stimulated PBMCs to secrete 
higher amounts of IL-10 and IL-12 than stationary-phase cells (Figure 2 and 3).
L. plantarum strains harboring the plnEFI, plnG or lamB loci were associated with the 
stimulation of lower IL-10/IL-12 ratios by L. plantarum in the PBMC assay (Table 2). 
In agreement with the gene-trait correlations, the plnEFI, plnG, and lamA lamR dele-
tion mutants of strain WCFS1 induced higher IL-10/IL-12 ratios than the wild-type strain 
(Figure 4 and Table 3). However, the effects of the plnEFI deletion on cytokine induc-
tion in different donors was not highly significant compared to wild-type L. plantarum 
when the p value was adjusted for multiple hypothesis testing (adjusted (adj.) p value 
= 0.071) (Figure 4 and Table 3). Mutants deficient in the ABC- transporter plnG induced 
significantly higher cytokine ratios compared with L. plantarum wild-type cells (Figure 
4 and Table 3). These differences were observed only for wild-type and mutant cells 
harvested during exponential phase growth (adj. p value = 0.005). Immunomodulation 
of the ΔlamA ΔlamR mutant was also substantially different compared to wild-type L. 
plantarum WCFS1. The ΔlamA ΔlamR mutant induced significantly higher IL-10/IL-12 
ratios (adj. p value = 0.016) and IL-12 (adj. p value < 0.001) and IL-10 (adj. p value 
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< 0.001) amounts in PBMCs (Table 3). These effects were partially dependent on the 
growth-phase of the L. plantarum cells. IL-10/IL-12 ratios and IL-10 amounts induced by 
wild-type and mutant cells were significantly different when exponential phase cultures 
were used in the PBMC assay, whereas IL-10 and IL-12 amounts also differed when 
stationary-phase cells were examined (Figure 2, 3, 4 and Table 3).
Figure 2. Boxplots of IL-10 amounts produced by PBMCs in response to L. plantarum wild-type and 
mutant cells. 2Log transformed IL-10 amounts induced by exponential and stationary phase L. plan-
tarum cells are shown. The dots indicate the median value, the boxes indicate first and third quartile, 
and the whiskers extend to outlying data points for a total of 12 measurements (3 PBMC donors were 
measured using 4 replicate cultures of each L. plantarum strain).
In agreement with the gene trait matching correlations, the Δpst19ADCBR mutant in-
duced significantly higher amounts of IL-10 than wild-type L. plantarum (adj. p value = 
0.031) (Figure 2 and Table 3). Similarly, the IL-10/IL-12 ratio was significantly higher (p 
< 0.001) upon stimulation with L. plantarum Δpst19ADCBR compared with the parental 
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strain (Figure 4 and Table 3). L. plantarum strains harboring lp_1953 were also pre-
dicted to induce higher IL-10 production levels compared with strains lacking this gene. 
However, the L. plantarum lp_1953 deletion mutant stimulated equivalent amounts of 
IL-10 and somewhat higher IL-10/IL -12 ratios (adj. p value = 0.024) relative to wild-type 
L. plantarum WCFS1 (Figure 4 and Table 3). Although the lp_1953 mutant induces a 
modest, yet significantly different, IL-10/IL-12 response relative to the parental strain, 
these results are not in agreement with the immunomodulatory effects predicted for 
this gene.
 
Figure 3. Boxplots of IL-12 amounts produced by PBMCs in response to L. plantarum wild-type and 
mutant cells. 2Log transformed IL-12 amounts induced by exponential and stationary phase L. plan-
tarum cells are shown. The dots indicate the median value, the boxes indicate first and third quartile, 
and the whiskers extend to outlying data points for a total of 12 measurements (3 PBMC donors were 
measured using 4 replicate cultures of each L. plantarum strain).
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Figure 4. Boxplots of IL-10/IL-12 amounts produced by PBMCs in response to L. plantarum wild-type 
and mutant cells. 2Log transformed IL-10/IL -12 ratios induced by exponential and stationary phase L. 
plantarum cells are shown. The dots indicate the median value, the boxes indicate first and third quar-
tile, and the whiskers extend to outlying data points for a total of 12 measurements (3 PBMC donors 
were measured using 4 replicate cultures of each L. plantarum strain).
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Table 3. Relative differences in cytokine amounts between L. plantarum WCFS1 wild-type and deletion 
mutants.
a L. plantarum WCFS1 deletion mutant measured in the PBMC assay.
b Phase of growth from which L. plantarum cells were harvested (log = exponential phase; stat = stationary phase).
c The value is the average difference in 2Log cytokine amounts induced by wild-type L. plantarum and mutant cells 
harvested in the same phase of growth (log or stat). A positive value indicates an increase in IL-10 levels produced 
by PBMCs in response to mutant L. plantarum compared to the wild-type cells. Calculations of t-test p-values and 
adjusted (adj.) p-values are described in the text (Materials and Methods). * (0.01 < p < 0.05); ** (0.002 < p < 0.01); 
*** (p <0.002) for the adj. p-values.
In summary, of the 5 mutants tested here, three (ΔlamA ΔlamR, Δpst19ADCBR, and 
ΔplnG) significantly affected the immune response of PBMCs in different donors ac-
cording to the phenotypes predicted from the gene-trait matching data (Table 2). The 
plnEFI mutant also affected the immune response in the predicted manner but this was 
not significant considering the adjusted p value. The ΔlamA ΔlamR mutant conferred 
the largest differences on the induction of IL-10 and IL-12 and the IL-10/IL-12 ratio by L. 
plantarum (Table 3).
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Discussion
This study demonstrated the diverse capacities of L. plantarum strains to stimulate 
cytokine production in human PBMCs and confirmed the contributions of specific L. 
plantarum genes to modulate these responses. Forty-two L. plantarum strains induced 
PBMCs to secrete IL-10 over an average 14-fold range. This range was similar to IL-10 
amounts stimulated by 7 Bifidobacterium longum strains [43] and the 10 to 15-fold 
differences in cytokine amounts induced in PBMCs by multiple Lactobacillus and Bifido-
bacterium species [7-11]. Moreover, we found that variation in IL-10 and IL-12 amounts 
and IL-10/IL-12 ratios induced by the distinct L. plantarum strains was higher than re-
ported previously [44]. This result was probably due to the analysis of more strains in 
the present study (42 versus 3), which were isolated from diverse environmental niches 
encompassing a greater genetic and phenotypic diversity of the L. plantarum species. 
Such strain-specific differences should therefore be taken into consideration when se-
lecting a probiotic Lactobacillus culture for health conditions which are dependent on 
modulating immunity such as in the prevention of allergy, eczema, or inflammatory 
bowel disease.
To identify L. plantarum genes with roles in modulating immune cell responses, L. 
plantarum genetic diversity was correlated with strain-specific capacities to induce cy-
tokines in PBMCs. Genes with putative contributions to the observed PBMC responses 
were further investigated in L. plantarum WCFS1. A similar gene-trait matching ap-
proach previously resulted in the identification of a L. plantarum mannose-specific ad-
hesin (Msa) [45] and genes which modulate dendritic cell responses [46]. Although the 
gene-trait matching approach has been successful, it should be recognized that only 
a subset of immunomodulatory cell components produced by L. plantarum was likely 
identified here. Firstly, the identified immunomodulatory genetic loci were restricted to 
genes in the L. plantarum WCFS1 reference strain genome. Secondly, genes with high 
levels of sequence conservation such that they are not distinguished by CGH (presence 
versus absence, rather than minor sequence variations) might be excluded from detec-
tion. For example, L. plantarum has highly conserved LTA biosynthesis and modification 
genes known to have established effects on mammalian immunity were not found in 
this biodiversity-based gene-trait matching approach. Finally, genetic assessments do 
not take into account strain-specific variations in gene expression, translation, or post-
translational modification of proteins with immunomodulatory effects.
Despite these limitations and the considerable variation in the production of cytokines 
by PBMCs from different donors, the present study demonstrated that gene-trait 
matching is also suitable for the identification of genes that affect cytokine levels in 
the mixture of immune cells collectively termed PBMCs. The products of AIP-based QS-
TCSs and the N-acetyl-galactosamine/glucosamine phosphotransferase system identi-
fied here might constitute a new class of bacterial cell products which are recognized by 
host receptors. The findings are significant because these genes were identified using 
intact cells which likely have multiple interactions with immune cells such that single 
genes only confer incremental effects.
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L. plantarum WCFS1 LamB, a processing/export protein of the AIP-based QS-TCS LamB-
DCA [47], was correlated with immunomodulation of PBMCs. LamB, a transmembrane 
protein, is under the control of two response regulators LamA and LamR [40]. A L. plan-
tarum ΔlamA ΔlamR mutant investigated in this study was found to induce PBMCs to se-
crete significantly higher amounts of the cytokines IL-10 and IL-12. In a previous report, 
global transcript profiling of the lamA lamR deletion mutant showed that the lamBDCA 
system is auto-regulated and controls the production of several surface-associated pro-
teins, stress-associated functions, and surface polysaccharides [40]. Higher amounts 
of surface polysaccharides produced by L. plantarum ΔlamA ΔlamR decreased the bio-
film-forming capacity of the mutant strain [40]. Polysaccharides produced by some 
Lactobacillus species are known for their immunomodulatory effects either by direct 
interactions with immune cells or by shielding MAMPs on the bacterial cell surface from 
detection by the immune system [18,48,49]. Therefore the observed PBMC IL-10/IL-12 
ratios for L. plantarum might either be mediated directly through the LamBDCA system 
and the cognate secreted peptide, or indirectly through cell products (e.g., polysaccha-
rides) under the control of this regulatory system. The latter is supported by the genetic 
similarities between LamBDCA and the Staphylococcus aureus agr system, an AIP-based 
QS-TCS which controls the evasion of innate host defenses by S. aureus through the 
production of secreted peptides and proteases [50].
The plantaricin biosynthesis pathway of L. plantarum WCFS1 is also controlled by an 
AIP-based QS-TCS [47] and genes required for plantaricin production and transport con-
tributed to L. plantarum effects on PBMCs. Plantaricin is a bacteriocin composed of two 
small secreted peptides (PlnE and PlnF) which destabilize the integrity of the plasma 
membrane of susceptible cells [51]. L. plantarum strains harboring plnEF and plnI en-
coding a plantaricin immunity protein, and/or plnG encoding a membrane bound ABC-
transporter induced PBMCs to secrete IL-10 and IL-12 in amounts that yielded lower 
IL -10/IL-12 ratios (Table 2). Similarly, wild-type L. plantarum WCFS1 conferred lower 
IL-10/IL-12 ratios compared to the plnEFI and plnG deletion mutants, although this was 
significant only for the plnG mutant (p = 0.005) and not the mutant lacking plnEFI (p 
= 0.071). The identification of the AIP plantaricin is intriguing because human antimi-
crobial peptides such as defensins secreted in the gut are known to modulate immune 
responses [52,53] and suggest that antimicrobial peptides of bacterial origin might have 
similar capacities. These findings are also compatible with a recent study showing that 
plantaricins can modulate dendritic cell responses [46]. Moreover, several independent 
studies showed that L. plantarum WCFS1 genes involved in plantaricin biosynthesis and 
activity, including plnI and plnF, are induced in the mouse gut [30-32], thereby indica-
ting that plantaricin production is active in the intestine where it might come into con-
tact with mucosal immune cells.
Another of the confirmed genes with immunomodulatory capacities was the pts19AD-
CBR locus coding for a cell membrane-associated N-acetyl-galactosamine/glucosamine 
phosphotransferase system. The relevance of the pts19ADCBR genes in adaptation to 
the intestinal ecosystem was also demonstrated by their higher expression levels in the 
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intestine of conventionally-raised and germ-free mice [31,32]. Moreover, in Lactobacil-
lus johnsonii, a putative mannose phosphotransferase gene locus with 43% amino acid 
identity to the L. plantarum WCFS1 pts19ADCBR cluster was found to be important for 
long term persistence in vivo [54]. Although the regulatory signals for expression of 
these genes are unknown, immunomodulatory effects conferred by Pts19ADCBR might 
influence the ability of L. plantarum to modify the intestinal environment for survival 
in the gut.
Cytokine profiles of the lp_1953 deletion mutant were not in agreement with the IL-10 
stimulating capacity predicted for this gene by gene-trait matching. This result exempli-
fies the need for mutation analysis to confirm gene-trait predictions, which are likely 
to encompass false-positive associations. A similar conclusion was drawn during the 
identification of the L. plantarum Msa gene [45]. Moreover, the product of lp_1953 is 
predicted to be intracellular, which contrasts the predicted subcellular location of all 
other genes examined here (secreted or cell envelope associated) [24,25]. This find-
ing supports the notion that surface-localized proteins or components are the most 
likely candidate-participants in host-microbe interactions [49,55]. Thus far, the major-
ity of the known immunomodulating MAMPs known for lactobacilli are extracellular 
or cell surface associated products such as LTA, exopolysaccharides, and peptidogly-
can, although intracellular CpG-containing oligodeoxynucleotides (ODNs) produced by 
some lactobacilli are able to induce IL-10 production in immune cells [21,49]. These 
MAMPs are recognized by specific pattern recognition receptors (PRRs) such as Toll-like 
receptors (TLRs) and nucleotide oligomerization domain (NOD)-like receptors [21]. To 
identify the mechanisms underlying the effects of AIP-based QS-TCSs and the N-acetyl-
galactosamine/glucosamine phosphotransferase system on immune cells, the cellular 
products encoded by the genes in these pathways should be investigated to identify the 
specific cell types among the PBMCs, which include lymphocytes, monocytes and mac-
rophages, that recognize these compounds as well as the specific mechanisms leading 
to altered cytokine production.
Comparisons of mutant and wild-type L. plantarum WCFS1 cells included examination 
of the effects of culture growth phase on the stimulation of PBMCs. Exponential- and 
stationary-phase L. plantarum WCFS1 cultures were evaluated because the growth 
phase of probiotic cells was previously shown to influence the immune responses to 
probiotic bacteria in vitro [56-59] and in vivo [35]. Using human PBMCs, we found sig-
nificant growth-phase dependent differences in the immunomodulatory capacities of 
the wild-type and mutant L. plantarum cultures. Collectively, the exponential-phase L. 
plantarum WCFS1 cultures stimulated higher absolute amounts of IL-10 and IL-12 and 
hence appear to induce heightened immune responses by PBMCs compared with sta-
tionary-phase cells. Notably, this result was not due to extensive L. plantarum growth 
because antibiotics were added to the PBMC growth medium to prevent bacterial over-
growth which would generate artifacts from acidification of the medium causing PBMC 
cell stress or death. Moreover, intact and lysed L. plantarum strains cells collected from 
the exponential and stationary phase of growth do not show striking differences in their 
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TLR-9 signaling activity and there was not a clear trend among all strains tested (per-
sonal observation, M. Meijerink and J. M. Wells). Therefore the higher amounts of cy-
tokines induced by exponential phase bacteria are unlikely to be caused by differential 
cell lysis resulting in the release of intracellular CpG DNA, a known MAMP recognized 
by TLR-9.
Comparisons of wild-type and mutant L. plantarum cultures also showed growth-phase 
dependent effects. The IL-10 amounts and IL-10/IL-12 ratios induced by the pts19AD-
CBR deletion mutant were significantly different from wild-type L. plantarum WCFS1 for 
only the stationary-phase cultures. Stationary-phase cells of the ΔlamA ΔlamR mutant 
also induced significantly higher amounts of IL-10 and IL-12 in compared with L. plan-
tarum WCFS1 harvested at the same growth phase. However, differences between IL-
10/IL-12 ratios induced by ΔlamA ΔlamR and wild-type cell differed only for exponential 
phase cultures. This result might have been partially due to the extensive alterations in 
expression of L. plantarum ΔlamA ΔlamR in actively growing cultures [39], such that dif-
ferences in expression of lamBDCA and lamKR regulated genes might have influenced 
the ability of the exponential-phase L. plantarum cells to stimulate different PBMC IL 
-10/IL-12 ratios. A similar result was found for the comparisons of L. plantarum plnG 
(and plnEFI), the other 2 TCS system examined, although the specific growth-phase-
dependent modifications of the plantaricin system on cytokine production in PBMCs is 
not presently known.
Conclusions
The present study compared the genetic and phenotypic diversity of L. plantarum 
WCFS1 to identify cell components of this species with the capacity to modulate human 
PBMC responses. We successfully identified several L. plantarum WCFS1 genes that are 
associated with the production of IL-10 and the IL-10/IL-12 ratio by PBMCs and estab-
lished that the immune response to L. plantarum can be significantly altered by the de-
letion of specific L. plantarum cell surface proteins. The increased IL-10/IL-12 ratios of 
the L. plantarum mutants indicate that these cultures would be more protective against 
intestinal inflammation compared with wild-type cells. These effects might be medi-
ated by the down-regulation of local inflammatory responses through various subsets 
of T cells producing a collection anti-inflammatory cytokines. As a result of this study, 
strain selection for protection against intestinal inflammation might include screening 
for strains lacking the LamB, PlnG, or Pts19 homologs or by modifying culture growth 
conditions or food delivery matrices to minimize the expression of these genes in vivo. 
Such studies are required to distinguish between health effects conferred by individual 
probiotic strains and to develop methods to ensure that probiotic cells express host-
modulatory cell products at the appropriate level and time in food products and the 
human gut.
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Methods
Bacterial strains
Immune assays and genetic analysis was performed on a total of 42 L. plantarum strains 
with distinct phenotypic profiles [27,28] (Table 1). Comparative genome hybridization 
(CGH) of these strains was performed previously [27,28]. For immunoprofiling, the L. 
plantarum strains were grown at 37°C in de Man Rogosa Sharpe (MRS) broth (Merck, 
Darmstadt, Germany) until mid-exponential (optical density (OD) 600 nm = 1) phase or 
stationary phase (24 h after the start of the culture, OD600 nm = 7.6 ± 1.1) [60]. The 
exponential and stationary phase cells were washed twice in phosphate buffered saline 
(PBS) at pH 7.4, suspended at 2 × 108 cells/ml in PBS containing 20% glycerol, and stored 
at -80°C until co-culturing with human immune cells. Quantification of the exponential 
and stationary phase viable cells before and after freezing showed no significant losses 
in cell viability (data not shown). Colony forming units (CFUs) were determined by pla-
ting serial dilutions of the cultures on MRS agar (data not shown).
Peripheral blood mononuclear cells assay
This study was approved by Wageningen University Ethical Committee and was per-
formed according to the principles of the Declaration of Helsinki. Peripheral blood of 
healthy donors was from the Sanquin Blood Bank, Nijmegen, The Netherlands. Before 
sample collection, a written informed consent was provided. Peripheral blood mononu-
clear cells (PBMCs) were separated from the blood of healthy donors using Ficoll-Paque 
Plus gradient centrifugation according to the manufacturer’s protocol (Amersham bio-
sciences, Uppsala, Sweden). After centrifugation the mononuclear cells were collected, 
washed in Iscove’s Modified Dulbecco’s Medium (IMDM) + glutamax (Invitrogen, Breda, 
The Netherlands) and adjusted to 1 × 106 cells/ml in IMDM + glutamax supplemented 
with penicillin (100 U/ml) (Invitrogen), streptomycin (100 μg/ml) (Invitrogen), and 1% 
human AB serum (Lonza, Basel, Switzerland). PBMCs (1 × 106 cells/well) were seeded in 
48-well tissue culture plates. After an overnight rest at 37°C in 5% CO2, 5 μl aliquots of 
thawed bacterial suspensions at 2 × 108 CFU/ml were added to the PBMCs (L. plantar-
um: PBMC ratio of 1:1). PBS (5 μl) and LPS (1 μg) served as negative (PBS) and positive 
(LPS, TLR-4 ligand) controls for the stimulation of PBMCs. IL-10 was produced in suffi-
cient amounts for quantification in response to LPS but not to PBS. Similarly, neither LPS 
nor the PBS buffer stimulated the production of IL-12. To test the capacity of the 42 L. 
plantarum strains to stimulate PBMC cytokine production, PBMCs from 3 different do-
nors were examined (donors A, B, and C). For donors A and B, separate stationary-phase 
cultures of each L. plantarum strain were used. For donor C, both replicate cultures of 
each L. plantarum strain were examined. In PBMC assays comparing responses to L. 
plantarum WCFS1 wild-type and mutant strains, PBMCs from 3 different donors were 
examined using 4 independent replicate wild-type and mutant L. plantarum cultures 
harvested during exponential-phase and stationary-phase of growth.
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Following 24 hr incubation at 37°C in 5% CO2, culture supernatants were collected and 
stored at -20°C until cytokine analysis. This time point was selected for analysis because 
previous studies showed that IL-12 levels remain unaltered after 4 days of L. plantarum 
incubation with PBMCs. Although IL-10 was shown to increase 2- fold after 4 days of 
co-incubation with L. plantarum, sufficient cytokine amounts were produced after 24 h 
to permit flow cytometric measurements [61]. No viable bacteria could be cultured and 
medium acidification was not observed after incubation of L. plantarum strains with the 
PBMCs for 24 h (data not shown). Cytokines were measured using a FACS CantoII flow 
cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and BD Cytometric Bead Array Flex-
sets (BD Biosciences) for IL-10 and IL-12p70 (in chapter 4 referred to as IL-12) according 
to the manufacturer’s recommendations. Detection limits were 0.13 and 0.6 pg/ml for 
IL-10 and IL-12, respectively. Concentrations of analytes were calculated with the use 
of known standards and plotting the sample values against a standard curve in the BD 
Biosciences FCAP software. Donor-specific variation in cytokine production capacities 
was taken into account by dividing the cytokine amounts induced by individual L. plan-
tarum strains against average cytokine quantities induced by all L. plantarum strains for 
the same donor. These values were then compared to amounts induced by L. plantarum 
WCFS1 and used for gene-trait matching.
Identification of candidate genes involved in cytokine secretion by gene-trait 
matching
L. plantarum genes with potential roles in modulation of PBMC cytokine production 
were identified by in silico matching using genotype information referenced from the 
L. plantarum WCFS1 genome (also termed gene-trait matching) [45]. Individual L. plan-
tarum WCFS1 gene presence or absence scores for the 42 strains were used as putative 
predictor variables for PBMC induced IL-10, IL-12 and IL-10/IL-12 amounts by regression 
using the Random Forest algorithm [38]. The “RandomForest” package for R [62] was 
used with standard parameter settings. L. plantarum WCFS1 genes with the highest 
variable importance measures by the Random Forest method were selected for dele-
tion analysis.
Construction of L. plantarum WCFS1 gene deletion mutants
A previously described L. plantarum ΔlamA ΔlamR mutant was used in this study [40]. 
Construction of L. plantarum lp_1953, lp_2647-2651, lp_0419-0422 and lp_0423 gene 
deletion mutants was performed as previously described [63] with several modifica-
tions. The mutagenesis vectors were generated by a splicing by overlap extension (SOE) 
procedure [64]. This procedure was designed to expedite mutagenesis vector construc-
tion for L. plantarum using a single step, blunt-ended cloning and positive selection 
for transformants based on chloramphenicol resistance. PCR was used to amplify ap-
proximately 1 kb of the 5’ and 3’ regions flanking the genes targeted for deletion (for 
primer sequences see Table 4). In addition, the loxP-cat-loxP region of pNZ5319 was 
amplified using primers Ecl-loxR and Pml-loxF (Table 4). For each mutagenesis vector, 
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the amplicons representing the corresponding 2 flanking regions and the loxP-cat-loxP 
region were mixed in a 1:1:1 molar ratio and used as template in a second PCR reaction 
with the 5’forward and 3’reverse flanking primers. These PCR reactions resulted in 3 kb 
amplicons which were cloned into the integration vector pNZ5319 [63] after prior diges-
tion of the vector with SwaI and Ecl136II. Plasmids were transformed into competent 
cells of E. coli JM109 by electroporation as recommended by the manufacturer (Invit-
rogen). Plasmid DNA was isolated from E. coli using Jetstar columns (Genomed GmbH, 
Bad Oeynhausen, Germany) using the manufacturer’s recommended protocol. DNA se-
quencing (BaseClear, Leiden, The Netherlands) was performed to confirm the integrity 
of the cloned genes. The resulting plasmids containing the complete gene replacement 
cassettes were used for mutagenesis [63].
Table 4. Primers used in this study.
Statistical analysis
Linear mixed effect models using restricted maximum likelihood (REML) were used to 
statistically compare the mean cytokine values of IL-10, IL-12, and IL-10/IL-12 produced 
in response to L. plantarum wild-type and mutant cells. The effect of the donor on the 
response variable was modeled as a random effect. The fixed effects in the model were 
the strains (WCFS1 [wild type], Δpts19ADCBR, Δlp_1953, ΔplnG, ΔplnEFI, and ΔlamA 
ΔlamR) and the growth phase at the time of harvest (exponential phase and station-
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ary phase). Logarithmic transformations of [IL-10], [IL-12] and [IL-10]/[IL-12] yielded 
residuals that showed approximately normal distributions (data not shown) and, hence, 
were used as the response variables in the fitting procedure. Statistical analysis was 
performed using R http://www.r-project.org webcite, with the package “nlme” [65] 
for mixed effect modeling. The donor random effect was modeled as a constant offset 
relative to the average level of the response variable (“model 1”), or alternatively, as a 
donor-dependent offset plus a donor-dependent variation in the effect of the bacte-
rial growth phase on the response variable (“model 2”). Model 2 yielded better fits 
for 2log([IL-10]) and 2log([IL-10]/[IL-12]) response variables whereas, indications of a 
donor dependent variation in growth phase effects were not found for the 2log([IL-12]) 
response, and hence model 2 was applied for comparison of these cytokine amounts. 
The resulting relative difference coefficients and t tests were calculated from the fixed 
effects (mutation, growth phase, and their interaction) using analysis of variance in R. 
The p-values were adjusted for multiple hypothesis testing using the correction proce-
dures by Hochberg [66].
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Abstract
Literature on the effects of cryopreservation and thawing of monocytes or monocyte-
derived immature dendritic cells (iDCs) on the subsequent functional capacities of the 
DCs is limited to a few specific maturation stimuli and is focused on applications in clini-
cal immunotherapy. Given the cardinal role of DCs in regulating tolerance and immunity 
at mucosal surfaces there is a growing interest in understanding the effect of stromal, 
microbial and probiotic signals on DC function. Therefore our aim was to investigate the 
effects of cryopreservation on the functional properties of DCs stimulated with bacteria
or bacterial components using a standardized method. Surface markers CD83 and CD86 
were expressed at similar levels on iDCs generated from cryopreserved or freshly iso-
lated monocytes. Cryopreservation of iDCs led to slightly decreased expression of CD86 
and CD83 compared to freshly generated iDCs prepared from unfrozen cells but this 
did not affect the capacity of DCs to acquire fully mature characteristics after stimula-
tion. In contrast the cytokine response to lipoteichoic acid and bacterial stimulation 
was altered by cryopreservation of monocytes or iDCs, particularly for IL-12p70 which 
was decreased up to 250 fold or not detected. Cryopreservation also decreased TNF-α 
and IL-1β production in stimulated iDCs but to a lesser extent than for IL-12p70, de-
pending on the maturation factors used. The amounts of IL-10 produced by stimulated 
iDCs were increased up to 3.6 fold when iDCs were cryopreserved, but decreased up to 
90 fold when generated from cryopreserved monocytes. Immature DCs are often used 
to investigate the immunomodulatory properties of probiotics and here we show for 
the first time that cryopreserved monocytes and cryopreserved iDCs have a skewed 
cytokine response to microbial stimulation. These findings have implications for the 
methods used in bacterial-DC immune assays and highlight the importance of compar-
ing different cytokines and stimuli in immune cell cryopreservation protocols. 
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Introduction
Dendritic cells (DCs) play a key role in mucosal immunity and tolerance, and are pre-
sent throughout the intestine including the follicular tissue of the mucosal associated 
lymphoid tissue as well as the lamina propria (LP). In the Peyer’s patches and isolated 
lymphoid follicles DCs are thought to prime Th2 responses leading to the induction of 
antigen specific IgA which is then transported into the lumen via the epithelial polyme-
ric IgA receptor [1]. Direct communication can also occur between intestinal microbiota 
and a subset of DCs have been shown to open the epithelial tight junctions and send 
protrusions to the luminal side [2]. Epithelial cells can also transport antigens from the 
lumen to the underlying DCs although with much less efficiency than M cells [3].
Maturation is triggered by ligand binding to pattern recognition receptors such as 
Toll-like receptors (TLRs) that bind conserved microbial-associated molecular patterns 
(MAMPs) such as lipoteichoic acid (LTA) and lipopolysaccharide (LPS). During matura-
tion, the major histocompatibility complex molecules for antigen presentation and co-
stimulatory molecules, such as CD40, CD54, CD83 and CD80 (B7.1) and CD86 (B7.2), are 
up regulated for an effective T-cell stimulation [4]. The nature of the signals encoun-
tered by DCs including epithelial derived factors are known to shape the course of the 
immune response [5]. 
Given the important role of DCs in intestinal homeostasis and disease there is a growing 
interest in understanding the effect of stromal and microbial signals on DC function and 
the potential to manipulate DCs through nutrition and the microbiota. Furthermore re-
cent therapeutic and mechanistic studies have highlighted the importance of determi-
ning the in vitro DC response to probiotic strains as a prerequisite to therapeutic studies 
[6, 7]. Several studies have shown that probiotic species of bacteria, and even different 
strains of the same species, differ markedly in their ability to induce DC maturation 
and cytokine production [8, 9]. Apart from the growing interest in the role of mucosal 
DCs and immunomodulation by food, enormous efforts have been given to DC-based 
vaccination against malignant diseases [10]. These approaches would benefit greatly 
from the ability to cryopreserve a single large batch of monocytes or immature DCs 
(iDCs) with the same viability, phenotype, and function as those generated from fresh 
blood. Few studies have examined the influence of cryopreservation/ thawing on the 
subsequent expansion of culture-generated DCs, the expression of surface molecules, 
and the functional capacities of immature and mature DCs [11-14]. Previous studies 
focused on the application of DCs in clinical immunotherapy and were limited to stim-
ulations with synthetic ligands, cytokines or antibodies including LPS, tumor necrosis 
factor alpha (TNF-α), interferon-gamma (IFN-γ), and CD40L. For example, Lewalle et al. 
studied the effect of cryopreservation on DC maturation and antigen specific responses 
using CD40L and IFN-γ as maturation factors and concluded that freezing did not alter 
the capacity of iDCs to capture, process and generate antigen-specific reactions after 
thawing. Additionally, cryopreservation did not alter the capacity of DCs to acquire 
fully mature characteristics, as shown by the immunophenotype and bioactive interleu-
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kin-12 (IL-12) secretion. A systematic comparison between fresh monocyte-derived DCs 
with cryopreserved DCs was also reported by John et al., who found that freezing led 
to semi-matured DCs, reduced endocytic activity and reduced transduction efficiency 
[12]. Hori et al. assessed the effect of cryopreservation on cell viability, maturation and 
the capacity of DCs for chemotactic migration and antigen presentation [14]. They con-
cluded that regardless of the stage of maturation at which the DCs were freeze-thawed, 
cryopreservation did not have an effect on cell phenotype, function or viability. Hayden 
et al., performed an extensive study to assess the effect of cryopreservation on recov-
ery, viability, phenotype, and function of monocytes and DCs at various developmen-
tal stages [11]. Cryopreserved cells were cultured with TNF-α, IFN-γ and LPS to obtain 
mature DCs. They found that the properties of the DCs derived from cryopreserved 
monocytes were equivalent to DCs generated from freshly isolated monocytes, but the 
cryopreservation of differentiated DCs led to a moderate increase in CD40, CD80 and 
CD83, a decreased capacity to stimulate expression of CD69, IFN-γ, and granzyme B and 
a reduced T-cell proliferation in co-culture with T-cells. As the previous studies have not 
included bacteria as maturation stimuli or do not provide data on cytokine responses, 
we have investigated the effects of cryopreservation and thawing of precursor mono-
cytes and iDCs on the maturation and immune response of DCs to probiotic strains and 
bacterial components. 
Our results demonstrate that cryopreservation of monocytes and/or iDCs can influence 
cytokine responses depending on the stimulus for maturation. 
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Material and methods
Bacterial strains
L. plantarum WCFS1, a human isolate from saliva obtained from the NIZO culture collec-
tion (Ede, The Netherlands) and L. fermentum AGR1485 a human oral isolate obtained 
from the AgResearch culture collection (Palmerston North, New Zealand) were grown 
overnight to stationary phase at 37oC in MRS. The bacteria were recovered by centrifu-
gation and washed twice in phosphate buffered saline (PBS, pH=7.4) and resuspended 
at 2*108 colony forming units (CFU)/ml in PBS containing 20% glycerol and stored at 
-80oC prior to use in the immunoassays. CFU were determined by plating serial dilutions 
of the cultures on MRS agar.
Blood donors
Buffy coats from blood donors were obtained from the Sanquin Blood bank Nijmegen 
(The Netherlands). An informed consent was obtained before the sample collection and 
the performed experiments were approved by the Local Ethical Committee.
Differentiation and maturation of dendritic cells
Human peripheral blood mononuclear cells (PBMCs) were isolated from the buffy coat 
using a combination of Ficoll density centrifugation and cell separation using antibody 
coated microbeads. The blood was diluted 1:1 with Iscove’s Modified Dulbecco’s Me-
dium (IMDM) containing GlutaMAX (Invitrogen, Breda, The Netherlands). The PBMCs 
were isolated by density gradient centrifugation on Ficoll-Plaque PLUS (GE Healthcare, 
Bucks, United Kingdom). The diluted plasma was removed and the layer of white blood 
cells was recovered and washed twice with IMDM. The CD14+ monocytes were then 
purified using magnetic cell sorting with CD14+ microbeads according to the manufac-
turer’s recommended protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). The pro-
portion of CD14+ cells was routinely determined using flow cytometry (BD FACSCanto 
II, BD, San Diego, USA) and antibody staining for CD14 following the same procedure as 
on days 3, 6 and 8 (described below). In all experiments the proportion of CD14+ cells 
was greater than 90%. To generate iDCs, approximately 106 CD14+ cells/ well were cul-
tivated in RPMI 1640 containing 10% FBS gold (PAA), 1% penicillin, streptomycin (v/v) 
(Invitrogen), 50 ng/mL IL-4 (R&D systems, Minneapolis, USA) and 50 ng/mL granulocyte 
macrophage-colony stimulating factor (GM-CSF) (R&D systems) in a 24 well plates. GM-
CSF combined with IL-4 induces monocytes to become myeloid dendritic cells in vitro in 
6 days. At day 3 and day 6 half of the medium was refreshed. At day 6 the cells were left 
unstimulated iDCs or were stimulated with LPS (1 µg/mL), LTA (5 µg/mL), L. plantarum 
or L. fermentum (1:1 and 10:1 bacteria to DC ratio) for 48 hours. LPS the major compo-
nent of the outer membrane of Gram-negative bacteria, was used as a TLR-4 agonist. 
LTA, a component of Gram-positive bacteria cell walls, was used as a TLR-2 agonist, as it 
is known to be recognised by TLR-2/ TLR-6 heterodimers. During the period of incuba-
tion with bacteria no acidification of the cell culture medium was observed.
110
Ch
ap
te
r 
5
Freezing and thawing of monocytes or day 6 iDCs
Cells for cryopreservation were resuspended at 2x107 cells/mL in cold freezing media 
(10% DMSO in FBS). Samples were placed in a freezing container (Cryo 1 °C freezing 
container, Nalgene Nunc Int., Rochester, NY, USA) and stored overnight at -80°C. Af-
ter freezing, the cryopreserved samples were rapidly thawed by immersing them in a 
water bath at 37°C until they could be decanted. The cell suspension was transferred 
to a 50 mL polypropylene tube containing pre-warmed IMDM containing 20% FBS and 
then washed twice with IMDM containing 20% FCS, to remove the DMSO. Cells were 
counted and checked for viability by tryphan blue staining. Cell viability was >95%.
Analysis of cell surface markers and measurement of cell death by flow cytometry
Monocyte-derived DCs were harvested at days 3, 6 and 8 and stained with specific 
monoclonal antibodies to CD1a, CD83, CD86 or their isotype-matched controls (BD bio-
sciences, San Diego, USA) for 30 min on ice, washed and analyzed by flow cytometry 
(FACSCanto II, BD). CD83 is only expressed on matured DCs so it was used as a marker 
to assess the immature status of the DCs generated from monocytes. CD86 expression 
was measured to check the activation status of the cells during the differentiation pro-
tocol and after cryopreservation.
Live, apoptotic and necrotic cells were discriminated by staining with Annexin V and 
propidium iodide (PI) on days 3, 6 and 8 according to the manufacturer’s protocol. The 
cells were analyzed on a flow cytometer. Cells that were negative for both Annexin V 
and PI were not apoptotic or necrotic as translocation of the membrane phospholipid 
phosphatidylserine had not occurred and the plasma membrane was still intact. There-
fore, Annexin V and PI double negative cells were considered to be viable cells; whereas 
both single and double positive cells were regarded as non-viable [15]. The flow cyto-
metry data were analyzed using the BD FACSDiva software. On days 3 to 8 the viability 
of the cells was between 60- 80%.
Cytokine analysis
Supernatants from the DC stimulation assays were collected after 48 hours of stimula-
tion and analyzed for the presence of cytokines (IL-12p70, TNF-α, IL-1β and IL-10) using 
a cytometric bead-based immunoassay that enables multiplex measurements of solu-
ble cytokines in the same sample [16], according to the manufacturer’s protocol (BD 
biosciences). The limits of sensitivity for detection were as follows: IL-12p70 0.6 pg/mL, 
TNF-α 0.7 pg/mL; IL-1β 1.1 pg/mL and IL-10 0.13 pg/mL. The flow cytometry data were 
analysed using the BD FCAP software. 
Statistical analysis
Mixed general linear model using restricted maximum likelihood was used to determine 
the statistical differences between cytokines produced by DCs differentiated from fresh 
monocytes and DCs differentiated from frozen monocytes and frozen iDCs stimulated 
with different stimuli within 3 donors. Each assay was performed in duplicate. A two-
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sided p-value of 0.05 or lower was considered to be significant. The statistical analysis 
was performed by using SAS software (version 9.1, SAS Institute Inc., Cary, NC, USA).
 
Figure 1 Schematic overview of the differentiation and stimulation protocol.
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Results and Discussion
It was not clear from the current literature whether or not cryopreserved monocytes 
or iDCs could be used to simplify and standardize a method for measuring bacteria-DC 
immune responses, including for example probiotic screening. To investigate the ef-
fects of cryopreservation on the functional properties of DCs stimulated with bacteria 
or the bacterial TLR agonists we describe a standardized method for generating DCs 
from peripheral blood monocytes. In the absence of DC maturation factors the cultured 
monocytes differentiate into immature DCs in the presence of GM-CSF and IL-4. Several 
monocyte isolation procedures have been described in the literature but in our hands 
the immunomagnetic enrichment method described here reproducibly yielded iDCs 
from different donors as revealed by the expression of a range of DC markers using flow 
cytometry. In this study differences between cryopreserved cells and fresh cells were 
compared within multiple donors. The freshly generated iDCs were stimulated on day 6 
of the protocol whereas the cryopreserved iDCs (frozen on day 6) were thawed the fol-
lowing day and then stimulated immediately. In the case of cryopreserved monocytes 
these cells were thawed, differentiated into iDCs and stimulated on day 6 (Fig. 1). 
To determine the maturation status of cryopreserved iDCs or those generated from 
fresh monocytes or cryopreserved monocytes, CD1a, CD83 and CD86 staining was per-
formed after day 3 and day 6 as shown in the differentiation protocol (Fig. 1). The matu-
ration markers were similarly expressed at low levels on unstimulated iDCs that were 
freshly prepared, cryopreserved or generated from cryopreserved monocytes (Fig. 1). 
Immature DCs expressed high levels of CD1a, a specific DC marker, and low levels of 
CD83 and CD86 compared to DCs that were treated with maturation factors, such as LPS 
or TNF-α and IL-1β. Taken together, these findings demonstrate that cryopreservation 
of monocytes or iDCs does not affect expression of maturation markers compared to 
freshly prepared iDCs. 
The maturation marker expression on iDCs differentiated from freshly isolated mono-
cytes or cryopreserved monocytes and cryopreserved iDCs generated from the same 
batch of blood was compared by stimulation with LPS, LTA or different bacterial strains. 
A similar activation status was observed for iDCs from fresh and cryopreserved mono-
cytes, in agreement with previous publications [11, 13]. In contrast to other studies we 
found that iDCs frozen and thawed on day 6 of the differentiation protocol (Fig. 2) had 
increased expression levels of CD83 and CD86 compared to fresh iDCs (Fig. 2). 
IL-12p70 was measured in the supernatant of stimulated DCs as it is known to be a 
potent promoter of Th1 type immune responses. IL-12p70 could be measured in the 
supernatants of LTA stimulated DCs generated from freshly isolated monocytes but not 
from cryopreserved monocytes (Fig. 3). Similarly, the IL-12p70 response to bacterial 
stimulation (but not to LPS) was also significantly decreased. Additionally, IL-12p70 se-
cretion was up to 10 fold lower for cryopreserved iDCs after stimulation with bacteria 
(L. plantarum and L. fermentum, at two different ratios, p<0.05). IL-12p70 secretion was 
significantly lower for cryopreserved iDCs than for freshly generated iDCs, especially
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Figure 2 Histograms for expression of surface markers CD1a, CD83 and CD86: a) on day 3 for iDCs 
derived from fresh and frozen monocytes. b) on day 6 for iDCs derived from fresh monocytes, frozen 
monocytes and day 6 frozen iDCs. c) on day 8 iDCs unstimulated or after stimulation with LPS, LTA or 
bacteria (L. plantarum or L. fermentum) bacteria: DC ratio 10:1. One of three representative experi-
ments is shown.
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after stimulation with LPS or LTA (p<0.05) (Fig. 3). Thus, cryopreservation of monocytes 
and iDCs affects IL-12p70 secretion upon stimulation with bacteria, LTA or LPS. The only 
exception was with cryopreserved monocytes stimulated with the TLR-4 agonist LPS. As 
LPS is often used as a control for iDC activation, it is important to be aware of the differ-
ences observed with other stimuli. 
Measurements of TNF-α secretion gave similar results to that for IL-12p70. Indeed, DCs 
derived from cryopreserved monocytes produced less TNF-α after stimulation with LTA 
(p<0.05) compared to freshly generated DCs. Also, after stimulation with bacteria (L. 
plantarum and L. fermentum, both ratios, p<0.01), there was a striking difference in the 
amounts of secreted TNF-α. For cryopreserved iDCs a significant decrease in TNF-α was 
only seen following stimulation with L. fermentum stimulation at two different ratios 
(p< 0.01). No significant effects of cell cryopreservation on TNF-α production were ob-
served using LPS as a stimulus (Fig. 3). 
Cryopreservation of monocytes did not induce of IL-1β secretion, except when stimu-
lated with highest ratio of L. plantarum. The cryopreserved DCs follow the same pat-
terns as DCs generated from freshly isolated monocytes, but in most cases the amount 
of IL-1β produced was lower (Fig. 3).
Interestingly, the IL-10 secretion by stimulated cryopreserved iDCs was slightly increased 
compared to freshly prepared DCs. In contrast, DCs generated from cryopreserved 
monocytes produced significantly less IL-10 than DCs derived from freshly prepared 
monocytes or cryopreserved DCs (p<0.01). IL-10 is a critical regulatory T-cell cytokine 
that suppresses IL-12 production and consequently other Th1 cytokines such as IFN-γ 
and TNF-α. The suppression of IL-12 in the gut by IL-10 prevents an inflammatory cas-
cade of Th1 cytokines and cellular migration. IL-10 and IL-12 are often used to screen 
for the immunomodulatory properties of probiotic bacteria and other nutritional com-
pounds as the ability of different lactobacilli to induce a high ratio of IL-10/IL-12 produc-
tion in immune cells is associated with protection from inflammatory diseases [6, 7].
Our results demonstrate that cryopreservation of monocytes or iDCs leads to an im-
paired cytokine response, particularly for IL-12p70. This is in contrast with the results 
of Lewalle et al. [13] but in agreement with those of Hayden et al. [11]. In the study by 
Hayden et al. IL-12p70 was the only cytokine measured, and LPS or pro-inflammatory 
cytokines were used as maturation factors [11] whereas Lewalle et al. used CD40L and 
IFN-γ as maturation stimuli. In our study the effect of cryopreservation on IL-12p70 se-
cretion was much greater (reduced up to 250-fold or no secretion) than that shown by 
Hayden et al. (reduced up to 6 fold). These differences in the IL-12p70 response could 
be due to the use of different maturation stimuli. 
Immature DCs are often used to investigate the immunomodulatory properties of pro-
biotics and here we show for the first time that cryopreserved monocytes and cryo-
preserved iDCs have an altered cytokine response to microbial stimulation, which is 
associated with the skewing of T helper cells responses towards Th2. These findings 
have implications for the methods used in bacterial DC immune assays and highlight the 
importance of comparing different cytokines and stimuli in immune cell cryopreserva-
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tion protocols. 
Figure 3 Cytokine levels of IL-10, TNF-α, IL-12p70 and IL-1β in DC culture supernatants after 48 hours: 
iDCs were unstimulated (negative control) or stimulated with LPS, LTA or bacteria (L. plantarum or L. 
fermentum) at ratios of 1:1 or 10:1 bacteria per DC. Amounts of secreted cytokines are plotted on a 
logarithmic scale. White bars represent DCs derived from fresh monocytes, grey bars represent frozen 
day 6 iDCs and black bars represent DCs derived from frozen monocytes. A two-sided p-value of 0.05 
or lower was considered to be significant indicated *p <0.05 or ** p<0.01. The average data is shown 
from three experiments. Error bars indicate SD. 
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A comparative study of the immunomodulatory 
properties of potential probiotics in vitro and in 
vivo using a mouse model of peanut allergy 
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Abstract 
Background 
Peanut allergy accounts for the majority of severe food-related allergic reactions and 
requires the development of new prevention and treatment methods. Probiotics may 
be considered for treatment of allergic individuals on the basis of their immune modu-
lating properties.
Objective 
To screen the immunomodulatory properties of 28 commercially available bacterial 
strains in vitro using human peripheral blood mononuclear cells (PBMCs) and inves-
tigate selected strains for their in vivo immunomodulatory potential in an established 
mouse peanut allergy model. 
Methods 
Cytokine profiles of the probiotic strains were determined by in vitro co-culturing with 
human PBMCs from four different donors. Three strains were selected to investigate 
their immunomodulatory role in the peanut allergic response by analyzing peanut-spe-
cific antibodies, mast cell degranulation and ex vivo cytokine production by splenocytes.
Results 
The probiotic strains induced highly variable cytokine profiles in PBMCs. L. salivarius 
HMI001 (HMI001), L. casei Shirota (LCS) and L. plantarum WCFS1 (WCFS1) were se-
lected for further investigation due to their distinct patterns of IL-10, IL-12 and IFN-γ 
induction. Prophylactic treatment with both HMI001 and LCS attenuated the Th2 phe-
notype in the mouse model (reduced mast cell responses and ex vivo IL-4 and/or IL-5 
production). In contrast, WCFS1 augmented the Th2 phenotype (increased mast cell 
and antibody responses and ex vivo IL-4 production).
Conclusion and Clinical relevance 
In vitro PBMC screening was useful in selecting strains with anti-inflammatory and Th1 
skewing properties. In case of HMI001 (inducing a high IL-10/IL-12 ratio) and LCS (in-
ducing high amounts of IFN-γ and IL-12) partial protection was seen in a mouse peanut 
allergy model. Selection of certain strains may worsen the allergic reaction as shown 
in the case of WCFS1. Although further research is needed to validate the immunomo-
dulatory mechanisms involved in vivo, this approach is likely to be useful for selecting 
strains for translational research in humans. 
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Introduction
Several species of the genus Lactobacillus are naturally present in the human intestinal 
tract and have been evaluated for their probiotic activity. Oral administration of certain 
probiotic strains has shown promising results in human clinical trials and experimental 
animal models of inflammatory bowel disease, irritable bowel syndrome and allergy 
[1-9]. Results obtained from in vitro and in vivo studies with probiotics indicate a strong 
role for immunomodulation and enhancement of the epithelial barrier function [10, 11]. 
Proposed immunomodulatory mechanisms include down-regulation of inflammatory 
responses through the modulation of dendritic cell (DC) function and subsequent ex-
pansion or induction of regulatory T cells (Tregs) producing anti-inflammatory cytokines 
such as TGF-β and IL-10, which suppresses inflammatory reactions in allergy and colitis 
[12, 13]. Additionally certain strains of Lactobacillus have been demonstrated to modu-
late T-cell responses to co-administered antigen towards a Th1-type immune response 
leading to an inhibition in IgE production and an increase in Th1 cytokines [9, 14-17]. 
Probiotics can decrease the IL-6 production by lamina propria mononuclear cells and 
PBMCs and increase their IL-10 and IL-12 production [18-21]. As IL-6 can skew Tregs and 
effector T cells into IL-17-producing T cells (Th17), its decrease in mucosal tissues might 
support Treg functions in the mucosa [22]. IL-12 promotes the differentiation of naïve 
T cells into Th1 cells and augments natural killer (NK) cell activity [23] leading to in-
creased IFN-γ and further skewing the immune response from a Th2 to a Th1 response. 
Exposure to probiotics in the gut can also stimulate the intestinal epithelial cells (IEC) to 
secrete anti-inflammatory cytokines, such as TSLP and TGF-β, which can promote the 
differentiation of immature DCs into tolerogenic DCs which play a key role in regulating 
oral tolerance through the induction of regulatory Foxp3+ T cells expressing gut-homing 
receptors [13, 24, 25]. Several studies have shown that the immunomodulatory proper-
ties of lactic acid bacteria differ among species [26-28] and even between strains of the 
same species [29-33]. 
Given the potential for probiotics to modulate host immune responses there is ongo-
ing interest in their application in the treatment and prevention of food allergy. Food 
allergy represents a failure to attain oral tolerance leading to elevated levels of Th2 
cytokines such as IL-4, IL-5, higher levels of allergen specific IgE and increased mast 
cell degranulation. There is evidence that differences in Treg activity may play a role in 
the development and resolution of food allergies. Karlsson et al. showed that children 
who outgrew cow’s milk allergy had higher numbers of Tregs with more potent function 
compared to children who had remained allergic [34]. Smith et al. demonstrated a link 
between lower numbers of Tregs and the development of food allergy to egg in infants 
up to the age of 12 months [35]. This is in line with the study by Shreffler et al. who 
showed that infants with higher numbers of allergen-specific Tregs had milder disease 
and a more favorable outcome than those with lower numbers of Tregs [36]. 
Of all food allergies, peanut allergy deserves extra attention as it is mostly frequently 
associated with anaphylaxis and fatal outcome [37]. Furthermore, peanut allergy usu-
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ally does not resolve itself and therefore has a high impact on the quality of life of the 
individual [38].  The prevalence of peanut allergic sensitisation varies between 1-2% (US 
and Canada) to 10% in the UK, of whom 2% have a clinical peanut allergy [39]. Currently 
allergen avoidance is the only way to prevent allergic responses [40] but in the case of 
peanut allergy, accidental ingestion is common due to the trace amount of peanut in 
many food products and cross-contamination during food processing [41]. Most hu-
man studies on probiotics and allergy have focused on the role of specific Lactobacil-
lus strains in the management and prevention of eczema, allergic eczema and allergic 
rhinitis [7]. Recent reviews on the large number of clinical trials performed so far pro-
vide stronger evidence for prevention of atopic disease rather than the management of 
atopic eczema and support the idea that probiotics deserve to be further explored. To 
date, there are only a few strains that have been reasonably well documented in clinical 
studies and they mostly show a positive but temporary effect on atopic dermatitis and 
eczema, in regard to allergic diseases [42-50]. 
As there are only a few studies comparing potential probiotic strains in vitro and in 
vivo our aim was to investigate the effects of three well characterized probiotic strains, 
which differ in their immunomodulatory properties, on the prevention of peanut al-
lergy. To select strains for this study strains of Lactobacillus and Bifidobacterium isolated 
from different commercially available products were screened for their immunomodu-
latory properties in a co-culture assay with human PBMCs. Based on these results L. 
plantarum WCFS1, L. salivarius HMI001 and L. casei Shirota were tested for their pro-
phylactic effect in a mouse model of allergic sensitization to peanut allergen. 
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Materials and Methods
Bacterial strains
Twenty-eight different strains comprising 12 species of probiotics or potential probiotic 
strains from commercially available products were tested in PBMC co-culture assays 
(Table 1). The species of the strains isolated from a product containing a mixture of bac-
teria were checked by 16S rDNA sequencing (data not shown). The bacteria were grown 
overnight to stationary phase in anaerobic conditions at 37oC in the recommended me-
dium. The bacteria were then recovered by centrifugation, washed twice in phosphate 
buffered saline (PBS, pH=7.4), resuspended at approximately 1*1010 colony forming 
units (CFU)/mL in PBS containing 20% glycerol, and stored in aliquots at – 80 oC prior to 
use. The exact number of bacterial CFU in a thawed aliquot was determined by plating 
serial dilutions of the cultures on MRS agar or MRS plus cysteine for the Bifidobacterium 
sp.
Human PBMC co-culture assays 
The study was approved by the Wageningen University Ethical Committee and was per-
formed according to the principles of the Declaration of Helsinki. Buffy coats from four 
blood donors were obtained from the Sanquin Blood bank Nijmegen, Netherlands. A 
written informed consent was obtained before the sample collection. PBMCs were iso-
lated by density gradient centrifugation (Ficoll-Plaque PLUS, Amersham, Roosendaal, 
Netherlands). PBMCs were cultivated in Iscove's Modified Dulbecco's Medium (IMDM) 
containing 1% heat-inactivated human AB serum, 1% penicillin, and 1% streptomycin 
(v/v) (Invitrogen, Breda, Netherlands). The cells were left unstimulated or were stimu-
lated with lipopolysaccharide (LPS, 1 µg/mL), Concanavalin A (ConA, 5 µg/mL ) or with 
bacteria in a 1:1 ratio with mononuclear cells. After 24hr incubation, the concentrations 
of IL-10, IL-12p70, and IFN-γ present in the co-culture supernatants were determined 
using the Becton and Dickinson (BD, San Diego, USA) cytometric bead array and flow 
cytometry (FACSCantoII, BD, San Diego, USA). The limits of sensitivity for detection were 
as follows: IL-10 (13 pg/mL); IL-12p70 (0.6 pg/mL); and IFN-γ (1.8 pg/mL).
Mice
Female C3H/HeOuJ mice, specific pathogen-free, were purchased from Charles River 
Laboratories (Lyon, France) and were maintained under barrier conditions in macrolon 
type III cages with wood chips bedding, at mean temperature of 22 ± 2°C, a relative 
humidity of at least 40% and not exceeding 70% and a 12-h light/dark cycle. Drink-
ing water and standard laboratory food pellets were provided ad libitum. Mice were 6 
weeks old at the start of probiotic dosing. The welfare of the animals was maintained 
in accordance with the general principles governing the use of animals in experiments 
of the European Communities (Directive 86/609/EEC) and Dutch legislation (The Experi-
ments on Animals Act, 1997). 
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Chemicals, reagents and monoclonal antibodies 
Cholera toxin (CT) was purchased from List Biological Laboratories, Inc (Campbell, CA, 
USA). All other chemicals were obtained from Sigma Aldrich (Zwijndrecht, The Nether-
lands) unless otherwise stated.
Table 1: Strains used in study
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Preparation of peanut extract (PE)
Peanut was kindly donated by Imco Nut Products, the Nut Company (Doetinchem, 
Netherlands) and was supplied by Golden Peanut, plant at Alpharetta (GA, USA). Pea-
nut protein extract was made by blending 500 g peanut with 500 mL 20 mM Tris buffer 
(pH 7.2). After 2 h blending at intervals of 20 min for 1 min at room temperature, the 
aqueous fraction (peanut extract) was collected by subsequent centrifugation (10,000 
g). The peanut extract was stored at -70 °C in aliquots prior to use.
Sensitization protocol
Groups of 8 mice were orally exposed to PBS (control) or PE plus cholera toxin (CT) 
(allergic sensitization) by intragastric dosing of PBS or 6 mg PE plus 10 µg CT in 200 
μL. Oral exposure was performed on days 0, 1, 2, 10, 17 and 24. Mice were intragastri-
cally administered 1x109 CFU of the different lactobacilli strains, diluted in 300 μL 0.2 
M NaHCO3. for three times per week, starting 14 days prior to the sensitization phase 
(day -14) until scheduled necropsy (day 31). The effect of LCS was tested in a separate 
animal experiment to HMI001 and WCFS1. To compare the results of the different ex-
periments, the measured parameters (i.e. mMCP-1 level, antibody levels and cytokines 
levels) were normalized to the vehicle-treated PE sensitized mice.
Measurement of serum mouse mast cell protease-1 (mMCP-I)
At day 30, mice were orally challenged with PE by intra-gastric gavage (0.4 mL of 30 
mg/mL). Blood samples were collected 30 minutes after oral challenge. Serum levels of 
mMCP-I were determined by ELISA according to the manufacturer’s instructions (More-
dun Scientific Ltd, Midlothian, Scotland).
Measurement of serum IgG1, IgG2a, and IgE antibodies
Blood samples were collected on day 31 and stored at -20°C until analysis. Levels of 
PE-specific IgG1and IgG2a in serum were determined by ELISA and levels of PE-specific 
IgE by sandwich ELISA. Plates (NUNC Immuno Maxisorp plate, Roskilde, Denmark) were 
coated overnight with 10 μg/mL PE (for IgG1 and IgG2a detection) or with 1 μg/mL puri-
fied rat anti-mouse IgE (BD Pharmingen) in PBS, followed by 1.5 h blocking with ELISA 
buffer. Each test serum was incubated for 2-2.5 h. For PE-specific antibody levels, a sera 
pool of mice, that were sensitized for three weeks with PE plus alum by intraperitoneal 
injection each week, was used as reference serum and a standard curve of the refer-
ence serum was included to determine antibody levels (in arbitrary units (AU)). For 
detection of PE-specific IgG1 and IgG2a, alkaline phosphatase-conjugated anti-IgG1 or 
anti-IgG2a, were added (1 h at RT). Subsequently, alkaline phosphatase buffer (Sigma) 
was used for the color reaction, which was stopped with a 3M NaOH and absorbance 
was measured at 405 nm using a Benchmark Plus Microplate Spectrophotometer (Bio-
Rad Laboratories, Richmond, CA, USA).
To measure PE-specific IgE antibodies, a PE-digoxigenin (DIG) conjugate solution (di-
luted in High Performance ELISA Buffer, from Sanquin, San Diego, CA, USA) was added 
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(1 h at RT). The coupling of DIG to PE was performed according to the manufacturer’s 
instructions (Boehringer Mannheim, Mannheim, Germany). After incubation (1.5 h at 
RT) with peroxidase-conjugated anti-DIG fragments (Roche Diagnostics, Mannheim, 
Germany), tetramethylbenzidine substrate solution was added and the color reaction 
was stopped with 1M H2SO4. Absorbance was measured at 450 nm.
Cell culture and cytokine measurement
On the day of necropsy (day 31), mouse spleens were processed to obtain single cell 
suspensions for ex vivo cytokine analysis. A suspension with a viable cell concentration 
of 5 x 106 cells/mL was prepared in enriched RPMI-1640 medium (RMPI 1640 with Glu-
tamax™ and 25 mM HEPES buffer supplemented with 10% heat inactivated FCS and 1% 
penicillin/ streptomycin). The splenocytes were stimulated in the presence or absence 
of PE (200 μg/mL) for 96 hours at 37oC and 5% CO2. Culture supernatants were stored 
in -80oC for cytokine measurements by multiplex analyses (BenderMed Systems, Ger-
many; mouse Th1/Th2 plex).
Statistics
Data were analyzed using GraphPad Prism 4 software. The significance of differences 
between group means were determined by using one-way ANOVA with the Bonferroni 
post hoc test. Statistical analyses were performed following logarithmic transformation 
(to achieve normal distribution). P<0.05 was considered to be statistically significant. 
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Results
Co-culture of hPBMCs with lactobacilli and bifodobacteria modulates production of IL-
10, IL-12, and IFN-γ 
PBMCs from four different healthy donors were cultured in the absence or presence of 
28 different bacterial strains comprising 12 species as well as LPS or ConA. Even though 
the levels of cytokines induced by the probiotic strains differed between donors, the 
ranking of the strains was highly consistent for each cytokine showing that the strain 
immune profiles were reproducible between donors. The different bacterial strains 
differed considerably in their ability to modulate PBMC immune responses (Fig. 1) as 
shown by the large range of cytokine responses: IL-10 (6 – 3789 pg/mL: 632-fold), IL-
12p70 (2 – 927 pg/mL: 464-fold), IFN-γ (1.8 pg/mL – 7.3 ng/mL: 4000-fold). 
For some species the level of induced cytokines were similar for the different isolates 
(strains) tested within that species (e.g L. salivarius) whereas for other species the 
strain immune profile varied considerably, especially for the L. casei strains where IL-10 
and IL-12p70 differed by 3-fold and 35-fold, respectively. Interestingly the B. animalis 
strain was not capable of inducing IL-10, IL-12p70 and IFN-γ. The L. salivarius HMI001 
(HMI001) induced high amounts of IL-10 and low amounts of IL-12p70 and IFN-γ, while 
the L. plantarum WCFS1 strain (WCFS1) induced less IL-10, and moderate amounts IL-
12p70 and IFN-γ (Table 2). Also L. casei Shirota (LCS) a probiotic previously shown to 
attenuate allergic responses [9] showed an interesting profile by inducing high amounts 
of Th1 cytokines, IFN-γ and IL-12p70, but low amounts of IL-10. Based on these distinct 
immunoprofiles the three strains were tested for their prophylactic effect in a mouse 
model of allergic sensitization to peanut allergen. Strain HMI001 has a relatively high IL-
10 /IL-12 ratio compared to other strains and was predicted to reduce the development 
of allergy by enhancing regulatory mechanisms to counteract allergic sensitization. The 
LCS strain was predicted to attenuate exaggerated Th2 responses due to the relatively 
high induction of Th1 cytokines such as IFN-γ which inhibits proliferation of Th2 cells. 
Strain WCFS1 was selected because it produces moderate amounts of pro- and anti-in-
flammatory cytokines and had an IL-10/IL-12 ratio which was lower than that of HMI001 
and higher than the LCS strain.
 
PE-specific antibody responses are modulated by treatment with lactobacilli
In order to investigate if prophylactic treatment with probiotics modulates the PE-
specific immune responses, mice were treated three times a week with 1x109 CFU of 
HMI001, WCFS1 or LCS starting 2 weeks before the sensitization phase with PE and CT 
and ending on day 31.
Compared to non-sensitized mice, all PE sensitized mice developed PE-specific IgG1, 
IgG2a, and IgE antibody responses, indicating that all mice became sensitized (Fig. 2). 
While administration of WCFS1 caused a significant increase in the PE-specific IgG1, 
IgG2a and IgE antibody levels, administration of HMI001 lead to a significant decrease 
in IgE levels (Fig. 2). In contrast, administration of the LCS strain had no significant effect 
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Figure 1: Effect of 28 probiotic strains on the cytokine production of human PBMCs (n=4 donors).
on the PE-specific antibody titers. 
 
In PE sensitized mice mast cell degranulation is modulated by treatment with lactobacilli
After a six week probiotic treatment and a four week oral exposure regime to PBS or PE 
with CT, all mice received an oral challenge with PE. Thirty minutes after PE challenge 
the serum concentration of mMCP-I was measured as a read-out for the type I hyper-
sensitivity response leading to mast cell degranulation. Control mice sensitized to PE 
had significantly higher levels of mMCP-1 in the serum after peanut allergen challenge 
compared to non-sensitized mice (Fig 2). Mice administered WCFS1 had significantly 
higher levels of serum mMCP-1 compared to the control, whereas serum mMCP-1 was 
lower in the mice given LCS or HMI001 (Fig. 2). 
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Figure 2: Effect of probiotic treatment in vivo on mast cell degranulation and PE-specific antibody 
response in a mouse model ofpeanut allergy. Data was normalized to sensitized vehicle treated mice. 
Values for sensitized vehicle treated mice were for HMI001 and WCFS1: mMCP-1 200 AU, IgG1 1229 
AU, IgG2a 12588 AU and IgE 2332 AU and for LCS: mMCP-1 6 , IgG1 7 , IgG2a 4 and IgE 3 .  
Note that the values for LCS are 2log antibody titers. *P <0.05 compared to the vehicle treated PE 
sensitized mice.
Treatment with lactobacilli modulated the ex vivo cytokine response to peanut allergen
Splenocytes from PE sensitized and non-sensitized mice were stimulated ex vivo in the 
presence or absence of PE. Unstimulated splenocytes secreted low amounts of cy-
tokines (data not shown). PE stimulated splenocytes from the vehicle control group of 
peanut sensitized mice produced increased amounts of IL-4, IL-5, and IL-10 compared 
to splenocytes from non-sensitized mice (Fig. 3). Prophylactic treatment with HMI001 
reduced IL-5 production compared to PE sensitized control mice, but this was not signif-
icant. A reduction in levels of induced Th2 cytokines IL-4 and IL-5 was also observed by 
treatment of PE-sensitized mice with LCS. In contrast, WCFS1 augmented the Th2 phe-
notype as shown by an increase in IL-4 production compared to the vehicle control (not 
significant) (Fig. 3). IL-10 and IFN-γ levels were not affected by any of the lactobacilli. 
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Figure 3: Effect of probiotic treatment on ex vivo cytokine production of PE-stimulated splenocytes 
from peanut sensitized mice. Data was normalized to sensitized vehicle treated mice. Values for sen-
sitized vehicle treated mice were for HMI001 and WCFS1: IL-4 213 pg/mL, IL-5 328 pg/mL, IL-10 5585 
pg/mL and IFN-γ 25599 pg/mL. and for LCS: IL-4 42 pg/mL, IL-5 156 pg/mL, IL-10 1622 pg/mL and IFN-γ 
4647 pg/mL *P <0.05 compared to the vehicle treated PE sensitized mice.
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Discussion
In this study we determined the immunomodulatory properties of 28 different bacterial 
strains, isolated from commercially available products, in a co-culture assay with human 
PBMCs. The different bacterial strains varied considerably in their ability to modulate 
PBMC immune responses. The strain differences in IL-10 (632-fold) and IL-12 (464-fold) 
induction, are much higher than that reported for different Bifidobacterium longum 
strains (8-fold) [29] and for multiple Lactobacillus and Bifidobacterium species in PBMC 
co-culture assays (10-15-fold) [15, 29, 51-53]. For some species, i.e. L. salivarius, the le-
vels of induced cytokines were similar for the different strains within the species, where-
as large variations in cytokine levels were measured using different strains of L. casei. 
These results are in line with other studies describing very different and even opposing 
effects of different species of Lactobacillus on DC activation [26]. Similarly, co-culture of 
DCs with different strains of B. longum led to variable cytokine responses and co-culture 
with PBMCs led to the secretion of either pro-inflammatory or regulatory cytokines 
[29]. Large variation in the ability of different Lactobacillus and Bifdobacterium strains 
to induce IL-12p70, IL-10, tumor necrosis factor alpha (TNF-α) and IFN-γ release in co-
culture with PBMCs was also reported by Foligne et al. [51]. The ability of the strains to 
confer protection against TNBS-induced colitis in vivo correlated with their potential to 
induce high amounts of IL-10 and low amounts of IL-12. Furthermore strains inducing 
high IL-10/IL-12 ratios in MLNs have recently been shown to induce tolerogenic DCs and 
expand the CD4+ Treg population in mice [13]. 
Based on the PBMC immune profiles of the strains tested in this study three different 
potential probiotic strains were selected to investigate their immunomodulatory pro-
perties in an established mouse model of peanut allergy. The L. salivarius strains (inclu-
ding the HMI001 strain) were capable to produce high amount of IL-10 and low amounts 
of IL-12p70 (i.e. a high IL-10/ IL-12 ratio; Fig. 1). Prophylactic treatment with HMI001 
treatment prior to sensitization to PE led to a slight, but significant, decrease in IgE ti-
tres compared to the vehicle-treated mice. In addition, HMI001 treatment also led to a 
significant diminution in mast cell degranulation (7-fold lower) upon oral challenge with 
peanut allergen. A reduction in mMCP-I is considered to be clinically relevant, as media-
tors released from mast cells cause clinical symptoms in allergic patients. Furthermore, 
prophylactic treatment with HMI001 reduced the ex vivo Th2-associated IL-5 produc-
tion, although this was not significant (p=0.15). A recent study showed that probiotics 
selected on the ability to induce a high IL-10/ IL-12 ratio can suppress experimental 
immune disorders in mice, such as inflammatory bowel disease, atopic dermatitis, and 
rheumatoid arthritis, by inducing Tregs [13]. This suggests a possible mechanism for 
the prophylactic effects of HMI001 in the peanut allergy model but flow cytometric 
analysis did not reveal any changes in the percentage of CD4+CD25+Foxp3+ T cells or 
CD4+CD25-Foxp3+ T cells in lactobacilli treated mice (data not shown). One possibil-
ity is that the Tregs in the HMI001 treated group have a greater suppressive activity 
on activated T cells as described in a recent immunodulation study using mixtures of 
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probiotics [13]. 
LCS induced high amounts of IFN-γ and IL-12p70, but low amounts of IL-10 in co-culture 
with PBMCs (Fig. 1), and was selected on the basis that it might counter balance the 
Th2 cell induced hyper responsiveness, by promoting Th1 cell development via IFN-γ 
and IL-12. Although prophylactic treatment with LCS did not significantly modulate the 
PE-specific antibody responses compared to vehicle-treated PE sensitized mice, Th2 
cytokine production (IL-4 and IL-5) in ex vivo stimulated splenocytes was significantly 
reduced. This is compatible with a skewing of the immune response towards Th1 and 
the immunomodulatory properties of the strain in vitro. Furthermore, LCS treatment 
led to a significant decrease in mast cell degranulation (7-fold lower) upon oral chal-
lenge with peanut allergen. LCS treatment was previously shown to reduce ovalbumin-
specific IgE and IgG1 responses and diminished systemic anaphylaxis by promoting a 
dominant Th1-type response mediated by IL-12 induction in a mouse model for food 
allergy [54, 55]. Furthermore LCS administration has been shown to attenuate seasonal 
allergic rhinitis in adults [9]. However, LCS did not decrease allergic responses to peanut 
extract in Brown Norway rats [56].  
The L. plantarum strain WCFS1 was selected because it produced moderate amounts 
of IL-10, IL-12 and IFN-γ compared to other strains and had an IL-10/IL-12 ratio which 
was lower than that of HMI001 and higher than the LCS strain. In the PE sensitization 
model, treatment with L. plantarum strain WCFS1 increased PE-specific antibody levels 
3-fold compared to vehicle-treated peanut sensitized mice, which was accompanied 
by a marked increase in mast cell degranulation after challenge. Additionally, WCFS1 
treatment augmented the ex vivo production of the Th2 cytokine IL-4 in PE- stimulated 
splenocytes. Interestingly, a study on Peyer’s Patches (PP)-DCs showed that antigenic 
challenge of PP-DCs from sensitized C3H/HeJ but not Balb/c mice in the presence of IL-4 
failed to inhibit the production of IL-10 and produced less IL-12p70, by that increasing 
the susceptibility to food allergy [57]. IL-4 promotes IL-12p70 production by DCs by 
suppressing the production of IL-10 by DCs themselves [58]. Taken together these data 
indicate that treatment with WCFS1 increased PE-specific humoral response and the 
development of type I hypersensitivity to peanut allergen. Based on these results we 
suggest that WCFS1 may be a useful strain to enhance immunity during infection or im-
mune responses to vaccination, but not in conditions of allergy. 
The mouse peanut allergy model used in this study mimics the clinical and immuno-
logic characteristics of peanut allergy in human subjects [59, 60]. In this mouse model 
the anaphylaxis induced by intragastric sensitization and challenge with peanut extract 
closely reflects the clinical characteristics in human subjects. This is based on the model 
described by Li et al., showing that peanut-induced anaphylaxis was IgE mediated, and 
mast cell degranulation and histamine release were associated with the anaphylactic 
symptoms [59]. Therefore we think that results obtained in our model are relevant to 
the human population.
Enhanced levels of PE-specific IgE and mast cell degranulation have been correlated as 
a worsening of food allergy [59, 61]. In contrast, helminth infections are known to in-
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crease a Th2 response, also characterized by an increase in IgE and IL-10, which protects 
against allergies. In the latter case, the stimulation of the Th2 response is accompanied 
by induction of local regulatory mechanisms, such as TGF-β production in the intestine 
[62-64]. An increase in TGF-β can lead to expansion of Tregs which may modulate aller-
gic responses [65]. However in this study the increase in PE specific IgE was coupled to 
increased mast cell degranulation and heightened sensitization to PE. 
Several in vitro experiments have evaluated the effects of lactobacilli strains on the 
modulation of the immune response. Different strains have been shown to induce 
maturation of DCs [26] stimulate the production of IFN-γ, IL-12, IL-10, and IL-18 [15], 
activate human monocytes [66], inhibit the production of Th2 classified cytokines, and 
induce IL-10-producing Tregs [16]. One or more of these immunomodulatory properties 
may play a role in the prevention of allergic sensitization. Different studies showed that 
differences in Treg activity may play a role in the development and resolution of food 
allergies, but for probiotic treatment this might not be the only protective mechanism. 
Using an animal model of food allergy, Zhang et al. showed that oral feeding of bifido-
bacteria favored the generation of IL-10+ DCs in the intestine, enhanced the number of 
Tregs and suppressed the Th2 pattern of inflammation [67]. In the current study flow 
cytometric analysis did not reveal any changes in the percentage of CD4+CD25+ and 
Foxp3+T cells in any of the lactobacilli treated mice compared to vehicle-treated mice 
(data not shown). Although it has been shown that naturally occurring CD4+CD25+ 
Tregs are important for the modulation of the PE allergic response [60, 68], it could 
be that other regulatory cells, such as Tr1 (IL-10 secreting) or Th3 (TGF-β secreting) 
cells play a more imperative role in probiotic modulation [69]. In food allergy multiple 
mechanisms might play simultaneous roles, making it difficult to predict the applica-
bility of probiotics to treat food allergy. If more detailed knowledge of the mechanisms 
underlying their effect becomes available, it might well be possible to improve therapy 
by using cocktails of different probiotics, combining specialized regulatory features of 
the various probiotics.
Screening potential probiotics using human PBMCs was useful in selecting strains with 
predicted anti-inflammatory and Th1 skewing properties. In the case of HMI001 (induc-
ing a high IL-10/IL-12 ratio) and LCS (inducing high amounts of IFN-γ and IL-12) partial 
protection was seen in a mouse peanut allergy model. Selection of strains with diffe-
rent profiles may worsen the allergic reaction as shown in the case of WCFS1. Although 
further research is needed to validate the immunomodulatory mechanisms involved in 
vivo, this approach is likely to be useful for selecting strains for translational research 
in humans. 
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Abstract 
Background 
Influenza is a globally important respiratory pathogen which causes a high degree of 
morbidity and mortality annually. Both mucosal and systemic immunity contributes to 
resistance to influenza infection and disease. Probiotics, including L. plantarum strains, 
may be considered as adjuvants to increase the efficacy of influenza vaccine.
Objective 
To test whether intragastric (i.g) administration of selected L. plantarum strains, pos-
sessing distinct immunomodulatory properties, can modulate systemic immune res-
ponses to an influenza vaccine in mice.
Methods 
We established an influenza vaccination model in young female Balb/c mice. Modula-
tion of cellular immune responses to vaccination by six L. plantarum strains was studied 
by measurement of delayed type hypersensitivity (DTH) responses to the vaccine, cy-
tokines, chemokines and innate receptors gene expression measurements in mesen-
teric lymph node cells and by cytokine secretion of mesenteric lymph node cells stimu-
lated ex vivo with ConA and vaccine HA antigen. The vaccine-specific serum antibody 
titres for IgG1 and IgG2a subclasses were measured in serum by ELISA. 
Results 
Oral (i.g.) administration of L. plantarum strains LMG18021 and WCFS1 significantly 
modulated the immune responses to an intranasal influenza vaccine. LMG18021 aug-
mented the Th1 phenotype in the mouse model (increased DTH, higher IgG2a/IgG1 
ratio, higher IL-12 and TNF-α expression levels and higher antigen specific response). In 
contrast, WCFS1 augmented the Th2 response (higher IgG1 response, higher IL-13 and 
lower TNF-α expression levels).
Conclusion and Clinical relevance
L. plantarum strains LMG18021 and WCFS1 are promising candidates to test in an intra-
nasal influenza vaccination and challenge model. In vitro immune assays with human 
dendritic cells are useful tools to select candidate strains for immune modulation stu-
dies in mice. 
 
141
Chapter 7
Introduction
Influenza is an important respiratory pathogen which causes a high degree of morbidity 
and an estimated 250,000 to 500,000 deaths each year worldwide (WHO). Vaccina-
tion is still the most effective method of preventing mortality and morbidity, despite 
the improvements in antiviral therapy with amantadine or rimantadine. The efficacy of 
antiviral therapy is about 70% in treating influenza type A infection [1]. In high-income 
countries influenza vaccination is used to reduce mortality in people aged over 65 and 
other risk groups. The current inactivated vaccines are aimed at eliciting high-levels of 
virus neutralizing antibody to influenza surface HA antigen thereby inhibiting binding 
to the host cells which provides efficient protection from influenza infection. However, 
due to the high mutation rate of the virus, caused by antigenic shift and antigenic drift, 
a particular vaccine formulation is effective for at most about one year. Therefore each 
year, three strains are chosen for development of the seasonal vaccine in the North-
ern and Southern Hemispheres based on the ‘The WHO Global Influenza Surveillance 
Network of National Influenza Centres’. The efficacy of influenza vaccine varies each 
year depending on the match between vaccine subtypes and circulating viral strains, 
patient’s age, and pre-existing immunity. Poor immunogenicity may also be a problem 
with certain vaccines as exemplified by the development of vaccines for the pandemic 
H5N1 avian influenza. In this case two 90 µg doses of the inactivated split virus were 
required to produce levels of seroconversion observed with only a single dose of the 
seasonal flu vaccine [2]. Despite the current vaccination policies influenza infection still 
remains a severe burden particularly in elderly individuals over 60 years [3-4]. 
In young healthy adults, the inactivated influenza vaccine provides protective clinical 
efficacy in 70-90% of cases, but this is reduced to only 17-53% in elderly individuals [5]. 
In addition to the inactivated vaccine a live attenuated influenza vaccine (LAIV) has been 
licensed by the Food and Drug Administration (FDA) since 2003. The LAIV contains live 
but attenuated influenza viruses, and is sprayed into the nostrils rather than injected 
intramuscularly. As the FDA have approved the use LAIV in healthy children and adults 
from 2-49 years of age, it could be used to control pandemic influenza outbreaks. To 
improve the efficacy of vaccines several approaches have been investigated such as 
increasing the antigen dose in the vaccine (Centers for Disease Control and Prevention, 
2010), using alternative routes of administration such as intradermal injection [6] and 
using mucosal immune adjuvants. None of these strategies are fully efficacious or suffer 
from specific drawbacks. Therefore novel approaches are still needed to increase the 
efficacy of oral vaccines such as polio, rotavirus and influenza. One attractive and rela-
tively easily implemented approach could be to utilize dietary supplementation with 
immune stimulating probiotics. 
Probiotics have been shown to enhance specific immune responses to vaccination in 
young children and in adults. In a study on cholera vaccination several probiotic strains 
were tested for their effect on antibody responses to the commercial oral cholera vac-
cine [7]. The probiotic strains were given daily over a period of three weeks in which 
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the oral cholera vaccine was also administered. In the early phase of the response se-
rum IgG responses tended to increase in most probiotic treated groups and significant 
increases were observed for Bifidobacterium lactis B1-04 and Lactobacillus acidophilus 
La-14 compared to controls [7]. However, no effects on the final end point immuno-
globulin titres to the vaccine were found [7]. The effects of L. rhamnosus LGG on a rhe-
sus-based rotavirus vaccine were shown to significantly increase humoral antibody IgM 
responses but not cell-mediated immunity (T cell responses to antigen stimulation). In 
a different study consumption of LGG or L. acidophilus CRL431 for five weeks doubled 
neutralization antibody titres to an oral polio vaccine given in the fifth week [8]. In the 
group consuming probiotics a marked increase in polio-virus specific IgA was observed 
after vaccination. The effects of LGG and L. lactis on a Salmonella typhi Ty21a vaccine 
were shown to not significantly increase numbers of IgA, IgG and IgM secreting cells 
[9]. There was however a trend towards a higher antigen-specific IgA levels in subjects 
treated with LGG treatment. Together these findings show that specific probiotic strains 
can enhance the immunogenicity of orally administered vaccines such as rotavirus [10], 
Salmonella [9], polio [8], and cholera [7].
Although the focus of much research on probiotics and immunity has centered on en-
teric infections and oral vaccination [7-10], there is also evidence that probiotics can 
stimulate immune responses to respiratory pathogens [11]. Furthermore a recent study 
on LGG as an immune adjuvant for LAIV in healthy adults showed significantly improved 
protective serum responses to one of the three viruses present in the vaccine [12]. This 
has important implications for the use of probiotics to stimulate immunity to respira-
tory pathogens and enhance responses to other intranasally delivered vaccines. 
Little is known about the mechanisms underlying the positive effects of probiotics on 
mucosal vaccines but it is generally assumed that this involves stimulation of innate 
immunity via microbe associated molecular patterns (MAMPs). Despite the fact that dif-
ferent MAMPs are generally conserved in major groups of bacteria, strikingly different 
immune responses to different species and strains are observed in vitro [13-14]. This 
should be given more consideration in relation to in vivo studies as it may reveal the 
underlying mechanisms and explain the different effects of probiotic strains observed in 
vivo. Recently probiotic strains that induce high IL-10 to IL-12 cytokine ratios in mouse 
bone marrow derived dendritic cells (DCs) were shown to expand the CD4+ Foxp3+ 
regulatory T cell population after oral administration [15]. This was linked to a beneficial 
effect in different mouse models of inflammatory disease but it might have converse 
effects with respect to enhancement of immunity or vaccination. The in vitro immu-
nomodulatory properties of probiotics have been largely ignored in previous studies on 
their use as adjuvants but it warrants further investigation. 
As certain strains of probiotic lactobacilli have been shown to enhance immunity to res-
piratory pathogens and intranasally administered vaccines such as LAIV, we undertook 
a mechanistic study to compare the effects of different selected strains on an intrana-
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sal influenza vaccine. In general the probiotic field suffers from a lack of comparative 
studies using the same models and assays with different strains in vitro and in vivo. 
In addition to LGG which was taken as a control, we selected 6 strains of Lactobacil-
lus plantarum that have strikingly different immunomodulatory properties in vitro (Ta-
ble 1). This selection was based on previous studies examining the in vitro immune 
responses of human monocyte derived DCs and peripheral mononuclear blood cells 
(PBMCs) to 42 different L. plantarum strains [13-14]. First we established an influenza 
vaccination model in Balb/c mice that would be sensitive to immunomodulation by lac-
tobacilli. Cellular immune responses were assessed after vaccination by measurement 
of delayed type hypersensitivity (DTH) responses and cytokine responses of mesenteric 
lymph node (MLN) cells after polyclonal stimulation with concanavalin A (Con A) or the 
vaccine. In addition mRNA levels of different cytokines, chemokines and innate recep-
tors were measured in naïve MLN cells after vaccination. Modulation of the humoral 
immune response to vaccination by different lactobacilli was assessed by measurement 
of the vaccine-specific serum antibody concentrations.
Table 1: Immunomodulating properties of selected strains in DCs [13] .
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Materials and Methods
Bacterial strains
Bacteria, stored at – 80 oC in de Man,Rogosa Sharpe (MRS) medium plus 10% glycerol, 
were streaked on MRS solidified with 1.4% agar and incubated overnight at 37 oC. Cul-
tivation was carried out until an optical density (OD)600 1- 1.5 was obtained. Bacteria 
were harvested by centrifugation, washed twice in 0.2 M NaHCO3, and resuspended in 
0.2 M NaHCO3 plus 10% glycerol to an estimated concentration of 2x10
9 colony forming 
units (CFU) per mL. Bacterial suspensions were dispensed into aliquots and stored at 
–80 oC. Aliquots of these stock suspensions were used to determine the actual number 
of CFU per mL. On each day of dosing, an aliquot of each bacterial strain was thawed 
and diluted in 0.2 M NaHCO3 buffer to a dose concentration of 10
9 CFU/mL.
Mice
Female Balb/c mice, specific pathogen-free, were purchased from Harlan (Correzzana, 
Italy) and were maintained under barrier conditions in macrolon type III cages with 
wood chips bedding, at mean temperature of 22 ± 2 °C, a relative humidity of between 
40% and 70% and a 12-h light/dark cycle. Drinking water and standard laboratory food 
pellets were provided ad libitum. Mice were 6 weeks old at the start of probiotic dosing. 
The welfare of the animals was maintained in accordance with the general principles 
governing the use of animals in experiments of the European Communities (Directive 
86/609/EEC) and Dutch legislation (The Experiments on Animals Act, 1997). 
Dose responsiveness to the intranasally administered Influvac vaccine 
The tri-valent influenza vaccine Influvac 2010/ 2011 (Solvay, Weesp, The Netherlands) 
contains an A/California/7/2009 (H1N1)-like strain (A/California/7/2009 NYMC X-179A 
reass., 15 μg haemagglutinin (HA)/ dose), an A/Perth/16/2009 (H3N2)-like strain (A/
Wisconsin/15/2009 NYMC X-183 reass., 15 μg HA/ dose) and a B/Brisbane/60/2008-
like strain (B/Brisbane/60/2008, 15 μg HA/ dose). In order to determine the appro-
priate vaccine dose to use in the immunization model with probiotics, five groups of 
mice (n=4) were intranasally administered 0.1, 0.3, 0.9, 1.8 or 3.6 µg of the Influvac 
2010/2011 vaccine. One group (n=4) was not immunized with the influenza vaccine and 
served as a control group. To obtain a positive reference serum, 4 mice were intramus-
cularly immunized with 9 µg influenza HA vaccine on days 0 and 14. Serum from these 
mice was pooled and used as a standard serum in the antibody ELISAs.
Vaccination and probiotic dosing protocol
The study comprised 9 groups of 6 week old Balb/c mice. Group 1 (n=10) consisted of 
vaccine control mice that were immunised with the influenza vaccine and given a buffer 
instead of lactobacilli as indicated below. Groups 2-8 (n=10) were immunised with the 
influenza vaccine and received one of the lactobacilli strains. Group 9 (n=5) were ad-
ministered a buffer instead of the vaccine and lactobacilli. The bacterial strains (1x109 
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CFU/ dose) were diluted to a volume of 250 µl and were administered three times a 
week by oral gavage (day 0-40). Groups 1-8 were intranasally immunized with a dose of 
3.6 µg influenza HA (Influvac 2010/2011) on days 14 and 28.
Detection of HA-specific IgG1 and IgG2a in serum
Vaccine-specific antibody concentrations were measured in serum after days 0, 28 and 
at the end of the intervention period (day 44). To do this, flat bottom plates (NUNC Im-
muno Plate, Roskilde, Denmark) were coated (overnight, 2-10 oC) with 2 µg HA/mL, dis-
solved in 0.2 M NaHCO3. After washing the plates three times in wash buffer (phosphate 
buffered saline (PBS) / 0.1% v/v Tween-20 solution; Sigma-Aldrich), the plates were 
blocked with 1%  w/v Bovine Serum Albumin (BSA) in PBS (1 hr, RT). After removing the 
blocking buffer, serial dilutions of the serum (in PBS / 1% w/v BSA) were incubated in 
duplicate (1.5 hr, RT). Eight dilutions of serum were used for ELISAs, the starting dilution 
of the serum was 15 times for IgG1 and 50 times for IgG2a. The plates were washed 
again 3 times in wash buffer and then incubated for 1.5 hr at RT with horseradish per-
oxidase (HRP)-conjugated goat anti-mouse IgG1 (AbD Serotec, Dusseldorf, Germany) or 
goat anti-mouse IgG2a [AbD Serotec] diluted 10.000 times in PBS / 1% BSA. After wash-
ing the plates three times, the HRP detection substrate 3,3',5,5'-tetramethylbenzidine 
solution was added for approximately 15 minutes at RT before stopping the reaction 
with  2N H2SO4. Optical density was measured at 450 nm using a Benchmark Plus Micro-
plate Spectrophotometer (Bio-Rad Laboratories, Richmond, CA). The standard curves 
were modeled using the four-parameter logistic regression and were used to calculate 
the antibody-concentrations. 
Delayed type hypersensitivity response
The delayed type hypersensitivity (DTH) reaction was evaluated by assessing ear swell-
ing reactions. On day 42, the animals were intradermally injected with Influvac HA vac-
cine in both ears (20 µL per ear, containing 1.8 µg HA). Ear thickness was measured in 
duplicate using a digital micrometer (Mitutoyo, Veenendaal, the Netherlands), shortly 
before challenge (reference ear thickness) and 24 and 48 hours after challenge. The ear 
swelling was calculated by subtracting the basal ear thickness from the value at 24h or 
48h after challenge.
Gene transcript quantification in MLNs 
Total RNA was isolated from the MLNs of each group using RNeasy kit (Qiagen) with a 
DNase digestion step. The quantity of RNA was determined using the nanodrop device 
(Thermoscientific, Wilmington, USA). Reverse transcription was performed on 0.5 µg 
of total RNA using qScript cDNA synthesis kit (Quanta Biosciences, Gaithersburg, MD, 
USA). The optimized blend of random and oligo(dT) primers provides robust, consistent, 
and unbiased first-strand synthesis over a broad range of RNA template concentrations. 
PRIMER EXPRESS (Applied Biosystems, Foster City, CA, USA) and primer3 software were 
used to design primers for use in real-time quantitative PCR (qPCR) (Table 2). Primers for 
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IL-10 (PPM03017B-200) and IL-13 (PPM03021A-200) were ordered from Qiagen (Venlo, 
The Netherlands). For qPCR 5 μl cDNA and forward and reverse primers (300 nM each) 
were added to 12.5 μl GoTaq qPCR Master Mix (Promega, Leiden, The Netherlands) and 
demineralized water was added to a final volume of 25 μl. qPCR (2 min 95 °C, 40 cycles 
of 15 s at 95 °C, 60 s at 60 °C followed by 2 min at 60 °C) was carried out on a Rotorgene 
2000 real-time cycler (Corbett Research, Sydney, Australia). Raw data were analysed 
with comparative quantitation of the Rotor-gene Analysis Software V5.0. Changes in 
transcript levels were calculated relative to the vaccinated control mice according to 
the Pfaffl equation: Ratio = (Etarget) Ct target (control-sample)/(Ereference)Ct reference (control-
sample) [16]. Two internal reference genes (L32 ribosomal protein and β-actin) were 
included in every q-PCR experiment and the results were similar using either gene for 
standardisation. To control for possible DNA contamination in the RNA samples ‘non-
RT’-controls were included in all experiments and no amplification above background 
levels was observed. No-template controls were also included for each gene in each run 
and no amplification above background levels was observed. Specificity of the ampli-
fication was ensured by checking the melting temperature and profile of each melting 
curve. The PCR product of each template was checked at least once by DNA sequencing 
(Baseclear, Leiden, The Netherlands).
Cell culture and cytokine measurement
On the day of necropsy (day 44), mouse MLNs were gently disrupted to obtain single 
cell suspensions for ex vivo cytokine analysis. The cell suspensions were adjusted to vi-
able 5 x 106 cells/mL in enriched RPMI-1640 medium (RMPI 1640 with Glutamax™ and 
25 mM HEPES buffer supplemented with 10% heat inactivated FCS and 1% penicillin/ 
streptomycin). The MLN cells were stimulated in the presence or absence of HA vac-
cine antigen (5 μg/ mL) for 72 hours or the mitogenic T cell stimulant Con A (5 μg/ mL) 
(Sigma) for 24 hours at 37oC and 5% CO2. Culture supernatants were stored in -80
oC until 
cytokines were measured by multiplex analyses (Mouse Th1/Th2/ Th17 CBA kit, BD).   
TLR signalling assays 
TLR signalling assays were performed on stably transformed cell lines of human embry-
onic kidney cells (HEK293) expressing TLR-2 and TLR-6 and transfected with a reporter 
plasmid (pNiFTY) containing firefly luciferase under the control of the human NF-κB 
promoter. HEK293 cells do not produce TLRs, but when stably transformed with TLRs 
they can activate NF-κB upon addition of the appropriate TLR agonists. TLR transfected 
cells were seeded at 5 x 105 cells/cm2. Cells were incubated with different probiotic 
strains (1:15 cell to bacteria ratio), or Pam2CSK4 (Invivogen) agonists as a control (5 
μg/mL). After six hours incubation the medium was replaced with Bright-Glo luciferase 
assay buffer (Promega) and luminescence intensity was measured in a Spectramax M5 
reader (Molecular devices) within 15 minutes. TLR-2 ligands signal through two types of 
TLR-2 receptors, one linked to TLR-1 and one to TLR-6. TLR-2/6 is known to be activated 
by MAMPs associated with Gram-positive bacteria, i.e. lipoteichoic acid and diacylated 
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lipoproteins and unmethylated CpG DNA. 
Table 2: Primer sequences used for qPCR
Statistics
Data were analyzed using GraphPad Prism 4 software. The significance of differences 
between group means were determined by using one-way ANOVA with the Bonferroni 
post hoc test. Statistical analyses were performed following logarithmic transformation 
(to achieve normal distribution). P<0.05 was considered to be statistically significant.
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Results
The intranasal vaccine-dose response 
In order to determine a vaccine-dose that would be suitable for an immunomodulation 
study with lactobacilli, the mouse were intranasally administered 0.1, 0.3, 0.9, 1.8 or 3.6 
µg of Influvac 2010/2011 vaccine on days 0 and 14. There was a clear dose–response 
relationship between the vaccine dose and vaccine specific antibody responses (Fig. 1A 
and B). Even at the lowest dose of 0.1 μg, vaccine-specific antibody responses were de-
tected by d14, but no high levels of IgG2a were detectable at d28. The response to the 
lowest dose however, was significantly lower than those of the higher vaccine doses. In 
the vehicle group, no vaccine specific antibody titres were measured. In the group vac-
cinated with 3.6 µg of HA, all mice responded with high antibody titres to the vaccine 
but these responses were still 385-fold (1334 AU) and 22-fold (22624 AU) lower than 
the titres obtained for IgG1 and IgG2a respectively in mice immunized intramuscularly 
with 9 µg HA (500.000 AU). These results indicated that a dose of 3.6 μg of HA would 
enable us to study both the potentiation and attenuation of vaccine antibody responses 
and was therefore used in subsequent experiments to test the immunomodulatory ef-
fects of different Lactobacillus strains on intranasal immunization.
Figure 1 Vaccine-dose responses in mice after intranasal immunization with different amounts of Influ-
vac 2010/2011.  Vaccine-specific IgG1 (a) and IgG2a (b) concentration in arbitrary units (AU) in serum 
of mice. The concentrations were calculated relative to pooled serum (500 times diluted) from intra-
muscular vaccinated animals, with a defined concentration of 1000 AU. Error bars indicate SEM; n = 4.
 
Selection of Lactobacillus strains for the immunization study
Based on the distinct immune profiles seven L. plantarum strains were tested for their 
prophylactic effect in a mouse vaccination model (Table 1). Strains KOG18 and CIP104448 
were both stimulating relatively high levels of Th1 promoting cytokines TNF-α and IL-12, 
and were predicted to enhance cell-mediated immunity. However the IL-10 and IL-12 
ratio differed for KOG18 (low ratio) and CIP104448 (high ratio), which might influence 
their ability to enhance regulatory T cells. Strain WCFS1 was selected because it produc-
es moderate amounts of both pro- and anti-inflammatory cytokines. Strains LMG18021 
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and CIP104450 were chosen for their intermediate stimulating capacities of all tested 
cytokines. Strain B1839 was selected because it induced barely detectable amounts of 
pro- and anti-inflammatory cytokines and was predicted not to enhance vaccination. L. 
rhamnosus LGG was selected as a control based on its previous use in influenza vaccina-
tion and challenge studies [8-10, 17-19]. 
Cytokine mRNA levels in unstimulated MLN cells
IL-12 mRNA levels were significantly higher in mice treated with CIP104450 or LMG18021 
than that in control (vaccinated) mice (Fig. 2A). TNF-α mRNA levels were also signifi-
cantly higher in the LMG18021 group but significantly lower in the mice administered 
WCFS1 or LGG. IL-13 mRNA levels tended to be higher in mice treated with WCFS1 than 
in the control group, but this difference was not statistically significant (p=0.062). IL-4 
mRNA levels were lower in most groups treated with L. plantarum strains except for 
strain CIP104448. IL-2 mRNA levels were lower in KOG18, CIP104448 and LGG. There 
were no significant differences in IL-10, IL-17A, TGF, IFN-γ , Foxp3, IDO, PD1L, ICOSL, 
CTLA-4, B7.1 and B7.2 mRNA expression levels (Fig. 2A and B). 
In these qPCR assays there were no significant differences between the control groups 
of vaccinated and non-vaccinated mice. These data suggest that strains LMG18021 and 
CIP104450 induce more Th1 skewing responses in unstimulated lymphoid cells draining 
the mucosal tissue. The increased levels of IL-13 and lower levels of TNF-α observed in 
the WCFS1 group are suggestive of increased Th2 responses in the mucosa-associated 
lymphoid tissue. 
Ex vivo stimulation of MLN cells.
Cytokine production was measured in the culture supernatants after ex vivo stimulation 
of MLN cells with ConA or the vaccine antigen HA(Fig 3A). Strikingly, WCFS1 treated 
mice showed a significant decrease in the IL-10, TNF-α, IL-2 and IL-6 response to ConA 
compared to the vaccine control (Fig. 3A, data IL-2 and IL-6 not shown). Significantly 
lower IL-10 was also observed in the KOG18, CIP104450, CIP104448 treated mice (Fig. 
3A). There were no significant effects of the Lactobacillus strains on the levels of IL-17A, 
IL-4 and IFN-γ compared to vaccinated mice administered a buffer control instead of 
lactobacilli (data not shown). 
As expected the ex vivo cytokine response to HA was significantly lower in non-vac-
cinated mice compared to all the vaccinated groups. IL-2 and IFN-γ responses were 
not altered in the probiotic treated mice (data not shown).Interestingly MLN cells from 
CIP104450, LMG18021, and CIP104448 treated mice showed a significant increased IL-
10, IL-17A, IL-6 and IL-4 in response to the vaccine  (Fig. 3B).  CIP104450 treated mice 
showed also an increased TNF-α vaccine induced cytokine response. As these differ-
ences were not apparent in ConA stimulated MLN cells, it can be concluded that the 
lactobacilli administration induced antigen-specific changes in the mucosal immune 
response.
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A
B
Figure 2 Gene transcript quantification in unstimulated MLN cells. qPCR was used to determine gene-
specific mRNA levels relative to the housekeeping gene L32. * indicates p < 0.05 compared to vac-
cinated mice group, tested using ANOVA; error bars indicate SEM; n = 5 in sham group, n = 10 in all 
other groups.
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Figure 3 Ex vivo cytokine responses in stimulated MLN cells. MLN cells were stimulated with ConA 5 
µg/mL (A) or HA antigen 5µg/mL (B) in pg/ mL. Probiotic treatment led to an increased vaccine-specific 
(HA) induced cytokine response ex vivo. *indicates p < 0.05 compared to vaccinated mice group, test-
ed using ANOVA; error bars indicate SEM; n = 5 in sham group, n = 10 in all other groups.
Effect of lactobacilli on vaccine DTH  response
The generation of a delayed-type hypersensitivity (DTH) response was used as a pri-
mary measurement of Th1-mediated immune response to HA although other cell types 
have been suggested to play a potential role in this hypersensitivity reaction [20]. On 
day 42, the DTH reaction was evaluated by assessing ear swelling reaction (Fig. 4). The 
DTH response in non-vaccinated mice was significantly lower than in all other groups 
of vaccinated mice. Administration of KOG18, CIP104450, LMG18021, LGG or B1839 
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resulted in a significant increase of the DTH response 24 hours after challenge, with LGG 
having the strongest effect. The WCFS1 strain gave a significant DTH response after 48 
h but not 24 h after challenge. Strain CIP104448 (showing a high IL-10 to IL-12 ratio in 
DCs) did not induce a significant DTH response compared to the vehicle control mice. In 
conclusion some of the lactobacilli were able to increase the DTH response to the vac-
cine compared to the control vaccine group.
 
Figure 4 Ear thickness after intradermal challenge. Lactobacilli treatment leads to an increased DTH 
response. DTH responses to the vaccine measured by ear swelling after a) 24h and b) 48h. * indicates 
p < 0. 05 compared to vaccinated mice group, tested using ANOVA; error bars indicate SEM; n = 5 in 
sham group, n = 10 in all other groups.
Modulation of vaccine-specific antibody titres by administration of lactobacilli
After the first immunization with Influvac 2010/2011, all groups had HA-specific anti-
body-titres at day 28, except the non-vaccinated mice (data not shown). The IgG1-titres 
increased  > 20 fold after the second immunization, whereas IgG2a increased  >35 fold.
As expected, no HA-specific antibody titers were detected in the serum of non-vaccinat-
ed mice at day 44. The evaluation of the effects of lactobacilli-treatment on IgG1 titres, 
revealed that mice orally treated with WCFS1, had significantly higher HA-specific IgG1 
titres (2-fold increase) (p=0.044) compared to the vaccine control group, administered 
a buffer instead of lactobacilli (Fig. 5A). This trend was also observed in KOG18-treated 
mice although it was not highly significant (p=0.055). Mice treated with LMG18021, 
CIP104448, LGG and B1839 showed statistically significantlower IgG2a titres as com-
pared to the vaccine control group (Fig. 5B). 
In mice, IgG2a antibodies are generally associated with Th1 activity, while IgG1 anti-
body responses are associated with Th2 activity, based on the ability of IFN-γ and IL-4 
to stimulate and cross-regulate the production of these IgG subclasses [21]. Therefore, 
IgG2a/IgG1 ratios give an indication of relative Th1/Th2 balance and revealed that ad-
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ministration of LMG18021 significantly increased the Th1 response to HA (p=0.008; Fig. 
5C). CIP104450 administration also elevated the antigen-specific IgG2a/ IgG1 ratio by 
3-fold compared to the vehicle control group, although this was not significant (p=0.07).
 
 
    
Figure 5 HA-specific serum antibody titres for subclasses IgG1 (A) and IgG2a (B) in arbitrary units (AU) 
and the IgG2a/IgG1 ratio (C). The concentrations were calculated relative to a pooled serum (500 
times diluted) from intramuscular vaccinated animals, with a defined concentration of 1000 AU. * in-
dicates p < 0.05 compared to vaccinated mice group, tested using ANOVA; error bars indicate SEM; n = 
5 in sham group, n = 10 in all other groups. Note that some data points were left out in the calculation 
of the IgG2a/IgG1 ratio, due to the low value in IgG1, using Dixon’s Q test.
L. plantarum strains differentially activate TLR-2
HEK-reporter cell lines that express TLR-2 and TLR-6 were used to compare the capac-
ity of the L. plantarum strains to activate TLR-2/6 signaling (Fig. 6). Exposure of the 
TLR-2/6-expressing HEK-reporter cell line to LMG18021 strongly activated NF-κB com-
pared to the other strains and the medium control. 
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Figure 6 TLR activating properties selected L. plantarum strains
NF-κB pathway activation measured by a luminescence reporter in HEK cell lines expressing TLR-2/6 
after exposure to different L. plantarum strains. The ratios of HEK reporter to bacterial cell were 1:15 
and error bars indicate SEM; n=5. 
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Discussion
Here we showed that oral administration of certain strains of lactobacilli could enhance 
humoral antibody responses and modulate T cell responses to an intranasal influenza 
vaccine in mice. This may have important implications for the current public health 
strategy of reducing influenza-related mortality and morbidity by annual vaccination. 
One of the high-risk groups for complications due to influenza infection is elderly over 
60 years for which the seasonal tri-valent inactivated vaccine (TIV) given by intramus-
cular injection is the current standard. Despite  current vaccination policies, the elderly 
population has the highest infection rates and novel strategies are needed to improve 
the efficacy of the influenza vaccine [3]. Recent studies indicate that the intranasally 
administered LAIV is safe in elderly subjects and tended to have a higher efficacy than 
the inactivated vaccine in people over 70 years [22]. Thus dietary supplementation with 
specific strains of L. plantarum strains might further increase the efficacy of LAIV.
Serum antibody responses are believed to correlate with protection efficacy of TIV for 
influenza [23-24]. A specific-HA antibody response was only detected in groups of mice 
administered the vaccine. Of the six L. plantarum strains evaluated in this model, the 
WCFS1 strain significantly increased HA-specific antibody responses to the intranasal 
vaccine compared to the vaccine control group, a trend which was also seen with strain 
KOG18. Interestingly both these strains induce the lowest IL-10 to IL-12 cytokine ratio in 
human DC co-culture assays except for strain B1839 which induces hardly any cytokine 
responses in this assay (Table 1). In the group of mice administered WCFS1 we ob-
served a significant decrease in IL-10 and TNF-α production after polyclonal stimulation 
of MLN cells with ConA. In unstimulated MLN cells, mRNA levels of the Th2 cytokine 
IL-13, also tended to be higher than in the vaccine control group but this did not reach 
significance (p= 0.062). In the WCFS1 group the TNF-α mRNA levels were lower than in 
the vaccine control group suggesting increased Th2 responses in the lymphoid tissue. 
Moreover a significantly higher IgG1 response (p= 0.044) was observed in the WCFS1 
group compared to the vaccine control which in mice indicates a skewing of the vaccine 
T helper response towards Th2. Interestingly, WCFS1 was recently shown to increase 
sensitization to peanut extract in an allergic sensitization model (Meijerink et al 2011, 
submitted), further supporting the idea that this strain enhances Th2 responses. Taken 
together these results indicate that oral administration of WCFS1 strain can enhance 
humoral immune responses to the intranasal vaccine. 
Several Lactobacillus strains appeared to increase DTH responses after vaccination com-
pared to the vaccine control group suggesting Th1-mediated vaccine responses. For 
strain LMG18021 this was also reflected in the significantly higher HA-specific IgG2a to 
IgG1 antibody ratio. The Fc portion of IgG2a interacts with complement factors [25] and 
activating Fc receptors [26-28] with a high affinity which efficiently activates receptor-
mediated effector function. This stimulates the antibody dependent cell-mediated cyto-
toxicity [29] and opsonisation and subsequent phagocytosis by macrophages [30], which 
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is important in the contribution to the clearance of influenza virus from the infected 
host [31]. The Fc portions of IgG1 antibodies are binding with a lower affinity to the Fc 
receptor than the Fc portion of IgG2a, [32-33] and increased IgG2a antibody titres to 
influenza have been associated with increased vaccination efficacy [31, 34-36]. In vitro 
LMG18201 induces relatively high amounts of Th1 promoting cytokines and relatively 
low amounts of IL-10 compared to the other strains. The induction of influenza-specific 
memory T cells producing IFN-γ (Th1 cytokine) is vital for a rapid response to influenza 
reinfection [37]. The importance of IFN-γ in protection against influenza has also been 
demonstrated in genetically altered mice [38]. The exact reasons why some strains like 
LMG18021 promote Th1 responses in vitro and in vivo are unknown but recent insights 
come from a study of a phosphoglycerol transferase gene mutant in L. acidophilus [39]. 
The mutant is unable to synthesize lipoteichoic acid (LTA) and in comparison to the wild 
type strain induction of IL-12 was substantially reduced. Moreover, IL-10 levels were 
increased in co-culture with human monocyte derived DCs [39]. As LTA is an agonist of 
TLR-2/6, the reduction in Th1 promoting cytokines observed in immune assays with the 
mutant may reflect a reduced ability to stimulate innate signalling via the TLR-2/6 path-
way. Circumstantial evidence supporting this hypothesis comes from our finding that 
the Th1 promoting strain LMG18021 was the strongest inducer of NF-κB activation in a 
TLR-2/6 reporter cell assay, which is also reflected in the significantly increased expres-
sion of TNF-α in naive MLN cells. LMG18021, CIP104448 and CIP104450, which induce 
the highest ratio of IL-10 to IL-12 among the strains tested, significantly enhanced the 
ex vivo HA-specific induction of IL-10, IL-17A, IL-6 and IL-4 in MLN cells. Elevation of 
these cytokines was not observed in MLN cells polyclonally stimulated with ConA, a 
lectin which cross-links the T cell receptor, thereby mimicking the T cell receptor acti-
vation without the requirement of co-stimulatory signals. ConA polyclonal stimulation 
of T cells is often used to assess their maximal immune responsiveness ex vivo. These 
results show that these strains specifically enhance the antigen-specific HA response to 
vaccination.
The mucosal immune system contains a large network of immune cells that traffic from 
inductive sites to effector sites in the mucosal tissues. Immunization studies have previ-
ously shown that cells traffic from the gut to the lungs, to enhance local immunity to 
clear Pseudomonas aeruginosa or Haemophilus influenza [40-41]. Thus the  HA-specific 
response measured in the MLN cells might be due to trafficking of vaccine-primed an-
tigen presenting cells or T cells from the nasal mucosa to the MLNs. This might be a 
mechanism by which orally administered lactobacilli can enhance responses to an in-
tranasal vaccine. HA-specific immune responses in the MLN cells could also result from 
some of the intranasal vaccines being swallowed but this seems less likely as the proto-
col has been optimized to specifically avoid this possibility. Furthermore, much higher 
doses of purified antigen are generally needed to elicit responses by the oral route of 
administration than via the intranasal route. 
Evidence to support the influence of intestinal microbiota on respiratory immune res-
ponses comes from recent work on mice treated with antibiotics [42]. Commensal 
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bacteria are crucial in maintaining immune homeostasis of the intestine, but also in 
regulating immune defense against respiratory tract influenza A infection [42]. Oral an-
tibiotic treatments resulted in defective CD4+ T, CD8+ T and B cell immunity following 
intranasal infection with influenza virus. Rectal inoculation of CpG (TLR-9 agonist), poly 
I:C (TLR-3 agonist) and to a lesser extent peptidoglycan/cell wall components (TLR-2 
agonists) could restore immunity in the lung. This indicates that signals coming from 
distal commensal bacteria may be sufficient to support immune priming in the lung. 
Antibiotic treatment led to impaired respiratory distribution, steady state synthesis of 
pro–IL-1β, pro–IL-18, and NLRP3 and reduced DC migration from lung to the draining 
lymph nodes. 
Several human and animal studies have shown the potential of probiotics to function as 
immune adjuvants. In one study healthy volunteers developed higher vaccine-specific 
IgA antibodies compared to the placebo group, consuming lyophilized LGG for seven 
days and receiving an attenuated oral Salmonella typhi vaccine capsule on days 1, 3 and 
5 [9]. Additionally healthy volunteers consuming fermented milk containing L. acidophi-
lus La1 and bifidobacteria had an increased S. typhi specific serum IgA, compared to the 
placebo group [45]. In a study with oral rotavirus vaccine infants supplemented with 
LGG had higher titres of IgA and higher numbers of rotavirus-specific IgM-secreting cells 
than the placebo group [10]. The administration of LGG before an oral polio booster, has 
also been associated with increased poliovirus-neutralizing antibody titres and poliovi-
rus- specific IgA and IgG [8]. In a placebo-controlled trial using a supplement containing 
L. paracasei, elderly patients receiving the influenza and pneumococcal vaccines had 
increased NK cell activity and IL-2 secretion in PBMCs and a decreased number of infec-
tions when compared with placebo group [46]. In another randomized placebo-con-
trolled trial, elderly patients who received Actimel containing L. casei DN-114 001 for six 
weeks had higher influenza-specific antibody titres after intramuscular vaccination [19]. 
In a trial of healthy adults, L. fermentum CECT5716 improved the immunogenicity of 
an intramuscular applied inactivated tri-valent influenza vaccine, showing an increased 
number of NK cells in blood, increased levels of serum Th1 cytokines and an increase 
in antigen specific IgA [47]. Additionally the incidence of influenza-like illness after vac-
cination was lower in the probiotic treated group. Collectively, these studies clearly in-
dicate the potential for specific strains of lactobacilli to enhance immune responses to 
vaccines administered via the intranasal or oral route. 
Besides the adjuvant effects of oral lactobacilli on vaccination, several studies in hu-
mans and animals that support the role of specific strains of Lactobacillus in the preven-
tion of influenza infection. In an animal study, where mice pups were fed L. casei Shirota 
supplement for 3 weeks before inoculation with influenza virus, the probiotic treated 
pups had better survival (40% versus 14%). Moreover the L. casei Shirota treated mice 
had lower viral titres in the nasal lavages, higher pulmonary NK cell activity, and higher 
IL-12 production by MLN cells compared with control mice [48]. In a separate study 
intranasal administration of L. casei Shirota, was reported to enhance cellular immunity 
in the respiratory tract and to protect against influenza virus infection in mice [49]. 
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Furthermore, oral administration of L. casei Shirota activated not only the systemic im-
mune system but also the local immune system and ameliorated influenza virus infec-
tion in aged mice [50]. In a mouse model of influenza infection with an H1N1 strain, 3 
days of intranasal exposure to LGG was significantly associated with a lower frequency 
of accumulated symptoms and a higher survival rate than in control mice [17]. Additio-
nally using the same mouse model of influenza infection, oral administration of LGG or 
L. gasseri TMC0356 for 19 days was associated with lower clinical symptom scores and 
pulmonary virus titres as compared with control mice [18]. In studies of children in day-
care centers, administration of LGG was associated with a decrease in upper respiratory 
infections and with the duration of infections [51-52]. 
In our study the probiotic LGG was included as it has been shown to confer protec-
tive effects in challenge studies with influenza [17-18] and to enhance the efficacy of 
intramuscular influenza vaccination [19]. In contrast in our study there was only an en-
hanced DTH response observed in the mice treated with LGG, but no effect on HA-
specific antibodies in serum and on ex vivo cell response. The challenge studies did not 
show any data on antibody titres in serum [17-18], so the serum levels might also be 
unaffected, indicating that LGG might be more beneficial for NK cell function, which was 
not measured in our study. 
Although the most common vaccination route of influenza A is intramuscular, we hy-
pothesized that intragastric probiotic treatment could lead to an enhanced respiratory 
immunity. It has been shown that mucosal immune responses can be more efficiently 
achieved by the mucosal administration of vaccines, i.e. oral, rectal, vaginal or intra-
nasal. Additionally, intranasal vaccines are easier to administer and avoid the use of 
needles and syringes leading to decreased risk of infection from contaminated blood, 
better public compliance and reduced costs. Nevertheless many vaccines could benefit 
from strategies to enhance the efficacy and the required type of immune response in 
different target populations. Our results suggest that L. plantarum strains LMG18021 
and WCFS1 could be used as probiotics to enhance immunity to intranasally adminis-
tered vaccines such as LAIV. Whether these increased vaccine-specific antibody titres 
and enhanced ex vivo vaccine induced T cell responses we have observed with certain 
lactobacilli will finally lead to increased protection has to be investigated in a future 
mouse study. In this study HA-specific IgA responses in the nasal lavages were too low 
to quantify in our assay. As intranasal vaccination has the potential to enhance protec-
tion by eliciting vaccine-specific secretory IgA in the respiratory tract which could block 
virus entry and neutralize intracellular virus assembly, more sensitive methods should 
be used to qualify the IgA in the nasal lavage or other time points should be taken to 
investigate the effects of probiotics. Additionally NK cell activity could also be altered by 
probiotic administration, as this seems to be another important route of the beneficial 
effects of for instance probiotic LGG [17-18, 48-49], therefore NK cell activity assays 
could be also included in future studies with these strains.
In conclusion, this study shows that oral administration of specific strains of lactobacilli 
can enhance humoral or Th1-mediated immune responses to an intranasal influenza 
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vaccine. Thus oral consumption of selected immunomodulatory probiotics may be one 
strategy to enhance vaccine responses to intranasal vaccination against influenza. 
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The aim of this thesis was to get a better understanding of the molecular mechanism 
of host responses to probiotics. Beneficial effects of strains of probiotics have been 
established in the treatment and prevention of various intestinal disorders, including al-
lergic diseases and diarrhea. However the precise molecular mechanisms and the strain 
dependent factors involved are poorly understood. This knowledge would facilitate the 
selection of the most effective strains or strain combinations and give new insights into 
how to measure the health effects of probiotic in animal models and eventually in hu-
mans.
Two key questions were central to the research described in this thesis: 
1. Which bacterial factors determine the immunomodulatory properties of   
 specific probiotic strains? 
2. Can the in vivo activity of a probiotic be predicted from its in vitro    
 immunomodulatory properties?
Initially immune responses were studied to different probiotic strains and different 
strains of the same species, namely L. plantarum, in order to determine the natural 
variation in the response (Chapter 3 and 4). In Chapters 3 and 4 this was combined with 
genomics data in a statistical approach to identify genetic loci in L. plantarum that influ-
enced the specific cytokine responses. Specific strains were then selected on the basis 
of their immune responses in vitro for studies in mouse models of peanut sensitization 
(Chapter 6) and influenza vaccination (Chapter 7). The aim of the in vivo work was to 
test the predicted immune effects of selected strains on allergic sensitization and vac-
cination and gain further mechanistic insights into the immunomodulatory properties 
of these strains. 
In the last part of this general discussion relevance of this thesis to industry and society 
is discussed and concluding remarks are given for future research.
Overview of probiotic mechanisms 
Over the past ten years, the role of the intestinal bacteria in shaping human physiology 
and immunity has become increasingly evident [1-7]. This has stimulated the interest 
in using probiotics to benefit human health and prevent disease, such as allergy and 
colitis. Probiotics are defined as living organisms that, when administered in sufficient 
numbers, are beneficial to the host [8]. The most common genera used as probiotics 
are Lactobacillus and Bifidobacterium. Probiotic effects seen in human or animal stu-
dies are species specific and even strains of the same species may differ in their ability 
to elicit beneficial effects [9]. In addition, the effects of probiotics are dependent on 
dose, formulation, route and frequency of delivery as well as the animal model or hu-
man study population. Probiotic effects may result from modulation of the composition 
and/ or activity of the commensal microbiota, and/ or their stimulation of the immune 
system including innate signaling pathway in epithelial cells (ECs). Probiotics can influ-
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ence the production of the short chain fatty acids (SCFAs) butyrate, propionate and 
acetate that have potent anti-inflammatory activities [10-12]. Probiotics can make the 
gut environment more favorable to the growth of bacteria considered to be benefi-
cial (e.g. of the genera Lactobacillus and Bifidobacterium) and less favorable for patho-
gens by lowering the intestinal pH, through the production of SCFAs and lactic acid and 
improving colonization resistance (Fig. 1, General introduction). Some probiotics are 
suggested to act in the lumen of the gut by producing antibacterial molecules such as 
bacteriocins [13]. Others enhance the mucosal barrier by increasing the production of 
innate defense molecules, including goblet cell–derived mucins [14] and trefoil factors 
and Paneth cell defensins via innate signaling pathways [15, 16]. Probiotics can also 
mediate their beneficial effects by promoting adaptive immune responses (secretory 
immune globulin A, regulatory T cells (Tregs), interleukin-(IL)10, NK cell activity) [17-19] 
in a strain-dependent fashion. Although probiotics are proposed to act via different 
mechanisms, this thesis is specifically focused on the immunomodulatory capacities of 
probiotics.
The fate of orally consumed probiotics and implications for understanding mecha-
nisms of action
Different species of lactic acid bacteria (LAB) vary in their capacity to survive passage 
through the stomach, and passage only transiently through the gastrointestinal tract 
[20, 21]. Studies on colonization with orally consumed lactobacilli have shown that they 
persist only during the periods of dosing and/ or for relatively short periods of time 
after administration [22-24]. The mucus present in the intestine presents a substantial 
barrier to microbial contact with ECs, although some commensal species are known to 
degrade and colonize the mucus (reviewed in [25]). 
Mucus is a viscous gel-like matrix formed by large heavily glycosylated proteins called 
mucins. The mucus layer contains several antimicrobial factors and secreted immuno-
globulins that are directed against specific microbial antigens. Specialized secretory 
cells called goblet cells found throughout the entire intestinal tract secrete and produce 
mucins. The composition of the mucus barrier varies throughout the gastrointestinal 
tract and is rapidly turned over, and is regulated by innate signaling pathways in goblet 
cells [26]. In mice, the colonic mucus consists of two layers extending 150 µm above 
the epithelial surface which have a similar protein composition [27]. The inner firmly 
adherent layer is thinner (50 µm) densely packed and devoid of bacteria, whereas the 
outer layer is less dense and colonized by bacteria [28]. In the small intestine the mucus 
layer is thinner than in the colon or even absent in places [25, 29]. The firmly adherent 
mucus is approximately 15 µm thick whereas the thickness of the outer mucus layer 
varies throughout the small intestine but is the thickest in the ileum, where the bacte-
rial content of the small intestine is highest [25, 29]. The barrier function of the mucus 
is evident from studies on human biopsy material showing that most commensal bac-
teria are present either in suspension in the lumen or trapped in the mucus [30]. Other 
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challenges to the persistence of bacteria in the small intestine are the fast transit time 
(ranging from 15 minutes to 5 hours with a mean of about 84 min) [31] and the pres-
ence of bile acids, which limit the bacterial growth and even kill most probiotic species, 
although many LAB can possess bile salt hydrolases [32]. 
The dome epithelium otherwise known as follicle-associated epithelium (FAE) covering 
the large aggregates of lymphoid follicles in the Peyer’s patches (PP) of the small intes-
tine lacks or has limited numbers of goblet cells [33-35] and may therefore be more 
accessible to consumed probiotics (Fig. 1). Microfold (M) cells present in the FAE are 
specialized in the uptake of particulate antigens, including bacteria and viruses which 
they transport to the basal membrane in endosomes [36]. M cells differ in structure 
compared to their surrounding enterocytes with fewer lysosomes, more mitochondria, 
a lack of mucous glycocalyx covering their surface, and a basolateral extracellular space 
that surrounds interdigitated lymphoid cells. In addition, the pattern and dominance of 
M cell surface receptors is different to that of enterocytes [37-39]. It has been shown 
that human M cells utilize receptor dependent transport mechanisms for bacterial up-
take [40]. Orally administered nanoparticles and GFP-labeled commensals are taken up 
by M cells in the PP and the same may be true for probiotics [36, 41, 42]. M cell medi-
ated uptake of bacteria is also likely to occur in the isolated lymphoid follicles (ILFs) 
associated with the colonic epithelium. Several studies have shown that commensal 
bacteria can translocate by an intracellular route through the ECs lining the intestine 
and subsequently travelling via the lymph to the mesenteric lymph nodes (MLN) [36, 
43-46]. This could also be important in the activation of the intestinal immune system.
In the sub-epithelial dome of the PP, dendritic cells (DCs) present bacteria sampled by 
M cells and subsequently activate the adaptive immune system by migration to the fol-
licular area and presentation of antigen to naïve lymphocytes, or migrate to the MLNs 
through the efferent lymphatic ducts. In the MLNs or in the PP, mature DCs drive the 
differentiation of naïve CD4+ T lymphocytes into effector T cells, helper T (Th) cells (Th1, 
Th2, Th17) or Tregs. (Fig. 1). 
DC subtypes that can open the epithelial tight junctions and send protrusions to the 
luminal side [48] play an important role in the sampling of luminal bacteria [49, 50]. 
The ability of DCs to produce IL-12 and prime naïve T cells for Th1 polarization to mi-
crobial stimuli can be abolished by in vitro conditioning monocyte-derived DCs with 
supernatant from intestinal eptihelial cells (ECs) [51]. Treatment of DCs with EC condi-
tioned growth medium conditions them to produce high amounts of IL-10 and promote 
regulatory T cell and Th2 cell responses, a phenotype that was shown in vitro to be 
dependent on epithelial production of thymic stromal lymphopoietin (TSLP) [51]. An-
other important immunoregulatory cytokine produced abundantly by intestinal ECs and 
stromal cells in the intestine is transforming growth factor beta (TGF-β), that inhibits 
NF-κB dependent gene expression and the production of pro-inflammatory cytokines 
by macrophages and DCs [52, 53]. Additionally, TGF-β acts in concert with TSLP to in-
duce a tolerogenic phenotype in monocyte derived DCs in vitro [54]. 
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Figure 1 (modified From [47]): The mucosal epithelium, lamina propria cells and gut-associated lym-
phoid tissue in the small intestine. A single layer of intestinal epithelial cells (ECs) separates the luminal 
contents from the lamina propria (LP). In the basolateral space between ECs, are positioned intraepi-
thelial lymphocytes. The epithelium is covered by a thick layer of mucus produced by goblet cells. 
Antimicrobial peptides (AMPs) and secretory antibodies provide additional protection mechanisms. 
Enterocytes and specialized Paneth cells in the crypts are able to secrete AMPs preventing bacterial 
growth in proximity to the epithelium. Plasma cells in the LP produce secretory immunoglobulin A 
(sIgA) that mediate bacterial exclusion. The luminal content is continuously sampled by specialized 
ECs and immune cells. In the follicle associated epithelium (FAE) of the Peyer’s patches (PP) or isolated 
lymphoid follicles, microfold (M) cells transcytose bacteria and antigens. In the LP and PPs, CX3CR1+ 
macrophages and dendritic cells (DCs) sample microbes and antigens through the epithelium to sup-
port inflammatory responses. DCs, macrophages and M cells deliver antigens and bacteria to antigen 
presenting cells (APCs), such as CCR6+ DCs. Activated APCs then move to the follicular area of the PP 
or they migrate to the mesenteric lymph nodes (MLN) through the lymphatic system and present the 
antigen to naïve lymphocytes. In the MLN or in the PP, mature DCs drive the differentiation of naïve 
CD4+ T lymphocytes into effector T cells, helper T cells (Th1, Th2, Th17) or regulatory T cells (Tregs). 
The CD103+ population of DCs in the LP play a key role in generating inducible Tregs. 
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In summary, the small intestine seems to be the most likely place for interaction of pro-
biotics with the immune system, due to a thinner or absent mucus layer, less competi-
tion of commensal bacteria and presence of M cells. Clearly DCs play a cardinal role in 
regulating tolerance and immunity in the mucosal tissues. Therefore this immune cell 
type is highly relevant and often used to study intestinal bacterial interactions in vitro. 
In vitro co-culture assays to assess the immunomodulating properties of 
probiotics
In vitro assays are generally considered as useful approaches to select promising strains 
to test in in vivo animal models or in human trials although there is presently little 
data in the literature to strongly supports this view [55-57]. Candidate strains are often 
tested for their immunomodulatory potential in in vitro co-culture assays with differ-
ent types of immune cells, such as human monocyte derived DCs, human peripheral 
mononuclear cells (PBMCs) and mouse bone marrow derived DCs [58]. Immune param-
eters such as IL-10, IL-12, tumor necrosis factor alpha (TNF-α) and interferon gamma 
(IFN-γ) are often measured to characterize the strains tested. IL-10 production is typi-
cally measured, because it is an anti-inflammatory cytokine that suppresses IL-12 pro-
duction and consequently IFN-γ production, thereby favouring a T-helper 2 (Th2) or a 
Treg response. In addition, IL-10 down-regulates antigen presentation and inhibits the 
activation of macrophages and thus the production of pro-inflammatory molecules and 
chemokines. IL-12 and TNF-α are commonly measured as production of these cytokines 
by DCs is associated with the induction of T-helper 1 (Th1) responses. Furthermore, IL-
12 elicits IFN-γ production by T cells and by NK cells.
There are some important considerations and potential limitations to the use of in vitro 
co-culture assays. As mentioned before epithelial conditioning can also play an impor-
tant role in the priming of DCs. DCs isolated from the PP behave differently compared to 
other subsets in the intestine. However, conditioned DCs probably may not reflect the 
response of all subtypes, e.g. in the PP or the epithelial-attached DCs. In addition, most 
immune co-culture assays with bacteria make use of antibiotics to prevent overgrowth 
and acidification of the culture, and therefore the probiotic strains will be killed, or ar-
rested in growth during the incubation period [55, 59-61]. Mileti et al. used a method 
by which live bacteria are in co-culture with DCs and after 1h incubation, the cells are 
washed and the medium is replaced by an antibiotic containing medium [9]. In future 
experiments, this method might be a better alternative than co-culture in only antibi-
otic containing medium as it would allow interaction of DCs with live bacteria and the 
production of secreted bacterial factors including metabolites to occur.
In vitro assays for pre-screening of probiotics would benefit from standardized me-
thods. Therefore in Chapter 5 we used a cryopreservation method, which was previ-
ously investigated in a small number of studies [62-65] concerning the application of 
171
Chapter 8
DCs in clinical immunotherapy. These prior studies were limited to DC stimulations with 
synthetic ligands, cytokines or antibodies including lipopolysaccharide (LPS), TNF-α, 
IFN-γ and CD40L but not bacteria. However, we found that cryopreservation of both 
monocytes and immature DCs led to a skewed Th2 cytokine response to microbial stim-
ulation. Therefore we consider that standardization of probiotic screening assays by the 
use of cryopreservation methods is currently not applicable. The detailed method for 
generating human monocyte derived DC described in Chapter 5 may however be useful 
for developing standardized immune assays.
Variation in the immune response to different species and strains of lactobacilli 
The in vitro cytokine responses of human PBMCs and DCs to lactobacilli and bifidobacte-
ria can be strikingly different depending on both the species and the strain [59, 66-68]. 
In Chapter 6 we determined the immunomodulatory properties of 12 different bacterial 
species encompassing 28 strains, isolated from commercially available products. The 
different bacterial strains varied considerably in their ability to modulate PBMC immune 
responses. The strain differences in IL-10 (632-fold) and IL-12 (464-fold) induction, was 
much higher than previously reported for Bifidobacterium longum strains (8-fold) [67] 
and for multiple Lactobacillus and Bifidobacterium species in PBMC co-culture assays 
(10-15-fold) [55, 67, 69-71]. 
In Chapter 4 PBMC co-culture with 42 L. plantarum strains induced mean levels of IL-10 
and IL-12 over a 14- and 16-fold range, respectively, and IL-10/IL-12 ratios over a 13.5-
fold range. In Chapter 3 we studied DC responses to these 42 L. plantarum strains and 
the amounts of IL-10 induced cytokines ranged from 28 pg/mL to 1095 pg/mL (39 fold) 
for IL-10 and from 20 to 11996 pg/mL (600 fold) for IL-12. From a comparison of IL-12 
to IL-10 ratios it was clear that these cytokines can vary independently of each other 
resulting in strains with distinct pro-inflammatory and anti-inflammatory profiles (Fig. 
2). This remarkable diversity in the immunomodulatory properties of different strains of 
the same species suggests that multiple genetic factors can influence the phenotype in 
immune assays. This was investigated further in Chapter 3 and 4 and is discussed in the 
section “Identification of genetic loci in L. plantarum that influence cytokine responses 
of human immune cells”.
Immunomodulatory factors of bacteria
Using genetic approaches, several cell-wall associated molecules of lactobacilli have 
been shown to affect and/ or modulate the response of immune cells [72]. Innate sig-
nalling pathways are the most well characterised mechanisms by which lactobacilli can 
activate and induce effector responses in immune cells. The innate receptors involved 
in microbe detection are known as pattern recognition receptors (PRRs) and are ex-
pressed on immune cells and many other tissues including the intestinal epithelium. 
The Toll-like receptor (TLR) family of PRRs have been characterised in many animals 
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Fig. 2: IL-10, IL-12p70 production and the IL-10/IL-12p70 ratio by monocyte-derived DCs stimulated 
with 20 different L. plantarum strains. The graphs were produced using data from Chapter 3, [59] 
based on one of the 5 representative donors. The different strains induce strikingly different amounts 
of IL-10 and IL-12 and have distinct pro-inflammatory and anti-inflammatory profiles based on their 
IL-10/IL-12 ratios. 
and their specificity for conserved microbe-associated molecular patterns (MAMPs) is 
well characterised for humans and rodents (see table 1 General introduction). 
A different set of receptors known as the nucleotide binding and oligomerization do-
main (NOD)-like receptors (NLRs), of which there are more than 20 family members, 
recognize intracellular ligands. NOD1 and NOD2 have been shown to detect the bacteri-
al peptidoglycan (PGN) fragments meso-DAP and muramyl dipeptide, whereas the spe-
cificities of most of the other NLRs remains uncharacterized. Recently, a study showed 
that the anti-inflammatory capacity of Lactobacillus salivarius Ls33 in a trinitrobenzene 
sulfonic acid (TNBS) induced colitis model was driven by NOD2-mediated recognition 
of a specific PGN-derived muropeptide. This anti-inflammatory activity was mediated 
through the induction of regulatory CD103+ DCs via NOD2 signalling and the expansion 
CD4+ regulatory T cells [73].
Recently, several lectin and C-type lectin receptors (CLRs) have been characterized 
that are involved in the recognition and capture of antigens by antigen presenting cells 
(APCs). One such CLR known as DC-specific intracellular adhesion molecule-3 grabbing 
non-integrin (DC-SIGN) recognizes high-mannose-containing structures.
The di-acylated membrane anchors of lipoproteins and lipoteichoic acids bind to TLR-
2 and TLR-6 promoting dimerization and MyD88-mediated activation of the canonical 
pathway of NF-κB. The capacity of different species to stimulate TLR-2 signalling varies 
considerably, even at the strain level for those species which have been extensively 
tested (Fig. 3). A D-alanyl transfer protein B (dltB)-mutant of Lactobacillus plantarum 
strain NCIMB8826 (WCFS1) was found to incorporate much less D-alanine in its teichoic 
acid (TA) than the wild-type strain [74]. This defect significantly impacted on the immu-
nomodulatory properties of the bacterium, as shown by a reduction in the secretion of 
pro-inflammatory cytokines by PBMCs and monocytes in co-culture with the dltB mu-
tant and wild type strain [74, 75]. Additionally in a recent study by Bron et al. the impact 
of wall TA (WTA) backbone in L. plantarum WCFS1 mutants was determined (Bron and 
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Meijerink, unpublished). Derivatives of L. plantarum WCFS1 were constructed that syn-
thesize alternative WTA variants and were used for WTA isolation and biochemical anal-
ysis. The mutants were shown to either completely lack WTA, or produce WTA and LTA 
that lack D-alanine substitution, or contain ribitol-backbone WTA instead of the wild-
type glycerol-containing backbone. A transcriptome analysis revealed which genetic 
determinants were involved in this alternative WTA backbone, and pinpointed ribose 
and arabinose as the possible biosynthetic precursors. Co-culture of these mutants with 
human DCs resulted in drastically decreased levels of pro-inflammatory cytokines as 
compared to the wild type (Bron and Meijerink, unpublished). Moreover, human em-
bryonic kidney NF-κB reporter cell line experiments indicated that WTA dampens TLR-2 
and TLR-1/2 signalling to different degrees, strongly depending on the backbone alditol, 
and to some extend on D-alanyl substitutions, whereas LTA signalling occurs via a TLR-
2/6 dependent mechanism completely dependent on D-alanyl substitutions. This study 
shows that the WTA structure-function can also contribute to the high variability in the 
host immune response to different strains of lactobacilli. Therefore, strain-dependent 
differences in the peptidoglycan structure could explain why the in vitro cytokine re-
sponses of human PBMCs and DCs to lactobacilli can be strikingly different depending 
on both the species and the strain. Furthermore, sugars present in the cell wall and the 
post-translational modification of proteins with carbohydrates can also modulate the 
immune response by binding to C-type lectin receptors. 
Fig. 3: TLR-2/6 activating properties 42 different L. plantarum strains. TLR signalling assays were per-
formed on stably transformed cell lines of human embryonic kidney cells (HEK293) expressing TLR-2 
and TLR-6 and transfected with a reporter plasmid containing the firefly luciferase under the control 
of the human NF-κB promoter. HEK293 cells do not produce TLRs, but when stably transformed with 
TLRs they can activate NF-κB upon addition of the appropriate TLR agonists. Cells were incubated 
with different L. plantarum strains (1:15 cell to bacteria ratio). for six hours incubation after which the 
luminescence intensity was measured 
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TLR-9 recognizes bacterial genomic DNA which unlike eukaryotic DNA contains a high 
frequency of unmethylated CpG motifs [76]. Different species of lactic acid bacteria 
might differ in their capacity to elicit TLR-9 signalling due to differences in C+G ccontent 
and the frequency of stimulatory motifs in the DNA. The expression of TLR-9 by im-
mune cells is intracellular and endosomal, and in polarized ECs it is expressed on both 
the apical and basolateral membrane. In polarized ECs TLR-9 has been shown to have 
tolerogenic effects to chronic TLR challenges depending on the location of the stimulus 
[77]. Human epithelial HT-29 monolayers treated in vitro with bacterial DNA, including 
DNA from lactobacilli, delayed NF-κB activation, stabilized levels of IκB and attenuated 
IL-8 secretion in response to pro-inflammatory stimuli [78]. Additionally, a recent study 
reported similar effects for HT29 and T84 cell monolayers using DNA from L. rhamnosus 
GG (LGG) [79]. In addition, IL-10 deficient mice orally treated with purified DNA from 
VSL#3 showed reduced mucosal secretion of TNF-α and IFN-γ and improved histologic 
disease scores [78]. Applying neutralizing antibodies against type I IFN abolished the 
anti-inflammatory effects induced by TLR-9 agonists, whereas the administration of 
recombinant IFN-β mimicked the anti-inflammatory effects induced by TLR-9 agonists 
[80]. In contrast to anti-inflammatory effects, pro-inflammatory effects have been ob-
served using bacterial DNA and synthetic oligonucleotides (ODN) containing CpG se-
quences in vitro and in vivo in combination with LPS challenge [81]. Interestingly, RAW 
264.7 cells pre-exposed for 1-3h to CpG-ODN, augmented a pro-inflammatory cytokine 
response to LPS, whereas prolonged exposure of the cells for 6-9 h induced the sup-
pression of inflammatory cytokines via the induction of IL-10 expression [81]. In vivo 
studies with experimental colitis showed conflicting effects of CpG-ODN, showing that 
CpG-ODN in active disease worsened inflammation [82] and prophylactic administra-
tion diminished colitis [80].
The large variation in strain immune profiles described in Chapter 3 and 4 suggested 
that there could be some underlying strain-dependent genetic differences influencing 
the innate response to L. plantarum. As TLRs recognize highly conserved MAMPs, we 
hypothesized that the differences were due to modification or differential expression 
of MAMPs or other novel factors interacting with host immune cells. In chapter 3 and 
4 (discussed below) genetic loci in L. plantarum that affect the immune response to 
PBMCs and DCs were investigated using a gene-trait matching approach.
Identification of genetic loci in L. plantarum that influence cytokine responses of human 
immune cells.
To identify novel strain-specific genes and factors that modulate innate recognition by 
the host, the natural diversity in the immune response to different strains of L. plantar-
um was used in Chapter 3 and 4. Microarray based comparative genome hybridization 
of WCFS1 was used to provide a one-directional comparison of gene-content profiles 
per strain. In Chapter 3 and 4 the secreted cytokine amounts or cytokine ratios for the 
L. plantarum strains were correlated with the presence or absence of specific genes by 
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regression using the Random Forest algorithm. Several genes or gene loci were identi-
fied to be potentially involved in the immunomodulation. These loci included genes 
encoding an N-acetyl-glucosamine/galactosamine phosphotransferase system, the 
LamBDCA quorum sensing system, a predicted transcriptional regulator gene (lp_2991) 
and components of the plantaricin (bacteriocin) biosynthesis and transport pathway. 
Deletion mutants of the candidate genes were constructed in the WCFS1 strain in order 
to validate their anticipated effect on cytokine induction. 
One of the confirmed genes with immunomodulatory capacities in PBMCs was the 
pts19ADCBR locus coding for a cell membrane-associated N-acetyl-galactosamine/
glucosamine phosphotransferase system, that might be important for utilization of dif-
ferent carbohydrates in the intestine. Another confirmed gene which correlated with 
immunomodulation of PBMCs was the L. plantarum WCFS1 lamB, encoding a proces-
sing/export protein of the autoinducer peptide quorum sensing two-component sys-
tem (AIP-based QS-TCS) LamBDCA. The observed PBMC IL-10/IL-12 ratios for L. plan-
tarum might either be mediated directly through the LamBDCA system and the cognate 
secreted peptide, or indirectly through cell products (e.g., polysaccharides) under the 
control of this regulatory system. 
An unknown transcriptional regulator Lp_2991 was also identified, as influencing the 
immune response. A deletion mutant of lp_2991 led to a significantly higher secretion 
of IL-10, IL-12p70 and TNF-α in DCs compared to the wild-type control. This gene lies 
upstream of gtcA3, a gene encoding a putative teichoic acid glycosylation protein. Tran-
scriptome analysis and qPCR data supported the hypothesis that Lp_2991 is a repressor 
of gtcA3 transcription and points to this enzyme as being a prime candidate for the 
altered immune response. Interestingly GtcA3 is predicted to glycosylate TAs including 
LTA which is a known TLR-2 agonist capable of modulating immune cell responses. LTA 
mutants and mutants affecting D-alanine substitution in LTA have already been found to 
have effects on the immune response [74, 75]. All of the mutations introduced into the 
plantaracin locus affected the immune response and were predicted to inhibit planta-
racin production. Thus it is possible that the plantaracins directly affect the immune 
response of DCs. Preliminary data suggest that specific plantaricins are indeed able to 
enhance cytokine expression of ECs after stimulation with LTA (Meijerink, unpublished 
work in progress). 
Our results showed that in silico analysis led to the identification of novel factors that 
are involved in the immunomodulating capacities of L. plantarum. For the selection of 
new candidate probiotics, the presence or absence of these genes can be used. Several 
other factors are found to be involved in immunomodulation of the host in other genera 
and species. For example, AvrA is an avirulent bacterial factor found in Salmonella, that 
is found to stabilize the expression and distribution of tight junction proteins such as 
zonula occludens-1 (ZO-1) and the function of tight junctions in vitro and in vivo [83]. In 
addition, a study showed that AvrA has deubiquitinase activity which removes ubiqui-
tins from ub-IκBα and inhibits activation of the pro-inflammatory NF-κB transcription 
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factor in cultured human ECs [84, 85]. Additionally, peptidoglycan N-deacetylation was 
shown to be a virulence factor in Listeria [86] and Streptococcus [87] species, playing an 
important role in evasion of the host innate immune response, which leads to survival 
of the pathogen in vivo. In addition, polysaccharide A (PSA) produced by Bacteroides 
fragilis was shown to be capable to activate T cell-dependent immune responses and 
homeostasis of the host immune system. PSA can provide protection in a in vivo coli-
tis models through the IL-10 dependent repression of pro-inflammatory cytokines (re-
viewed in [88]). 
The differences found between the WCFS1 and the deletion mutants of genes/loci iden-
tified in Chapters 3 and 4 were much smaller than found among the 42 different L. 
plantarum strains, indicating that other factors play an important role in immunomodu-
lation, and/ or that there are synergistic effects between one or more factors. Thus it 
might be insightful to sequence the other strains used in the study described above 
and apply the gene-trait matching approach to identify other genetic loci. A different 
approach would be to compare levels of different gene transcripts under different fer-
mentation conditions with the cytokine responses to the bacteria (in progress, unpub-
lished). 
Use of probiotics to treat or prevent immune-related disorders
Most therapeutic or preventative applications of probiotics have been concerned with 
immune-related disorders such as atopy, colitis or have been aimed at enhancing as-
pects of innate immunity. 
In mice, the Th1/Th2 hypothesis has proven to be a fruitful paradigm in describing the 
overreaction of either humoral immunity or cell immunity in different disease states 
such as allergy (Th2 dominance) and inflammatory bowel disease (IBD) and auto-im-
munity (Th1 dominance). Central to this hypothesis is that the T helper cells directing 
the different arms of the immune system express different cytokine patterns and that 
either pathway can down-regulate the other [89, 90]. In humans the Th1/Th2 paradigm 
has major inconsistencies, but remains a useful tool to measure imbalances in the im-
mune system and evaluate immunomodulatory treatments especially in rodent models. 
T helper cell cytokine expression in humans rarely falls into exclusively pro-Th1 or -Th2 
patterns. In addition to Th1 and Th2 cells as effector cells, there are also Th17 cells, 
which produce the pro-inflammatory cytokine IL-17 and are involved in the induction of 
inflammation and play an important role in IBD, multiple sclerosis, psoriasis and rheu-
matoid arthritis [91]. Moreover, the Tregs and APCs are equally important in regulating 
immune homeostasis. In the past few decades the incidence of allergies, autoimmu-
nity and IBD (in industrialized countries) has risen and the simultaneous occurrence 
of Th1- and Th2-mediated disorders suggest that the simple Th1/Th2 balance assump-
tion is unable to explain the underlying mechanisms [92]. Recently patients with type 
1 diabetes and multiple sclerosis, and individuals with predisposition to allergy were 
shown to have a defective regulatory T cell activity [92]. Tregs are known to suppress 
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both Th1-and Th2-type immune responses through production of IL-10 and TGF-β. Re-
cent evidence from in vitro and in vivo studies suggests that probiotics may mediate 
their beneficial effects through induction of Tregs, in addition to skewing of Th1 or Th2 
responses. 
The use of probiotics to prevent and treat Th2-mediated food allergy by skewing the 
immune response towards a more Th1/ Treg type has been described in several studies 
[93-98]. For example, a study by Shida et al. showed that in ovalbumin (OVA)-specific 
T cell receptor transgenic mice, intraperitoneal injection of L. casei Shirota led to an 
induced IL-12 response in serum. In this model of food allergy the applied probiotic 
strain skewed the splenocyte cytokine response towards Th1 and suppressed IgE and 
IgG1 response, which could be blocked by anti-IL-12 antibodies [93]. In a study by Kim 
et al. using a different food allergy model, mice were orally sensitized to OVA and chol-
era toxin (CT). In this model orally administered probiotic strains B. bifidum BGN4 and 
L. casei 911, both displaying in vitro Th1 skewing properties, were shown to decrease 
levels of OVA-specific IgE, total IgE and IgG1, decreased levels of mast cell degranula-
tion and tail scabs [94]. Frossard et al. showed that oral application of a genetically 
modified L. lactis, engineered to secrete IL-10 could prevent allergic sensitization to 
β-lactoglobulin and attenuate the levels of antigen-specific serum IgE and total IgE and 
increase the antigen-specific IgA in the gut compared to the wildtype L. lactis [95]. This 
study shows the importance of IL-10 in food allergy. Numerous studies in animals and 
humans have shown protective or therapeutic effects of probiotics in other models or 
diseases including antibiotic induced diarrhoea, irritable bowel syndrome and colitis. 
Interestingly specific strains of probiotics have also shown encouraging results in mu-
cosal vaccination studies and in protection from illness suggesting they can enhance 
immunity. Nevertheless demonstrating the beneficial effects of probiotics in healthy 
persons remains one of the major future challenges (discussed in section ”The future 
potential of probiotics”). 
Linking in vitro and in vivo data on the immune effects of lactobacilli
Most in vivo studies are performed with one probiotic strain, which makes compari-
sons difficult. Indeed only a few studies have compared the in vitro immunomodulatory 
properties of different lactic acid bacteria with their in vivo properties. For instance, 
the ability of different lactobacilli to induce a high ratio of IL-10/ IL-12 or IL-10/ TNF-α 
production in immune cells correlates with their capacity to provide significant protec-
tion in TNBS induced colitis in mice and rats [55, 99, 100]. However, Mileti et al, demon-
strated that L. paracasei B21060 and LGG induced a similar cytokine ratio in DCs, but 
did not show comparable protective effects in vivo in a mouse DSS model of colitis [9]. 
However, the strains used in this study were not associated with high IL-10/ IL-12 ratios 
(L. plantarum: 0,877; LGG: 1,222; L. paracasei: 1,176) as shown in the study by Foligne 
et al. (IL-10/IL-12 ratios >10), which might account for the apparent contrasting find-
ings. Moreover, L. paracasei was a poor inducer of both pro- and anti-inflammatory 
cytokines in vitro.
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Multiple strain comparison in vivo is the most preferred approach for comparing their 
potential probiotic functionality, to validate the immunomodulatory capacities in vitro. 
Foligne et al. showed that the ability of different lactobacilli to induce a high ratio of 
IL-10/IL-12 production in PBMCs was shown to correlate with their capacity to provide 
significant protection from TNBS induced colitis in mice [55]. Similarly a study by Kwon 
et al. identified bacterial strains that could specifically up-regulate CD4+Foxp3+ Tregs 
by co-culturing MLNs ex vivo with bacteria. These strains were selected on the basis 
of a high IL-10/IL-12 ratio (>4) and enhanced Foxp3 expression (>1.5-fold). This study 
underlines the important role of DCs in the induction of Tregs and how in vitro assays 
(pre-selection on IL-10 / IL-12 ratio and induction of Foxp3 levels in MLNs) can be used 
for the selection of probiotic strains and species that have therapeutic effects in models 
of IBD, atopic dermatitis and rheumatoid arthritis. To really prove this, it would have 
been better to show also results of strains with a IL-10/IL-12 ratio <4. A different study 
by Snel et al. showed that a methodology to compare candidate probiotic bacteria for 
their immunomodulatory properties in PBMCs from patients with a proven pollen al-
lergy was appropriate to select strains with proven effect on the immune system in vivo 
[57]. This method using PBMCs from blood from birch pollen allergic patients can be an 
intermediate step between in vitro screening and testing for clinical efficacy.
In this thesis several strains with distinct in vitro immunomodulatory activity were test-
ed in two different animal models. (i) a mouse model of sensitization to peanut extract 
(Chapter 6) and (ii) an intranasal mouse model of influenza vaccination (Chapter 7).
A model of peanut allergy was selected as it is one of the most common and severe food 
allergies. In Chapter 6 human PBMC co-cultures with (potential) probiotics were used 
to determine the immunostimulating properties of different commercially available 
strains. Three strains were selected on basis of their distinct properties. One strain, L. 
salivarius HMI001, had a relatively high IL-10/IL-12 ratio compared to the other strains 
tested, and was predicted to enhance regulatory mechanisms to suppress the allergic 
sensitization to peanut, based on a study of Kwon et al., which showed that strains with 
a high IL-10/IL-12 ratio enhanced regulatory responses [56]. The second selected strain, 
L. casei Shirota (LCS), a probiotic previously shown to attenuate allergic responses [101] 
and inducing high secretion of IFN-γ and IL-12, was predicted to skew the antigen re-
sponse towards Th1 as IFN-γ is known to inhibit proliferation of Th2 cells. The third 
strain, WCFS1, was selected as it induced moderate levels of IL-10 and IL-12 with a 
IL-10/IL-12 ratio that was lower than strain HMI001 but higher than LCS. The study in 
Chapter 6 showed that screening these probiotics using human PBMCs was useful in se-
lecting strains with predicted anti-inflammatory and Th1 skewing properties. In the case 
of HMI001 (inducing a high IL-10/IL-12 ratio) and LCS (inducing high amounts of IFN-γ 
and IL-12) attenuation of the allergic response was seen in the mouse peanut allergy 
model. Strikingly, we observed that certain strains may worsen the allergic reaction, 
as shown in the case of WCFS1, inducing moderate levels of IL-10 and IL-12. Although 
further research is needed to validate the immunomodulatory mechanisms involved in 
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vivo, this approach is likely to be useful for selecting strains for translational research 
in humans. 
Most studies on probiotics and food allergy, evaluated the potential of prophylactic 
treatment of probiotics orally administered before or during allergen sensitization [93-
96]. However, a recent study using mice intragastrically immunized with shrimp tro-
pomyosin showed that a probiotic mixture (VSL#3) was able to inhibit established Th2 
driven inflammation and the induced symptoms in this model. This study shows that 
probiotics might also be used in a therapeutical setting in food allergy [98]. This ap-
proach might be more relevant for allergic patients, as they already suffer from allergies 
and their symptoms need to be treated. However, for people with a genetic predisposi-
tion, it might be still relevant to look for preventive strategies to avoid the development 
of atopic disease/ allergy, particularly in infants. 
As we observed that strain WCFS1 had a deteriorating effect in an allergic sensitization 
model we hypothesized that it might enhance humoral (Th2) mediated responses to a 
vaccine. This was tested in a mouse intranasal vaccination model using Influvac influ-
enza vaccine (Chapter 7). Although the most common vaccination route of influenza 
A is intramuscular, we hypothesized that intragastric probiotic treatment could lead 
to an enhanced respiratory immunity. The other L. plantarum strains evaluated in this 
model were selected on basis of their cytokine inducing properties in co-culture with 
DCs and their TLR-2/6 activating properties and included strains inducing Th1 promot-
ing cytokines or relatively high IL-10 /IL-12 cytokine ratios. As expected, strain WCFS1, 
inducing the lowest IL-10 to IL-12 cytokine ratio in DC co-culture, significantly increased 
HA-specific antibody responses to the intranasal vaccine compared to the vaccine con-
trol group. Several of the Lactobacillus strains appeared to increase delayed-type hyper-
sensitivity (DTH) responses after vaccination compared to the vaccine control group in-
dicating increased Th1-mediated vaccine responses. For strain LMG18021 this was also 
reflected in the significantly higher HA-specific IgG2a to IgG1 antibody ratio. LMG18021, 
CIP104448 and CIP104450 which have the highest IL-10 to IL-12 ratios of the strains 
tested, significantly enhanced the ex vivo HA-specific induction of IL-10, IL-17A, IL-6 and 
IL-4 in MLN cells. B1839 (a very low cytokine inducer in co-culture assays) was included 
as negative control. This strain did not enhance the HA-specific antibody response and 
the HA-specific immune response indicating that the immune-stimulatory properties of 
a strain are indeed important in mediating their effects on the host vaccine response. 
Further research is needed to demonstrate that these effects on the vaccine response 
impact on protection to a challenge with influenza and to validate the immunomodu-
latory mechanisms involved. Nevertheless, the in vivo studies described in this thesis 
support other publications proposing that in vitro immune assays can be useful for pre-
dicting which candidate probiotic strains will be most effective in vivo. Positive results 
in animal models are encouraging but they raise a number of questions such as the suit-
ability of mouse models for predicting applications in humans, variability of responses 
to probiotics in humans and the reasons for conflicting results reported in the literature 
even for the same probiotic strain. These topics are discussed in the following sections. 
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Considerations for further translational research 
The assessment of probiotic functionality should preferably be tested directly in the 
target group, representing either the general population or a subgroup of subjects with 
a given condition, for example elderly, physically active subjects, allergic individuals or 
pregnant women. In addition, data from infants and young children cannot be extrapo-
lated to the adult population or vice versa, as the immune system in early childhood is 
still developing, and is different from adults [102].
Human intervention studies focussing on for instance the risk reduction for a certain 
infection, should take into account that there is a lot of variation in immune status 
within the healthy population. Genetic variability strongly influences the immune re-
sponse of the host [103]. Specific polymorphisms in genes encoding human leukocyte 
antigens [104] or proteins involved in the immune response can influence quantities of 
cytokines [105] in a healthy population or disease state. In addition, individuals could 
also respond differently to bacterial signals (TLR ligands) due to single nucleotide poly-
morphisms within TLR genes [106]. NOD2 mutation has been shown to be linked to 
increased risk for IBD, supporting the importance of SNPs and inter-individual differ-
ences in TLR signalling [107, 108]. Remarkably, a study where the virulence of H1N1 
Neth/09 isolate was evaluated showed a considerably higher virulence in C57B/6 mice, 
compared to Balb/c mice indicating that the genetic background of mice can influence 
the virus susceptibility [109]. Additionally, host genetic variation has been shown to 
significantly impact on survival after infection with a highly pathogenic H5N1 influenza 
A virus [110].
Although it is clear that intestinal bacteria can shape human physiology and immunity 
[1-7], little is known about how differences in microbiota composition and/ or func-
tion can influence the results of clinical trials. Recent studies showed that intestinal 
microbes influence host immune development, immune responses and susceptibility to 
human diseases such as IBD, diabetes mellitus, and obesity (recently reviewed in [111-
114]). Germ-free mice have been shown to have extensive defects in humoral antibody 
responses and lack the maturation of gut associated lymphoid tissues. In addition, spe-
cific commensal microbes can have a great impact on the mucosal T-cell response. For 
example segmented filamentous bacteria (SFB) have been shown to be potent stimu-
lators of small intestinal Th17 cells, evidenced by the lack of Th17 cells in germ-free 
mice and their restoration after colonization with SFB [115, 116]. Interestingly, another 
commensal bacteria, Bacteroides fragilis, producing PSA, or purified PSA can treat or 
protect germ-free mice against the development of experimental colitis by inducing 
Foxp3+ Tregs, producing IL-10, via a TLR-2 and PSA dependent mechanism [6, 117]. A 
recent study showed the identification of three microbiota enterotypes, by combining 
22 newly sequenced faecal metagenomes of individuals from four countries [118], high-
lighting the importance of a functional analysis to understand microbial communities. 
The strain WCFS1 was included in an allergic sensitization (Chapter 6) and in an influ-
enza mice model (Chapter 7) and interestingly in both models it enhanced the Th2 re-
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sponses in the mice, by enhancing the allergic sensitization and the HA-specific IgG1 
responses. This indicates that this strain is behaving similarly in the different mouse 
models in Balb/c and C3H/HeOuJ mice. Interestingly, WCFS1 (NCIM8826) has previously 
been shown to attenuate TNBS induced colitis [55], however its efficacy was not as good 
as some other strains used in the same study. Both Balb/c and C3H/HeOuJ are known 
to exhibit a predominant Th2 immunity [119, 120], and therefore it might be easier for 
the strain WCFS1 to further enhance the Th2 response. However we found in Chapter 
7 in the vaccination model, that the strain LMG18021 was able to skew the immune re-
sponse towards Th1, although this strain of mouse is a genetically predisposed to a Th2 
bias [120]. This suggests that probiotics can potentially have strong immunomodulatory 
effects in some models. 
Many models used to assess the immune effects of probiotics have compromised epi-
thelial integrity and altered gut microbiota, such as colitis, food allergy or infectious 
diarrhea models. This is also the case with the peanut sensitization model described in 
Chapter 6 due to the use of cholera toxin which has been shown to increase paracellu-
lar permeability of the epithelium [121]. As an impaired barrier and altered microbiota 
may impact on immune sampling of orally consumed probiotics such models cannot be 
used to predict their impact in a healthy host (e.g. in the case of vaccination). However, 
the results obtained in our vaccination model (Chapter 7) showed that lactobacilli can 
indeed modulate the immune response of a healthy host.
Another interesting observation was that WCFS1 can be beneficial in the vaccination 
model by promoting a Th2 response, however the same strain is harmful in peanut sen-
sitization model putting more emphasis on the fact that probiotics should be carefully 
selected on a strain by strain basis depending on what disease model is used or on the 
basis of the desired effect. It was interesting to see that WCFS1 modulated the immune 
response similarly in both the allergic sensitization and vaccination model. Therefore, it 
might be useful to test same strains in multiple models to have a better knowledge how 
the strains will immunomodulate in the target population.
Modulation of intestinal bacteria by probiotics 
The strain-dependent effects of probiotics were shown both in vitro (Chapter 3 and 4) 
and in vivo (Chapters 6 and 7). In Chapter 7, six different L. plantarum strains were test-
ed for their capacity to enhance the efficacy of the influenza vaccination. As expected 
the effects shown in this model were strain dependent, showing that some specific 
strains can enhance the HA-specific antibody levels or the HA-specific T cell response. 
It is possible that these effects are linked to the effects of the probiotic strain on the 
resident microbiota [122]. Little is known about how the microbiota composition af-
fects specific immunity, although a recent study showed that oral antibiotic treatment 
resulted in defective CD4+ T, CD8+ T and B cell immunity following intranasal infection 
with influenza virus. Rectal inoculation of CpG, poly I:C and to a lesser extent peptidog-
lycan could restore immunity in the lung [1]. 
As some (anaerobic) strains are difficult or unable to culture (yet), techniques such as 
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pyrosequencing or 16S hybridization have recently emerged as powerful techniques to 
determine the composition of the microbiota [123] and could be used to investigate 
the effects of probiotics on microbiota composition. An important limitation of pyrose-
quencing is its relative inability to sequence longer stretches of DNA, rarely exceeding 
100-200 bases with the first- and second-generation high throughput pyrosequencing 
chemistries. Compared to Sanger sequencing, nexgen pyrosequencing of individual ge-
nomes and assembly of many overlapping reads appear to yield comparable sequenc-
ing accuracy with error rates between 0.03%-0.07% depending on the study [124-127]. 
Genera and species are typically distinguished at levels of 95% and 97% pairwise se-
quence identities, respectively using 16S rRNA gene sequence data [128]. Metagen-
omics studies highlighted differences between colonic mucosa-associated and fecal 
populations in man [129-134]. To date the majority of studies have been performed on 
fecal material but probiotics may also affect the microbiota in the small intestine where 
most of the immune cells associated with the mucosal lymphoid tissue reside. However 
sampling the small intestine is relatively difficult in humans limiting the number of stud-
ies performed to date. Studies have shown that probiotics can inhibit the colonization 
of certain pathogenic groups such as H. pylori [135]. Several species of Bifidobacte-
rium and Lactobacillus are generally associated with beneficial effects. However these 
species include strains that have both pro- as well as anti-inflammatory effects on the 
host (cells). Given the results described in this thesis and emerging evidence from the 
literature on the strain dependency of probiotic effects it now seems inappropriate to 
consider all strains of certain Bifidobacterium or Lactobacillus strains as being beneficial 
even though they may not be detrimental. Clearly any health benefit will depend on the 
strain (including its dose, frequency of dosis and formulation) and on the health status 
of the host.
Conflicting results in probiotic research 
Some published animal studies and trials on probiotics have produced contradictory 
results even using the same strain. For example, LGG was shown to prevent atopic ec-
zema or dermatitis [136, 137]. Subsequent studies on the use of LGG in the treatment 
of atopic eczema suggested a therapeutic effect [138-140], whereas more recent stu-
dies show no therapeutic or preventative benefits in the development of sensitization 
and atopic disease, particularly in infants with atopic dermatitis (AD) [141-143]. This 
could be partly explained by the inherent complexity of the allergic syndrome and the 
differences in study design, e.g. applied probiotic type (e.g. killed/ live or species), pe-
riod of probiotic supplementation, different target population and additional treatment 
such as topical treatment or feeding hydrolysed infant formula [97], which is limiting 
the comparability of the results. Moreover, a recent study showed that the timing of 
the application of probiotics is crucial for their efficacy using a mouse model of allergic 
sensitization to birch and grass pollen [144]. Mucosal delivery of L. paracasei NCC2461 
or B. longum NCC3001 at the time of sensitization and challenge led to a significant 
suppression of airway inflammation and down-regulated allergen-specific immune re-
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sponse. However, when mice were treated with the individual bacterial strains before 
sensitization and challenge, only B. longum NCC3001 was protective [144]. Both strains 
induced similar amounts of IL-10 in vitro, however they exhibited different abilities to 
induce inflammatory cytokine production, with B. longum NCC3001 being the less pro-
inflammatory strain. The results might be explained by the fact that a strain (like B. 
longum NCC3001) enhancing regulatory mechanisms could be efficient given before 
sensitization as well as during challenge, while L. paracasei NCC2461 having different 
immunomodulatory effects, could only skew the immune response during sensitization. 
Also the duration of probiotic feeding can impact on the probiotic effect. The results 
of different studies can also be influenced by mixing of probiotics with prebiotics or a 
hydrolysed whey formula or using probiotic combinations. 
In Chapter 7 the probiotic LGG was included as it has been shown to confer protec-
tive effects in challenge studies with influenza [145, 146] and enhanced the efficacy of 
intramuscular influenza vaccination [147]. Despite the fact that LGG increased DTH re-
sponses in our vaccination study (Chapter 7) the HA-specific antibodies in serum and ex 
vivo cell response were unaffected. The challenge studies did not show any data differ-
ences in antibody titers in serum [145, 146], so in that study the serum levels might also 
be unaffected, indicating that it might be that LGG can be more beneficial for NK cell 
function [145, 146], which was not a parameter measured in our study. This highlights 
the importance of standardizing biomarkers and immune assays to evaluate probiotics 
and their potential mechanisms of action.
The results of in vivo studies in this thesis (Chapters 6 and 7) showed that the tested 
strains all behaved differently in these models and that one cannot expect different 
species or strains of the same species to have the same effects in vivo. Additionally,  
differences in formulation may impact on the results obtained with the same strain, 
as shown in Chapter 4: differences in immune profiles were seen in vitro using strains 
harvested in stationary and exponential phase of growth. Similarly, a study by van Baar-
len et al., showed that exponential phase and stationary phase grown L. plantarum 
WCFS1 eli-cited distinct transcript profiles in human duodenal tissue samples [148]. 
As discussed above host factors such as genetic differences in microbial responses and 
allergic pre-disposition, and also other environmental factors such as individual micro-
biota, diet and treatment with antibiotics may affect the outcomes of the studies.
Suitability of mouse models in translational research on probiotics
Testing potential probiotic strains directly in humans to treat diseases e.g. allergy, is cor-
rectly restricted for ethical reasons. However, translational research based on mouse 
studies are inherently complex due to the differences between mice and humans and 
uncertainties about the reliability of the inbred mouse models as predictors of efficacy 
in a human population. The immune system of humans and mice differs with respect 
to structural and functional aspects of the IgG isotypes and their binding affinities for 
FcγRI, FcγRIII, and FcεRI receptors. Nevertheless there are also clear similarities between 
humans and mice with respect to IgE and IgG antibodies that bind to the homologous 
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FcεRI and FcεRIII receptors, and with respect to their expression on different cells types 
e.g. mast cells, macrophages and DCs. In addition, some of the inflammatory media-
tors (e.g. histamine) are expressed in both humans and mice. Because of these simi-
larities and despite of differences mentioned earlier, the mouse peanut allergy model 
described in Chapter 6 mimics the clinical and immunological characteristics of peanut 
allergy in human subjects [149, 150]. This is based on the model described by Li et al., 
showing that peanut-induced anaphylaxis was IgE mediated, and mast cell degranula-
tion and histamine release were associated with the anaphylactic symptoms. Thus the 
model seems likely to be relevant to the human population.
The future potential of probiotics 
In the EU, the functional food industry is selling an increasing number of foods that 
bear nutrition and health claims. Health claims are statements given on labels, in ad-
vertising or other marketing products that health benefits can results from consuming 
a given product. In the case of probiotics, the main benefits attributed to probiotics 
are based on strengthen the gut barrier, modulation of the intestinal tract microbiota, 
enhancement of the mucosal integrity, and competitive exclusion of pathogens. Specific 
probiotics may also be associated with other health benefits, including prevention and 
reduction of symptoms of lactose intolerance, diarrhea and gut comfort (transit time, 
stool consistency), prevention of allergy response, mineral absorption, and inhibition 
of procarcinogen-activating enzymes (reviewed in [151]). Over the last decade industry 
has shown a growing interest in probiotics, but it is only recently that their health ben-
efits have begun to be demonstrated in clinical trials [136, 152]. Health benefits should 
be demonstrated in humans by providing a scientific basis for establishing health claims 
related to food products. Health claim regulations are currently under intensive discus-
sion in public as well as by experts, and new legislative developments have been imple-
mented in the European Union, as well as in the United States, Australia/ New Zealand, 
India, China and Japan. In December 2006 the EU approved new European regulations 
on the requirement for nutrition and health claims food. This was considered neces-
sary to harmonize the national rules for the use of health or nutritional claims on foods 
based on nutritional composition for the European market. 
The European Food Safety Authority (EFSA) is responsible for verifying the scientific 
substantiation of the submitted claims. The advice given by the EFSA serves as a basis 
for the European Commission and Member States, to decide whether or not a claim will 
be accepted. To date probiotics represent 8% of the food ingredients for which applica-
tions for health claims have been made under this new legislation. However, up to now 
all health claims for probiotics related to gut and immune function have been rejected 
by EFSA. It would be incorrect to conclude that the regulatory hurdles imposed by the 
initial negative comments on probiotic health claims are only obstacles for researchers 
and industry. In fact this legislation could induce a boost in basic science as well as in 
clinical studies, supporting the launch of new products. The research should be  
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established in healthy people or at least in people without a defined disease. This is 
challenging due to the lack of accepted biomarkers to measure health in the absence of 
disease.
The EFSA guidance on the scientific requirements for health claims related to immune 
function states: “for the substantiation of claims on immune function many markers 
of the function of the immune system have been proposed as outcomes, including the 
numbers of various lymphoid subpopulations in the circulation, proliferative responses 
of lymphocytes, phagocytic activity of phagocytes, lytic activity of natural killer cells and 
cytolytic T cells, production of cellular mediators, serum and secretory immunoglobu-
lin levels, delayed-type hypersensitivity responses, etc.“ EFSA also indicated that in the 
case of health claims concerning probiotics and vaccination, it is generally accepted 
that higher vaccination responses (as measured by increased numbers of individuals 
attaining protective levels, as well as by increments in antigen-specific antibody titers 
in groups of individuals) are beneficial. Therefore the EFSA stated that the stimulation 
of protective titers, as measured by increased numbers of individuals attaining protec-
tive levels, could be used to substantiate a health claim on the function of the immune 
system related to defense against pathogens. In Chapter 7 L. plantarum WCSF1 was 
shown to enhance the antibody titer levels compared to the vaccinated control group. 
Implying that the administered probiotic was increasing the defense against influenza. 
A follow up study should be performed to check the protective effect of these increased 
antibody titers in an influenza challenge model, to serve as basis for a health claim. 
These data can form a good starting point to explore the possibility of obtaining better 
protection, however additional data obtained from human trials with the vaccine are 
needed for a claim approved by the EFSA. 
Concerning the prevention of allergy, the EFSA stated that “if it can be shown that if an 
alteration of a (immunological) marker(s) is accompanied by an improvement of clinical 
outcomes related to allergy (e.g. a reduced incidence, severity or frequency of aller-
gic manifestations) then such alteration in the (immunological) marker might be consi-
dered beneficial in the context of a reduction of disease risk claim for allergy for that 
specific dietary intervention”. In Chapter 6 it was clear that prophylactic treatment with 
both HMI001 and LCS before sensitization of the mice with peanut extract, attenuated 
production of allergen-specific cytokine responses associated with allergic sensitization 
and mast cell activation marker mast cell protease-1 (MCP-1) upon challenge with the 
allergen. To obtain a health claim for humans these probiotics would need to be shown 
to prevent the development of allergy or reduce the severity of allergy (e.g. allergic ec-
zema etc) in human individuals. EFSA stated that human studies are central for substan-
tiation of health claims. Therefore a clinical trial(s) would need to be performed in hu-
mans to confirm the beneficial effect of the bacterial strains. However prior to human 
intervention studies it is important to establish the rationale for the particular probiotic 
strain and to gain information on the pre-clinical properties of the strain. Additionally, 
most probiotic studies in humans have been conducted in subjects who have been ill or 
critically ill. However the research/ effects should be also established in healthy people.
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Safety issues of probiotics in humans
Probiotics have been advocated for the prevention and treatment of a wide range of 
diseases, and there is evidence for their efficacy in some clinical scenarios [97]. Given 
the increasingly widespread use of probiotics, a good understanding of their risks and 
benefits is imperative. Most probiotics are strains of bifidobacteria or lactobacilli, but 
species from other bacterial genera such as Streptococcus, Bacillus and Enterococcus 
have also been used as probiotics. There are concerns about the safety especially of the 
latter groups, as these genera contain many pathogenic species, particularly Enterococ-
cus and Streptococcus (FAO/WHO. Guidelines for the evaluation of probiotics in food. 
2002. Internet: http://www.who.int/foodsafety/fs_management/en/probiotic_guide-
lines.pdf (accessed 27 May 2011)). Probiotics are often regulated as dietary supple-
ments rather than as pharmaceuticals or biological products. Therefore there is usually 
no requirement to demonstrate safety, purity, or potency before marketing probiotics. 
In Europe, specific compositional legal requirements are for dietary supplements in-
tended to be used by infants and young children. Unique to probiotics is however that 
they are alive when administered, and unlike other food or drug ingredients, possess 
the potential for infectivity or in situ toxin production.
Humans are regularly exposed to lactobacilli and bifidobacteria via their own micro-
biota, as well by consumption of foods such as yoghurt, cheese, sauerkraut and olives. 
In many traditional foods, these bacteria play an important role in preventing spoilage 
and the growth of pathogenic microorganisms [153]. Lactobacilli are normally present 
in the oral cavity (103-104 colony forming units (CFU)/g), in the ileum (103-107 CFU/g) 
and the colon (104-108 CFU/g). An important concern with probiotics is the risk of sep-
sis. In humans, lactobacilli and bifidobacteria are extremely rare causes of infection 
and are estimated to be 0.05%-0.4% of cases of infective endocarditis and bactere-
mia [154, 155]. These cases of infection with lactobacilli occur mostly in patients with 
underlying conditions that are predominantly of a severe nature and lactobacillemia 
is a frequent marker of serious or fatal underlying disease [154-157]. One reported 
case is of a 74-year-old diabetic woman who developed liver abscess and pneumonia 
4 months after starting daily LGG supplementation. The infective and probiotic strains 
were indistinguishable by pulse-filed electrophoresis of chromosomal DNA restriction 
fragments [158]. Another case showed the development of L. rhamnosus endocarditis 
(strain not specified) after a dental extraction in a 67-year-old man with mitral regur-
gitation who was taking probiotic capsules daily. The authors found no differences be-
tween the probiotic and the infective L. rhamnosus with the use of standard API 50 CH 
biochemical analysis and pyrolysis mass spectrometry [159]. Another study reported 
that two patients, who received LGG to treat antibiotic-associated diarrhea, developed 
subsequently bacteremia and sepsis attributable to Lactobacillus species [160]. Mole-
cular DNA fingerprinting analysis showed that the Lactobacillus isolated from the blood 
sample was indistinguishable from the probiotic ingested by these two patients. This 
indicates that invasive disease can be associated with probiotic lactobacilli. However, 
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in these cases the individuals had a serious underlying disease, that made them more 
susceptible to sepsis.
In general, immune-compromised patients are more vulnerable to infection with 
pathogens and have a higher incidence of opportunistic infections. There is published 
evidence, showing that consumption of probiotic products containing lactobacilli or bi-
fidobacteria increases the risk of opportunistic infection among these individuals. In 
a study described by Besselink et al. 296 predicted severe acute pancreatitis patients 
were allocated to receive either a probiotic mixture comprising six strains (four Lacto-
bacillus and two Bifidobacterium strains) at 1010 CFU/day or placebo, starting within 72 
hours of onset of symptoms for 28 days [161]. This mixture was found to diminish acute 
pancreatitis-induced intestinal barrier dysfunction in rats [162]. In the human study, the 
incidence of infectious complications was comparable between the groups (probiotics 
vs. placebo, 30% vs. 28%, respectively). However mortality rates were significantly high-
er in the probiotic group (16% vs. 6%) as was the incidence of bowel ischemia, which 
occurred in nine probiotic-treated patients compared to none in the placebo group. 
This study demonstrated that probiotics are not completely innocuous and should not 
be given to patients that have potential for increased bacterial translocation and risk of 
severe life threatening complications.
Two clinical studies in immune compromised patients (i.e. with HIV infection) showed 
that probiotic consumption is safe in these groups [163, 164]. There has been a marked 
increase in the use of the probiotic LGG since its introduction in Finland in 1990. Despite 
this increased use, no significant increase in Lactobacillus bacteremia or bacteremia at-
tributable to probiotic strains has been observed in Finland [155, 156]. 
Pregnant women might be at increased risk of adverse immune stimulation. During 
pregnancy there is a shift in T cell responses toward a Th2 phenotype, which is thought 
to be important in maintaining fetal viability because Th1 cytokines are associated with 
pregnancy loss [165]. Some probiotic lactobacilli have been shown to down regulate 
Th2 cytokine responses in vitro, and in some human studies were also found to increase 
production of the Th1 cytokine IFN [166, 167]. Probiotics might skew thus the immune 
response into a Th1 phenotype which might be harmful to pregnancy viability. At pre-
sent there is little support for the hypothesis that probiotics cause adverse immune 
development from empirical studies, but this is an area that warrants further investiga-
tion. However, a study by Kaliomaki et al. did not report any adverse effects when LGG, 
which induces Th1 cytokines, was supplemented to mothers during pregnancy [136].
Unpredictability of immune modulation through change in intestinal microbiota in cer-
tain disease states are also of safety concern. For instance in patients taking some pro-
biotic formulations Crohn’s disease worsened [168]. Another study showed that LGG 
worsened the indomethacin induced enteropathy in an animal model [169].
It is necessary that in the selection of new probiotic strains these strains are derived 
from the commensal microbiota of humans or from fermented foods that have been 
consumed for a long time by humans and that they should not carry antibiotic resist-
ance genes that would prevent treatment in case of a rare probiotic infection. Many 
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strains of lactobacilli are naturally resistant to vancomycin and the vancomycin resistant 
genes of lactobacilli appear to be chromosomally located and are not easily transfer-
able to other genera [170]. In case of lactobacillemia, vancomycin would not be used 
for treatment, therefore selected probiotic strains should be susceptible to two of the 
major antibiotics. At this moment it is difficult to predict the frequency of gene transfer 
from lactobacilli to other bacterial species in vivo, but the main concern is the transfer 
of resistance genes to pathogenic strains of Enterococcus species and Staphylococcus 
aureus.
Manufacturers of probiotics have to closely observe potential adverse events. Current 
evidence suggests that the risk of infection with probiotic lactobacilli or bifidobacteria 
is similar to that of a commensal strain. In healthy individuals the risk appears to be 
negligible, but despite a low risk of infection due to probiotics, carefulness should be 
maintained and isolates should be checked by molecular characterization and confirma-
tion [171, 172]. The safety of probiotics should be confirmed in studies with humans, 
because the classical safety measurements such as the determination of toxicity or 
pathogenicity of probiotic bacteria will always be hampered by the fact that simplified 
animal models or cell assays will inadequately mimic the complex gene-environment 
interaction in genetically susceptible human populations that might be at risk for the 
development of chronic degenerative diseases such as autoimmune, atopic, neurode-
generative or metabolic disorders or complex acute diseases such as pancreatitis and 
sepsis. Although probiotics have an excellent overall safety record, they should be used 
with caution in certain individuals, such as pregnant women or individuals with immune 
deficiency.
Viability of probiotics: do they need to be alive to be beneficial?
The definition of probiotics states specifically that the bacteria should be alive during 
administration. For this reason it is for the industry a great challenge to deliver live, vi-
able microorganisms. Moreover the culture method as well as the growth stage of the 
bacteria can induce differential responses in humans [148]. Physiological characteristics 
as well as the delivery format (for instance in a dairy product or pills) are important 
in maintaining the viability of probiotics. For example, dairy products have a naturally 
shorter shelf-life than freeze-dried probiotic products in the form of powders and pills. 
However, levels of oxygen, moisture and storage temperature play an important role in 
the stability of the bacteria even with dried formulations. If dead microorganisms could 
also retain their probiotic activity it might facilitate their formulation, enhance shelf life 
and increase standardization [173-175]. 
Inactivated microbes, although not defined as probiotics according to the generally ac-
cepted definition by WHO, have been investigated for beneficial effects. However in the 
published studies to date, viable probiotics appear to have superior efficacy to heat-
inactivated microbes for both in vitro and clinical studies [176-178]. It should be recog-
nized that the presence of dead or injured microbes in commercial products is unavoid-
able, as some death occurs during storage of products and the standard approach to 
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maintaining the target dosage of live probiotic entails addition of surplus probiotics to 
account for any death occurring during storage [179, 180].
Different results have been obtained in studies that compared directly the effects of live 
and killed bacteria. One study showed that both live and heat-killed LGG, ameliorates 
intestinal and other inflammation in infant rats, by decreasing LPS-induced pro-inflam-
matory mediators and increasing anti-inflammatory mediators [181]. Another study 
comparing UV killed bacteria and live bacteria showed similar PBMC responses [182]. 
Interestingly, a study has revealed adverse effects resulting from ingestion of heat-killed 
probiotics by Kirjavainen et al. One group that ingested live, viable LGG was compared 
with another group ingesting heat-killed LGG for the prevention of allergies in infants. 
The authors reported increased gastrointestinal symptoms and diarrhea in those in-
gesting the formula with the heat-killed product, which led the Review Ethics Board to 
prematurely discontinue the study [183]. 
To conclude, although it might be more attractive from a safety and commercial view to 
use inactivated bacteria, studies so far showed that the beneficial effects are not always 
comparable for live and dead probiotic strains.
Major conclusions and future research
Certain strains of probiotics have been shown to confer health benefits in clinical trials 
and experimental animal models but there have also been a number of inconclusive, 
negative and even contrasting outcomes from in vivo studies. It is clear from both the li-
terature and the research described in this thesis, that the effects of probiotics are high-
ly dependent on the strain properties. Thus probiotics should be selected on a strain by 
strain basis in comparative studies, because their effects on the immune system and 
other properties can vary considerably even within a species. Furthermore, our lack of 
knowledge concerning the precise mechanisms of different probiotics is hampering the 
rational selection of strains and the correlation of in vitro data with the outcomes in 
vivo. Nevertheless, recent studies including those presented in this thesis suggest that 
in vitro immune assays are useful in selecting candidate strains for effects on the host 
immune system. 
In Chapters 6 and 7, different strains of lactobacilli were tested for their effects on the 
immune function in different mouse models. A study by Kwon et al. showed that a mix-
ture of strains was more effective in enhancing Foxp3 levels in MLN cells compared to 
individual strains [56]. The use of multiple-species or multiple-strain probiotic mixture 
has been recently reviewed by Chapman et al. [184], suggesting that the evidence of us-
ing probiotic mixtures is limited especially in the area of immunomodulation. The com-
parison is also difficult, due to different doses and routes of application. More research 
is needed to show that multi-strain probiotics have a greater effectiveness, using stan-
dardized doses in the same target population. Interestingly, Chapman et al. also found 
that bifidobacteria might inhibit probiotic efficiency in the presence of other species 
within a multi-strain mixture. They suggested that different species might inhibit each 
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other, possibly by the production of antagonist agents, or by competition for either 
nutrients or binding sites within the gastrointestinal tract. Given the current interest in 
combining multiple strains [56, 184], some of the strains in this thesis could be tested in 
a mouse vaccination model (Chapter 7) for their antagonistic or synergistic effects, e.g. 
identified candidate strains WCFS1 (Th2 promoting) and LMG18021 (Th1 promoting) or 
WCFS1 and KOG18 (both Th2 promoting). 
To have a better mechanistic understanding of the immunomodulation by lactic acid 
bacteria, it is important to determine the regions of the gastrointestinal tract where 
probiotic strains encounter immune cells (especially APCs) of the host. This could be 
achieved for example by the use of genetically tagged bacteria or by genetically modi-
fied bacteria expressing fluorescence molecules, using new techniques as 2-photon im-
aging in live tissue. 
The probiotics used in our animal studies were applied intragastrically, to avoid the 
interaction with food components and passage through the stomach, however survival 
in the stomach is known to vary among species/ strains and growth phase. Additional-
ly, the food industry is more interested to make functional food by adding probiotics 
in their products. This means that there can be interactions with dietary components, 
which can influence the efficiency of probiotic strains. It would be interesting to test in 
more depth how food components can influence the probiotic efficiency. 
Many published studies on the immune system and probiotics have not described the 
immune properties of the strains in vitro or compared different strains. In the past 
this somewhat empirical approach may have limited progress in understanding of the 
mechanisms and importance of strain selection. However, over the past 5 years the 
field has progressed enormously, largely due to developments in mucosal immunology 
and new insights into the mechanisms controlling tolerance and immunity in mucosal 
tissues. More research is performed aimed at identifying the underlying mechanisms of 
probiotics which will ultimately enable the potential societal/health benefits of probio-
tics to be fully realized. 
191
Chapter 8
References
1. Ichinohe, T., et al., Microbiota regulates immune defense against respiratory tract influenza  
 A virus infection. Proc Natl Acad Sci U S A, 2011. 108(13): p. 5354-9.
2. Round, J.L. and S.K. Mazmanian, The gut microbiota shapes intestinal immune responses  
 during health and disease. Nature reviews. Immunology, 2009. 9(5): p. 313-23.
3. Rakoff-Nahoum, S., et al., Recognition of commensal microflora by toll-like receptors is   
 required for intestinal homeostasis. Cell, 2004. 118(2): p. 229-41.
4. Hall, J.A., et al., Commensal DNA limits regulatory T cell conversion and is a natural   
 adjuvant  of intestinal immune responses. Immunity, 2008. 29(4): p. 637-49.
5. O'Mahony, C., et al., Commensal-induced regulatory T cells mediate  protection against   
 pathogen-stimulated NF-kappaB activation. PLoS pathogens, 2008. 4(8): p. e1000112.
6. Round, J.L. and S.K. Mazmanian, Inducible Foxp3+ regulatory T-cell development by a 
 commensal bacterium of the intestinal microbiota. Proceedings of the National Academy  
 of Sciences of the United States of America, 2010. 107(27): p. 12204-9.
7. Niess, J.H., et al., Commensal gut flora drives the expansion of proinflammatory CD4 T cells  
 in the colonic lamina propria under normal and inflammatory conditions.    
 Journal of immunology, 2008. 180(1): p. 559-68.
8. FAO and WHO, Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health   
 and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid  
 Bacteria. 2001.
9. Mileti, E., et al., Comparison of the immunomodulatory properties of three probiotic   
 strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy.   
 PLoS One, 2009. 4(9): p. e7056.
10. Licciardi, P.V., et al., Epigenome targeting by probiotic metabolites. 
 Gut Pathog, 2010. 2(1): p. 24.
11. Fukuda, S., et al., Bifidobacteria can protect from enteropathogenic infection through   
 production of acetate. Nature, 2011. 469(7331): p. 543-7.
12. Maslowski, K.M., et al., Regulation of inflammatory responses by gut  microbiota and   
 chemoattractant receptor GPR43. Nature, 2009. 461(7268): p. 1282-6.
13. Corr, S.C., et al., Bacteriocin production as a mechanism for the antiinfective activity of   
 Lactobacillus salivarius UCC118. Proceedings of the National Academy of Sciences of the  
 United States of America, 2007. 104(18): p. 7617-21.
14. Mack, D.R., et al., Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing  
 intestinal mucin gene expression. The American journal of physiology, 1999. 276(4 Pt 1): p.  
 G941-50.
15. Wehkamp, J., et al., NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in  
 intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic   
 bacterium. Infection and immunity, 2004. 72(10): p. 5750-8.
16. Schlee, M., et al., Probiotic lactobacilli and VSL#3 induce enterocyte  beta-defensin 2.   
 Clinical and experimental immunology, 2008. 151(3): p. 528-35.
17. Walker, W.A., Mechanisms of action of probiotics. Clinical infectious diseases : an official   
 publication of the Infectious Diseases Society of America, 2008. 46 Suppl 2: p. S87-91;   
 discussion S144-51.
18. Corthesy, B., H.R. Gaskins, and A. Mercenier, Cross-talk between probiotic bacteria and the  
 host immune system. The Journal of nutrition, 2007. 137(3 Suppl 2): p. 781S-90S.
19. Gill, H.S., et al., Enhancement of immunity in the elderly by dietary supplementation with  
192
Ch
ap
te
r 
8
 the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr, 2001. 74(6): p. 833-9.
20. Klijn, N., A.H. Weerkamp, and W.M. de Vos, Genetic marking of Lactococcus lactis shows   
 its survival in the human gastrointestinal tract. Appl Environ Microbiol, 1995. 61(7):   
 p. 2771-4.
21. Vesa, T., P. Pochart, and P. Marteau, Pharmacokinetics of Lactobacillus plantarum NCIMB  
 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human 
 gastrointestinal tract. Aliment Pharmacol Ther, 2000. 14(6): p. 823-8.
22. Tannock, G.W., Probiotic properties of lactic-acid bacteria: plenty of scope for fundamental  
 R & D. Trends Biotechnol, 1997. 15(7): p. 270-4.
23. Gardiner, G.E., et al., Relative ability of orally administered Lactobacillus murinus to pre  
 dominate and persist in the porcine gastrointestinal tract. Appl Environ Microbiol, 2004.   
 70(4): p. 1895-906.
24. Klingberg, T.D. and B.B. Budde, The survival and persistence in the human gastrointestinal  
 tract of five potential probiotic lactobacilli consumed as freeze-dried cultures or as   
 probiotic  sausage. Int J Food Microbiol, 2006. 109(1-2): p. 157-9.
25. McGuckin, M.A., et al., Mucin dynamics and enteric pathogens. Nat Rev Microbiol, 2011.  
 9(4): p. 265-78.
26. Wang, M.L., et al., Immune-mediated signaling in intestinal goblet cells via PI3-kinase- and  
 AKT-dependent pathways. American journal of physiology.  Gastrointestinal and liver   
 physiology, 2008. 295(5): p. G1122-30.
27. Johansson, M.E., et al., The inner of the two Muc2 mucin-dependent mucus layers in colon  
 is devoid of bacteria. Proc Natl Acad Sci U S A, 2008. 105(39): p. 15064-9.
28. Johansson, M.E., K.A. Thomsson, and G.C. Hansson, Proteomic analyses of the two   
 mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is   
 strongly bound to the Fcgbp protein. J Proteome Res, 2009. 8(7): p. 3549-57.
29. Atuma, C., et al., The adherent gastrointestinal mucus gel layer: thickness and physical   
 state in vivo. Am J Physiol Gastrointest Liver Physiol, 2001. 280(5): p. G922-9.
30. van der Waaij, L.A., et al., Bacterial population analysis of human colon and terminal   
 ileum biopsies with 16S rRNA-based fluorescent probes: commensal bacteria live in   
 suspension and have no direct contact  with epithelial cells. Inflamm Bowel Dis,   
 2005. 11(10): p. 865-71.
31. Kim, S.K., Small intestine transit time in the normal small bowel study. Am J Roentgenol   
 Radium Ther Nucl Med, 1968. 104(3): p. 522-4.
32. Lambert, J.M., et al., Functional analysis of four bile salt hydrolase and penicillin acylase   
 family members in Lactobacillus plantarum WCFS1. Appl Environ Microbiol, 2008. 74(15):  
 p. 4719-26.
33. Gebert, A., et al., The development of M cells in Peyer's patches is restricted to specialized  
 dome-associated crypts. Am J Pathol, 1999. 154(5): p. 1573-82.
34. Onori, P., et al., Peyer's patches epithelium in the rat: a morphological,    
 immunohistochemical, and morphometrical study. Dig Dis Sci, 2001. 46(5): p. 1095-104.
35. Sharma, R., U. Schumacher, and E. Adam, Lectin histochemistry reveals the appearance of  
 M-cells in Peyer's patches of SCID mice after syngeneic normal bone marrow    
 transplantation. J Histochem Cytochem, 1998. 46(2): p. 143-8.
36. Macpherson, A.J. and T. Uhr, Induction of protective IgA by intestinal  dendritic cells   
 carrying commensal bacteria. Science, 2004. 303(5664): p. 1662-5.   
37. Tyrer, P., et al., Microbial pattern recognition receptors mediate M-cell uptake of a   
 gram-negative bacterium. Infect Immun, 2006. 74(1): p. 625-31.
38. Gullberg, E., et al., Identification of cell adhesion molecules in the human    
 follicle-associated epithelium that improve nanoparticle uptake into the 
193
Chapter 8
 Peyer's patches. J Pharmacol Exp Ther, 2006. 319(2): p. 632-9.
39. Begue, B., et al., Microbial induction of CARD15 expression in intestinal epithelial cells via  
 toll-like receptor 5 triggers an antibacterial response loop. J Cell Physiol, 2006. 209(2): p.  
 241-52.
40. Tyrer, P., et al., Validation and quantitation of an in vitro M-cell model. Biochem Biophys   
 Res Commun, 2002. 299(3): p. 377-83.
41. Perdigon, G., et al., Study of the possible mechanisms involved in the mucosal immune   
 system activation by lactic acid bacteria. J Dairy Sci, 1999. 82(6): p. 1108-14.
42. Perdigon, G., et al., Intestinal pathway of internalisation of lactic acid bacteria and gut   
 mucosal immunostimulation. Int J Immunopathol Pharmacol, 2000. 13(3): p. 141-150.
43. Berg, R.D. and W.E. Owens, Inhibition of translocation of viable Escherichia coli from the   
 gastrointestinal tract of mice by bacterial antagonism. Infect Immun, 1979. 25(3): p. 820-27.
44. Berg, R.D., Bacterial translocation from the gastrointestinal tract. Adv Exp Med Biol, 1999.  
 473: p. 11-30.
45. Berg, R.D., Bacterial translocation from the gastrointestinal tract. Trends Microbiol, 1995.  
 3(4): p. 149-54.
46. Gautreaux, M.D., E.A. Deitch, and R.D. Berg, Bacterial translocation from the    
 gastrointestinal tract to various segments of the mesenteric lymph node complex.   
 Infect Immun, 1994. 62(5): p. 2132-4.
47. Rossi, O., P. Van Baarlen, and J. Wells, Mammalian Intestinal Host-Microbe Relationships.  
 Curr Top Microbiol Immunol, 2011.
48. Rescigno, M., et al., Dendritic cells express tight junction proteins and penetrate gut   
 epithelial monolayers to sample bacteria. Nat Immunol, 2001. 2(4): p. 361-7.
49. Rescigno, M., et al., Dendritic cells shuttle microbes across gut epithelial monolayers.   
 Immunobiology, 2001. 204(5): p. 572-81.
50. Niess, J.H., et al., CX3CR1-mediated dendritic cell access to the intestinal lumen and   
 bacterial clearance. Science, 2005. 307(5707): p. 254-8.
51. Rimoldi, M., et al., Monocyte-derived dendritic cells activated by bacteria or by bacteria-  
 stimulated epithelial cells are functionally different. Blood, 2005. 106(8): p. 2818-26.
52. Kalinski, P., et al., Prostaglandin E(2) is a selective inducer of interleukin-12p40 (IL-12p40)  
 production and an inhibitor of bioactive IL-12p70 heterodimer. Blood, 2001. 97(11): p.   
 3466-9.
53. Smythies, L.E., et al., Human intestinal macrophages display profound inflammatory anergy  
 despite avid phagocytic and bacteriocidal activity. J Clin Invest, 2005. 115(1): p. 66-75.
54. Zeuthen, L.H., L.N. Fink, and H. Frokiaer, Epithelial cells prime the immune response to an  
 array of gut-derived commensals towards a tolerogenic phenotype through distinct actions  
 of thymic stromal lymphopoietin and transforming growth factor-beta. Immunology, 2007.  
 123(2): p. 197-208.
55. Foligne, B., et al., Correlation between in vitro and in vivo immunomodulatory properties  
 of lactic acid bacteria. World J Gastroenterol, 2007. 13(2): p. 236-43.
56. Kwon, H.K., et al., Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by 
 probiotics administration suppresses immune disorders. Proc Natl Acad Sci U S A, 2010.   
 107(5): p. 2159-64.
57. Snel, J., et al., Strain-specific immunomodulatory effects of Lactobacillus plantarum strains  
 on birch-pollen-allergic subjects out of season. Clin Exp Allergy, 2011. 41(2): p. 232-42.
58. Meijerink, M. and J. Wells, Probiotic modulation of dendritic cells and T cell responses in  
 the intestine. Beneficial microbes, 2010. 1(4): p. 317-326.
59. Meijerink, M., et al., Identification of genetic loci in Lactobacillus plantarum that modulate  
 the immune response of dendritic cells using comparative genome hybridization.   
194
Ch
ap
te
r 
8
 PLoS One, 2010. 5(5): p. e10632.
60. van Hemert, S., et al., Identification of Lactobacillus plantarum genes modulating the 
 cytokine response of human peripheral blood mononuclear cells Submitted, 2010.
61. Ghadimi, D., et al., Effects of probiotic bacteria and their genomic DNA on    
 TH1/TH2-cytokine  production by peripheral blood mononuclear cells(PBMCs) of healthy  
 and allergic subjects. Immunobiology, 2008. 213(8): p. 677-92.
62. Hayden, H., et al., Cryopreservation of monocytes is superior to cryopreservation of   
 immature or semi-mature dendritic cells for dendritic cell-based immunotherapy.   
 J Immunother, 2009. 32(6): p. 638-54.
63. John, J., et al., Cryopreservation of immature monocyte-derived dendritic cells results in   
 enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral
 transduction. J Immunol Methods, 2003. 272(1-2): p. 35-48.
64. Lewalle, P., et al., Freezing of dendritic cells, generated from cryopreserved leukaphereses,  
 does not influence their ability to induce antigen-specific immune responses or   
 functionally react to maturation stimuli. J Immunol Methods, 2000. 240(1-2): p. 69-78.
65. Hori, S., et al., Freeze-thawing procedures have no influence on the phenotypic and   
 functional development of dendritic cells generated from peripheral blood CD14+   
 monocytes. J Immunother, 2004. 27(1): p. 27-35.
66. Delcenserie, V., et al., Immunomodulatory effects of probiotics in the intestinal tract.   
 Curr Issues Mol Biol, 2008. 10(1-2): p. 37-54.
67. Medina, M., et al., Differential immunomodulatory properties of Bifidobacterium longum  
 strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol, 2007.  
 150(3): p. 531-8.
68. van Hemert, S., et al., Identification of Lactobacillus plantarum genes modulating the 
 cytokine response of human peripheral bloodmononuclear cells. BMC Microbiology, 2010.  
 10(1): p. 293.
69. Miettinen, M., et al., Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18,   
 and gamma interferon production in human peripheral blood mononuclear cells.   
 Infect Immun, 1998. 66(12): p. 6058-62.
70. Miettinen, M., J. Vuopio-Varkila, and K. Varkila, Production of human tumor necrosis factor  
 alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. 
 Infect Immun, 1996. 64(12): p. 5403-5.
71. Niers, L.E., et al., Identification of strong interleukin-10 inducing lactic acid bacteria which  
 down-regulate T helper type 2 cytokines. Clin Exp Allergy, 2005. 35(11): p. 1481-9.
72. Lebeer, S., J. Vanderleyden, and S.C. De Keersmaecker, Genes and molecules of lactobacilli  
 supporting probiotic action. Microbiol Mol Biol Rev, 2008. 72(4): p. 728-64, 
73. Fernandez, E.M., et al., Anti-inflammatory capacity of selected lactobacilli in experimental  
 colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived   
 muropeptide. Gut, 2011. 60(8): p. 1050-9.
74. Grangette, C., et al., Enhanced antiinflammatory capacity of a Lactobacillus plantarum   
 mutant synthesizing modified teichoic acids. Proc Natl Acad Sci U S A, 2005. 102(29): p.   
 10321-6.
75. Mohamadzadeh, M., et al., Regulation of induced colonic inflammation by Lactobacillus   
 acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A, 2011. 108 
 Suppl 1: p. 4623-30.
76. Hemmi, H., et al., A Toll-like receptor recognizes bacterial DNA. Nature, 2000. 408(6813): p.  
 740-5.
77. Lee, J., et al., Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in   
 intestinal epithelial cells. Nat Cell Biol, 2006. 8(12): p. 1327-36.
195
Chapter 8
78. Jijon, H., et al., DNA from probiotic bacteria modulates murine and human epithelial and  
 immune function. Gastroenterology, 2004. 126(5): p. 1358-73.
79. Ghadimi, D., et al., Effect of natural commensal-origin DNA on toll-like receptor 9 (TLR9)   
 signaling cascade, chemokine IL-8 expression, and barrier  integritiy of polarized intestinal  
 epithelial cells. Inflamm Bowel Dis, 2010. 16(3): p. 410-27.
80. Katakura, K., et al., Toll-like receptor 9-induced type I IFN protects mice from experimental  
 colitis. J Clin Invest, 2005. 115(3): p. 695-702.
81. Crabtree, T.D., et al., Preexposure of murine macrophages to CpG oligonucleotide results in  
 a biphasic tumor necrosis factor alpha response to subsequent lipopolysaccharide   
 challenge. Infect Immun, 2001. 69(4): p.2123-9.
82. Obermeier, F., et al., CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate   
 sodium-treated mice. Eur J Immunol, 2002. 32(7): p. 2084-92.
83. Liao, A.P., et al., Salmonella type III effector AvrA stabilizes cell tight junctions to inhibit   
 inflammation in intestinal epithelial cells. PLoS One, 2008. 3(6): p. e2369.
84. Collier-Hyams, L.S., et al., Cutting edge: Salmonella AvrA effector inhibits the key   
 proinflammatory, anti-apoptotic NF-kappa B pathway. J Immunol, 2002. 169(6): p. 2846-50.
85. Ye, Z., et al., Salmonella effector AvrA regulation of colonic epithelial cell inflammation   
 by deubiquitination. Am J Pathol, 2007. 171(3): p. 882-92.
86. Boneca, I.G., et al., A critical role for peptidoglycan N-deacetylation in Listeria evasion from  
 the host innate immune system. Proc Natl Acad Sci U S A, 2007. 104(3): p. 997-1002.
87. Fittipaldi, N., et al., Significant contribution of the pgdA gene to the virulence of   
 Streptococcus suis. Mol Microbiol, 2008. 70(5): p. 1120-35.
88. Troy, E.B. and D.L. Kasper, Beneficial effects of Bacteroides fragilis polysaccharides on the  
 immune system. Front Biosci, 2010. 15: p. 25-34.
89. Mosmann, T.R., et al., Two types of murine helper T cell clone. I. Definition according to   
 profiles of lymphokine activities and secreted proteins. 1986. J Immunol, 2005. 175(1): p.  
 5-14.
90. Mosmann, T.R., et al., Two types of murine helper T cell clone. I. Definition according to   
 profiles of lymphokine activities and secreted proteins. J Immunol, 1986. 136(7): p. 2348-57.
91. Crome, S.Q., A.Y. Wang, and M.K. Levings, Translational mini-review series on Th17 cells:   
 function and regulation of human T helper 17 cells in health and disease. Clin Exp mmunol,  
 2010. 159(2): p. 109-19.
92. Guarner, F., et al., Mechanisms of disease: the hygiene hypothesis revisited. Nat Clin Pract  
 Gastroenterol Hepatol, 2006. 3(5): p. 275-84.
93. Shida, K., et al., Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and  
 immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. Clin Exp  
 Allergy, 2002. 32(4): p. 563-70.
94. Kim, H., et al., Oral probiotic bacterial administration suppressed allergic responses in an  
 ovalbumin-induced allergy mouse model. FEMS Immunol Med Microbiol, 2005. 45(2): p.  
 259-67.
95. Frossard, C.P., L. Steidler, and P.A. Eigenmann, Oral administration of an IL-10-secreting   
 Lactococcus lactis strain prevents food-induced IgE sensitization.    
  J Allergy Clin Immunol, 2007. 119(4): p. 952-9.
96. Kim, J.Y., Y.O. Choi, and G.E. Ji, Effect of oral probiotics (Bifidobacterium lactis AD011 and   
 Lactobacillus acidophilus AD031) administration on ovalbumin-induced food allergy mouse  
 model. J Microbiol Biotechnol, 2008. 18(8): p. 1393-400.
97. Kalliomaki, M., et al., Guidance for Substantiating the Evidence for Beneficial Effects of   
 Probiotics: Prevention and Management of Allergic Diseases by Probiotics. J Nutr, 2010.
98. Schiavi, E., et al., Oral therapeutic administration of a probiotic mixture suppresses   
196
Ch
ap
te
r 
8
 established Th2 responses and systemic anaphylaxis in a murine model of food allergy.   
 Allergy, 2011. 66(4): p. 499-508.
99. Peran, L., et al., Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in  
 the TNBS model of rat colitis. World J Gastroenterol, 2005. 11(33): p. 5185-92.
100. Zoumpopoulou, G., et al., Lactobacillus fermentum ACA-DC 179 displays probiotic potential  
 in vitro and protects against trinitrobenzene sulfonic acid (TNBS)-induced colitis and   
 Salmonella infection in murine models. Int J Food Microbiol, 2008. 121(1): p. 18-26.
101. Ivory, K., et al., Oral delivery of Lactobacillus casei Shirota modifies allergen-induced 
 immune responses in allergic rhinitis. Clin Exp Allergy, 2008. 38(8): p. 1282-9.
102. Holt, P.G. and C.A. Jones, The development of the immune system during pregnancy and  
 early life. Allergy, 2000. 55(8): p. 688-97.
103. Trammell, R.A. and L.A. Toth, Genetic susceptibility and resistance to  influenza infection   
 and disease in humans and mice. Expert Rev Mol Diagn, 2008. 8(4): p. 515-29.
104. Howell, W.M., P.C. Calder, and R.F. Grimble, Gene polymorphisms, inflammatory diseases  
 and cancer. Proc Nutr Soc, 2002. 61(4): p. 447-56.
105. Yaqoob, P., E.A. Newsholme, and P.C. Calder, Comparison of cytokine  production in cultures  
 of whole human blood and purified mononuclear cells. Cytokine, 1999. 11(8): p. 600-5.
106. Schroder, N.W. and R.R. Schumann, Single nucleotide polymorphisms of Toll-like receptors  
 and susceptibility to infectious disease. Lancet Infect Dis, 2005. 5(3): p. 156-64.
107. Ogura, Y., et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's   
 disease. Nature, 2001. 411(6837): p. 603-6.
108. Hampe, J., et al., Association between insertion mutation in NOD2 gene and Crohn's   
 disease in German and British populations. Lancet, 2001. 357(9272): p. 1925-8.
109. Manicassamy, B., et al., Protection of mice against lethal challenge with 2009 H1N1   
 influenza A virus by 1918-like and classical swine H1N1 based vaccines.    
 PLoS Pathog, 2010. 6(1): p. e1000745.
110. Boon, A.C., et al., Host genetic variation affects resistance to infection with a highly   
 pathogenic H5N1 influenza A virus in mice. J Virol, 2009. 83(20): p.10417-26.
111. Sun, L., G.M. Nava, and T.S. Stappenbeck, Host genetic susceptibility, dysbiosis, and viral   
 triggers in inflammatory bowel disease. Curr Opin Gastroenterol, 2011. 27(4): p. 321-7.
112. Abraham, C. and R. Medzhitov, Interactions between the host innate  mmune system and  
 microbes in inflammatory bowel disease. Gastroenterology, 2011. 140(6): p. 1729-37.
113. Saleh, M. and C.O. Elson, Experimental inflammatory bowel disease:  insights into the host- 
 microbiota dialog. Immunity, 2011. 34(3): p. 293-302.
114. Feng, T. and C.O. Elson, Adaptive immunity in the host-microbiota dialog. Mucosal   
 Immunol, 2011. 4(1): p. 15-21.
115. Ivanov, II, et al., Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell,  
 2009. 139(3): p. 485-98.
116. Gaboriau-Routhiau, V., et al., The key role of segmented filamentous  bacteria in the   
 coordinated maturation of gut helper T cell responses.Immunity, 2009. 31(4): p. 677-89.
117. Mazmanian, S.K., J.L. Round, and D.L. Kasper, A microbial symbiosis factor prevents   
 intestinal  inflammatory disease. Nature,2008.453(7195):p. 620-5.
118. Arumugam, M., et al., Enterotypes of the human gut microbiome. Nature, 2011.   
 473(7346): p. 174-80.
119. Morafo, V., et al., Genetic susceptibility to food allergy is linked to differential TH2-TH1   
 responses in C3H/HeJ and BALB/c mice. J Allergy Clin Immunol, 2003. 111(5): p. 1122-8.
120. Nishimura, T., et al., Involvement of IL-4-producing Vbeta8.2+ CD4+ CD62L- CD45RB- T cells  
 in non-MHC gene-controlled predisposition toward skewing into T helper type-2 immunity  
 in BALB/c mice. J Immunol, 1997. 158(12): p. 5698-706.
197
Chapter 8
121. Fullner, K.J., W.I. Lencer, and J.J. Mekalanos, Vibrio cholerae-induced  cellular responses of  
 polarized T84 intestinal epithelial cells are dependent on production of cholera toxin and  
 the RTX toxin. Infect Immun, 2001. 69(10): p. 6310-7.
122. O'Toole, P.W. and J.C. Cooney, Probiotic bacteria influence the composition and function of
  the intestinal microbiota. Interdiscip Perspect Infect Dis, 2008. 2008: p. 175285. 
123.  Petrosino, J.F., et al., Metagenomic pyrosequencing and microbialidentification.   
 Clin Chem, 2009.  55(5): p. 856-66.
124. Goldberg, S.M., et al., A Sanger/pyrosequencing hybrid approach for the generation of   
 high-quality draft assemblies of marine microbial genomes. Proc Natl Acad Sci U S A, 2006.  
 103(30): p. 11240-5.
125. Moore, M.J., et al., Rapid and accurate pyrosequencing of angiosperm plastid genomes.   
 BMC Plant Biol, 2006. 6: p. 17.
126. Wicker, T., et al., 454 sequencing put to the test using the complex genome of barley.   
 BMC Genomics, 2006. 7: p. 275.
127. Gharizadeh, B., et al., Large-scale pyrosequencing of synthetic DNA: a comparison with   
 results from Sanger dideoxy sequencing. Electrophoresis, 2006. 27(15): p. 3042-7.
128. Peterson, D.A., et al., Metagenomic approaches for defining the pathogenesis of   
 inflammatory bowel diseases. Cell Host Microbe, 2008. 3(6): p. 417-27.
129. Delgado, S., A. Suarez, and B. Mayo, Identification of dominant bacteria in feces and   
 colonic mucosa from healthy Spanish adults by culturing and by 16S rDNA sequence   
 analysis. Dig Dis Sci, 2006. 51(4): p. 744-51.
130. Lucke, K., et al., Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis.   
 J Med Microbiol, 2006. 55(Pt 5): p. 617-24.
131. Prindiville, T., M. Cantrell, and K.H. Wilson, Ribosomal DNA sequence analysis of   
 mucosa-associated bacteria in Crohn's disease. Inflamm Bowel Dis, 2004. 10(6): p. 824-33.
132. Hold, G.L., et al., Assessment of microbial diversity in human colonic samples by 16S rDNA  
 sequence analysis. FEMS Microbiol Ecol, 2002. 39(1): p. 33-9.
133. Hayashi, H., M. Sakamoto, and Y. Benno, Phylogenetic analysis of the human gut   
 microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods.   
 Microbiol Immunol, 2002. 46(8): p. 535-48.
134. Suau, A., et al., Direct analysis of genes encoding 16S rRNA from complex communities   
 reveals many novel molecular species within the human gut. Appl Environ Microbiol,   
 1999. 65(11): p. 4799-807.
135. Ryan, K.A., et al., Strain-specific inhibition of Helicobacter pylori by Lactobacillus   
 salivarius and other lactobacilli. J Antimicrob Chemother, 2008. 61(4): p. 831-4.
136. Kalliomaki, M., et al., Probiotics in primary prevention of atopic disease: a randomised   
 placebo-controlled trial. Lancet, 2001. 357(9262): p. 1076-9.
137. Kalliomaki, M., et al., Probiotics and prevention of atopic disease: 4-year follow-up of a  
  randomised placebo-controlled trial. Lancet, 2003. 361(9372): p. 1869-71.
138. Majamaa, H. and E. Isolauri, Probiotics: a novel approach in the management of food   
 allergy. J Allergy Clin Immunol, 1997. 99(2): p. 179-85.
139. Isolauri, E., et al., Probiotics in the management of atopic eczema. Clin Exp Allergy, 2000.  
 30(11): p. 1604-10.
140. Viljanen, M., et al., Probiotics in the treatment of atopic eczema/dermatitis syndrome in   
 infants: a double-blind placebo-controlled trial. Allergy, 2005. 60(4): p. 494-500.
141. Brouwer, M.L., et al., No effects of probiotics on atopic dermatitis in infancy: a randomized  
 placebo-controlled trial. Clin Exp Allergy, 2006. 36(7): p. 899-906.
142. Folster-Holst, R., et al., Prospective, randomized controlled trial on Lactobacillus 
 rhamnosusin infants with moderate to severe atopic dermatitis. Br J Dermatol, 2006.   
198
Ch
ap
te
r 
8
 155(6):  p. 1256-61.
143. Gruber, C., et al., Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as  
 treatment of atopic dermatitis in infancy. Allergy, 2007. 62(11): p. 1270-6.
144. Schabussova, I., et al., Distinctive anti-allergy properties of two probiotic bacterial strains  
 in a mouse model of allergic poly-sensitization. Vaccine, 2011. 29(10): p. 1981-90.
145. Harata, G., et al., Intranasal administration of Lactobacillus rhamnosus GG protects mice   
 from H1N1 influenza virus infection by regulating respiratory immune responses. Lett Appl  
 Microbiol, 2010. 50(6): p. 597-602.
146. Kawase, M., et al., Oral administration of lactobacilli from human intestinal tract protects  
 mice against influenza virus infection. Lett Appl Microbiol, 2010. 51(1): p. 6-10.
147. Boge, T., et al., A probiotic fermented dairy drink improves antibody response to influenza  
 vaccination in the elderly in two randomised controlled trials. Vaccine, 2009. 27(41): p.   
 5677-84.
148. van Baarlen, P., et al., Differential NF-kappaB pathways induction by Lactobacillus   
 plantarum in the duodenum of healthy humans correlating with immune tolerance.   
 Proc Natl Acad Sci U S A, 2009. 106(7): p. 2371-6.
149. Li, X.M., et al., A murine model of peanut anaphylaxis: T- and B-cell responses to a major  
 peanut allergen mimic human responses. J Allergy Clin Immunol, 2000. 106(1 Pt 1): p. 150-8.
150. van Wijk, F., et al., The CD28/CTLA-4-B7 signaling pathway is involved in both allergic   
 sensitization and tolerance induction to orally administered peanut proteins. J Immunol,   
 2007. 178(11): p. 6894-900.
151. Lin, D.C., Probiotics as functional foods. Nutr Clin Pract, 2003. 18(6): p. 497-506.
152. Basu, S., et al., Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute   
 watery diarrhea in Indian children: a randomized controlled trial.     
 J Clin Gastroenterol, 2009. 43(3): p. 208-13.
153. Hammes, W.P. and P.S. Tichaczek, The potential of lactic acid bacteria for the production of  
 safe and wholesome food. Z Lebensm Unters Forsch, 1994. 198(3): p. 193-201.
154. Gasser, F., Safety of lactic-acid bacteria and their occurrence in human clinical infections.  
 Bulletin de L’Institut Pasteur, 1994. 92: p. 45–67.
155. Saxelin, M., et al., Lactobacilli and bacteremia in southern Finland, 1989-1992.    
 Clin Infect Dis, 1996. 22(3): p. 564-6.
156. Salminen, M.K., et al., Lactobacillus bacteremia during a rapid increase in probiotic use   
 of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis, 2002. 35(10): p. 1155-60.
157. Husni, R.N., et al., Lactobacillus bacteremia and endocarditis: review of 45 cases.   
 Clin Infect Dis, 1997. 25(5): p. 1048-55.
158. Rautio, M., et al., Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable  
 from L. rhamnosus strain GG. Clin Infect Dis, 1999. 28(5): p. 1159-60.
159. Mackay, A.D., et al., Lactobacillus endocarditis caused by a probiotic organism.    
 Clin Microbiol Infect, 1999. 5(5): p. 290-292.
160. Land, M.H., et al., Lactobacillus sepsis associated with probiotic therapy. Pediatrics, 2005.  
 115(1): p. 178-81.
161. Besselink, M.G., et al., Probiotic prophylaxis in predicted severe acute pancreatitis: a   
 randomised, double-blind, placebo-controlled trial. Lancet, 2008. 371(9613): p. 651-9.
162. Lutgendorff, F., et al., Probiotics prevent intestinal barrier dysfunction in acute    
 pancreatitis in rats via induction of ileal mucosal glutathione biosynthesis. PLoS One, 2009.  
 4(2): p. e4512.
163. Wolf, B.W., et al., Safety and tolerance of Lactobacillus reuteri supplementation to a   
 population infected with the human immunodeficiency virus. Food Chem Toxicol,   
 1998. 36(12): p. 1085-94.
199
Chapter 8
164. Cunningham-Rundles, S., et al., Probiotics and immune response. Am J Gastroenterol,   
 2000. 95(1 Suppl): p. S22-5.
165. Wegmann, T.G., et al., Bidirectional cytokine interactions in the maternal-fetal relationship:  
 is successful pregnancy a TH2 phenomenon? Immunol Today, 1993. 14(7): p. 353-6.
166. Pochard, P., et al., Lactic acid bacteria inhibit TH2 cytokine production by mononuclear   
 cells from allergic patients. J Allergy Clin Immunol, 2002. 110(4): p. 617-23.
167. Pohjavuori, E., et al., Lactobacillus GG effect in increasing IFN-gamma production in infants  
 with cow's milk allergy. J Allergy Clin Immunol, 2004. 114(1): p. 131-6.
168. Rolfe, V.E., et al., Probiotics for maintenance of remission in Crohn's disease. Cochrane   
 Database Syst Rev, 2006(4): p. CD004826.
169. Kamil, R., et al., Lactobacillus rhamnosus GG exacerbates intestinal ulceration in a model of  
 indomethacin-induced enteropathy. Dig Dis Sci, 2007. 52(5): p. 1247-52.
170. Tynkkynen, S., K.V. Singh, and P. Varmanen, Vancomycin resistance factor of Lactobacillus  
 rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Int J Food   
 Microbiol, 1998. 41(3): p. 195-204.
171. Sanders, M.E., et al., Safety assessment of probiotics for human use. Gut Microbes, 2010.  
 1(3): p. 164-185.
172. Ezendam, J. and H. van Loveren, Probiotics: immunomodulation and evaluation of safety  
 and efficacy. Nutr Rev, 2006. 64(1): p. 1-14.
173. Adams, C.A., The probiotic paradox: live and dead cells are biological response modifiers.  
 Nutr Res Rev, 2010. 23(1): p. 37-46.
174. Kataria, J., et al., Probiotic microbes: do they need to be alive to be beneficial? Nutr Rev,   
 2009. 67(9): p. 546-50.
175. Ouwehand, A.C., S. Salminen, and E. Isolauri, Probiotics: an overview of beneficial effects.  
 Antonie Van Leeuwenhoek, 2002. 82(1-4): p. 279-89.
176. Yan, F. and D.B. Polk, Probiotic bacterium prevents cytokine-induced apoptosis in intestinal  
 epithelial cells. J Biol Chem, 2002. 277(52): p. 50959-65.
177. Olah, A., et al., Randomized clinical trial of specific lactobacillus and fibre supplement to   
 early enteral nutrition in patients with acute pancreatitis. Br J Surg, 2002. 89(9): p. 1103-7.
178. Rayes, N., et al., Early enteral supply of lactobacillus and fiber versus selective bowel   
 decontamination: a controlled trial in liver transplant recipients. Transplantation,   
 2002. 74(1): p. 123-7.
179. Drago, L., et al., Microbiological evaluation of commercial probiotic products available in   
 the USA in 2009. J Chemother, 2010. 22(6): p. 373-7.
180. Wannaprasat, W., et al., Quality analysis of commercial probiotic products for food   
 animals. Southeast Asian J Trop Med Public Health, 2009. 40(5): p. 1103-12.
181. Li, N., et al., Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory  
 and anti-inflammatory cytokines/chemokines in gastrostomy-fed infant rats. Pediatr Res,  
 2009. 66(2): p. 203-7.
182. van Hoffen, E., et al., Exposure of intestinal epithelial cells to UV-killed Lactobacillus GG   
 but not Bifidobacterium breve enhances the effector immune response in vitro. Int Arch   
 Allergy Immunol, 2010. 152(2): p. 159-68.
183. Kirjavainen, P.V., S.J. Salminen, and E. Isolauri, Probiotic bacteria in the management of   
 atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr, 2003.  
 36(2): p. 223-7.
184. Chapman, C.M., G.R. Gibson, and I. Rowland, Health benefits of probiotics: are mixtures   
 more effective than single strains? Eur J Nutr, 2011. 50(1): p. 1-17.

Summary
202
203
The aim of this thesis was to better understand the molecular mechanism of host res-
ponses to probiotics. Probiotics can be used to stimulate or regulate immune responses 
in epithelial and immune cells of the intestinal mucosa and generate beneficial effects 
on the immune system. Carefully selected probiotics are able to steer the activity of the 
immune response in a predetermined manner by increasing or decreasing the activity 
of different aspects of the immune system (e.g. development and activity of T helper 
subsets). Beneficial effects of strains of probiotics have been established in the treat-
ment and prevention of various intestinal disorders, including allergic diseases and di-
arrhea. However the precise molecular mechanisms and the strain dependent factors 
involved are poorly understood. Here in vitro molecular studies and in vivo mechanistic 
studies were combined in different mouse models to generate new insights into the 
beneficial mechanisms of selected lactobacilli and identify novel bacterial genes influ-
encing the immune response. A further aim was to investigate the predictive value of in 
vitro immune assays for the effects of probiotics in vivo.
Chapter 1 and chapter 2 describe the current knowledge and understanding of the im-
munomodulatory effects of different probiotic species and strains on mucosal immune 
system, dendritic cells (DCs) and the adaptive immune system. The relevance and the 
implications of in vitro studies for clinical trials or mechanistic research in animal mo-
dels are discussed.
Chapter 3 and chapter 4 present new insights gained from research on the strain-de-
pendent factors involved in probiotic immune modulation. Extensive variation was ob-
served in the immune responses to 42 L. plantarum strains. These results were used to 
identify genetic loci that correlated with levels of induced cytokines (such as IL-10 or 
IL-12) following co-culture with DCs (chapter 3) or peripheral blood mononuclear cells 
(PBMCs) (chapter 4). This in silico “gene-trait matching” approach led to the identifica-
tion of several candidate genes in the L. plantarum genome that might modulate the 
immune cytokine response to L. plantarum. Selective gene deletions mutants were con-
structed for the candidate genes in L. plantarum WCFS1 and compared to the wild-type 
strain in immune assays with PBMCs and DCs. The predicted phenotype of the genetic 
knock-out was confirmed for most of the candidate loci including genes encoding an N-
acetyl-glucosamine/galactosamine phosphotransferase system, the LamBDCA quorum 
sensing system, a predicted transcriptional regulator gene (lp_2991) and components 
of the plantaricin (bacteriocin) biosynthesis and transport pathway. Transcriptome 
analysis and qPCR data showed that transcript level of gtcA3, which is predicted to be 
involved in the glycosylation of cell wall teichoic acids, was substantially increased in the 
lp_2991 deletion mutant (44- and 29-fold respectively). 
In vitro assays for pre-screening of candidate probiotics would benefit from standar-
dized methods and cryopreservation techniques for immature DCs (iDCs) or precursor 
monocytes. Literature on the effects of cryopreservation and thawing of monocytes 
or monocyte-derived iDCs suggested that this strategy might be useful although bac-
teria had not been previously used as a stimulus. Thus in chapter 5 we investigated 
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the effects of cryopreservation and thawing of precursor monocytes and iDCs on the 
maturation and immune response of DCs to potential probiotic strains and bacterial 
TLR agonists. Surface markers CD83 and CD86 were expressed at similar levels on iDCs 
generated from cryopreserved or freshly isolated monocytes. Cryopreservation of iDCs 
led to slightly decreased expression of CD86 and CD83 compared to freshly generated 
iDCs prepared from unfrozen cells but this did not affect the capacity of DCs to acquire 
fully mature characteristics after stimulation. In contrast the cytokine response to li-
poteichoic acid and bacterial stimulation was altered by cryopreservation of monocytes 
or iDCs, particularly for IL-12 which was decreased up to 250 fold or even not detected 
at all. Cryopreservation also decreased TNF-α and IL-1β production in stimulated iDCs 
but to a lesser extent than for IL-12, depending on the maturation factors used. The 
amounts of IL-10 produced by stimulated iDCs were increased up to 3.6 fold when iDCs 
were cryopreserved, but decreased up to 90 fold when generated from cryopreserved 
monocytes. Immature DCs are often used to investigate the immunomodulatory prop-
erties of probiotics and here we showed for the first time that cryopreserved mono-
cytes and cryopreserved iDCs have a skewed cytokine response to microbial stimula-
tion. Therefore we consider that standardization of probiotic screening assays by the 
use of cryopreservation methods is currently not applicable. The detailed method for 
generating human monocyte derived DC described in chapter 5 may however be useful 
for developing standardized immune assays.
In chapter 6 we screened the immunomodulatory properties of 28 commercially avail-
able bacterial strains in vitro using human PBMCs and investigated selected strains 
for their in vivo immunomodulatory potential in an established mouse peanut allergy 
model. The 28 probiotic strains induced highly variable cytokine profiles in PBMCs. L. 
salivarius HMI001 (HMI001), L. casei Shirota (LCS) and L. plantarum WCFS1 (WCFS1) 
were selected for further investigation due to their distinct patterns of IL-10, IL-12 and 
IFN-γ induction. Prophylactic treatment with both HMI001 and LCS attenuated the Th2 
phenotype in the mouse model (reduced mast cell responses and ex vivo IL-4 and/or 
IL-5 production). In contrast, WCFS1 augmented the Th2 phenotype (increased mast 
cell and antibody responses and ex vivo IL-4 production). In vitro PBMC screening was 
useful in selecting strains with anti-inflammatory and Th1 skewing properties. In the 
case of HMI001 (inducing a high IL-10/IL-12 ratio) and LCS (inducing high amounts of 
IFN-γ and IL-12) partial protection was seen in a mouse peanut allergy model. However, 
certain strains may worsen the allergic reaction as shown in the case of WCFS1. This  
approach indicated that pre-selection of candidate probiotics using in vitro immune as-
says is useful for selecting strains for translational research in humans. 
Probiotics have been shown to increase the efficacy of different vaccines and can be 
easily consumed in food, and therefore probiotics might be useful in the improvement 
of current mucosal vaccines. In chapter 7 we have investigated the mechanisms behind 
the effect of lactobacilli on humoral responses to an intranasal vaccine. In addition to 
L. rhamnosus GG we selected 6 strains of Lactobacillus plantarum which have strikingly 
different immunomodulatory properties in vitro and TLR-2/6 activating properties. This 
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selection was based on the approach outlined in chapter 3 and chapter 4 examining the 
in vitro immune responses of human monocyte derived DCs and PBMCs to 42 different 
L. plantarum strains. First we established an influenza vaccination model in Balb/c mice 
that would be sensitive to immunomodulation by lactobacilli, which allowed potential 
up- and down-regulation by the lactobacilli of the immune response. Strain WCFS1, that 
induced the lowest IL-10 to IL-12 cytokine ratio in DC co-culture significantly increased 
vaccine-specific antibody responses to the intranasal vaccine compared to the vaccine 
control group. Several Lactobacillus strains appeared to increase delayed-type hyper-
sensitivity responses after vaccination compared to the vaccine control group indicating 
increased Th1-mediated vaccine responses. For strain LMG18021 this was also reflect-
ed in the significantly higher vaccine-specific IgG2a to IgG1 antibody ratio. LMG18021, 
CIP104448 and CIP104450 which have the highest IL-10 to IL-12 ratios of the strains 
tested, significantly enhanced the ex vivo vaccine-specific induction of IL-10, IL-17A, 
IL-6 and IL-4 in MLN cells. B1839 which was included as negative control, as it was a low 
cytokine inducer, did not enhance the vaccine-specific antibody or immune response in-
dicating that the immune-stimulatory properties are important in mediating effects on 
the vaccine response. Further research is needed to demonstrate that these effects on 
the vaccine response impact on protection from influenza challenge and to validate the 
immunomodulatory mechanisms involved. Nevertheless, the in vivo studies described 
in this thesis support other publications proposing that in vitro immune assays can be 
useful for predicting which candidate probiotic strains will be most effective in vivo. 
Chapter 8 completes this thesis with an overview of the most important findings of 
this thesis and discusses possible research limitations and future research perspectives. 
We stress the importance of proper strain selection using in vitro assays, and the use 
of strategies to identify novel immunomodulatory factors. The results described in this 
thesis support the rationale of using in vitro co-culture assays for selection of candidate 
probiotics for in vivo animal experiments or human trials.

Samenvatting
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Het doel van dit proefschrift was om beter inzicht te krijgen in de moleculaire mechanis-
men van de gastheer reacties op probiotica. Probiotica kunnen worden gebruikt om het 
immuun systeem te stimuleren of reguleren in het epitheel van het darmslijmvlies en 
op die manier positieve effecten genereren op het immuunsysteem. Zorgvuldig geselec-
teerde probiotica zijn in staat zijn om de activiteit van de immuunrespons te sturen op 
een vooraf bepaalde manier door middel van het verhogen of verlagen van de activiteit 
van verschillende aspecten van het immuunsysteem (bijv. de ontwikkeling en activiteit 
van T-helper subsets). Gunstige effecten van stammen van probiotica zijn aangetoond 
in de behandeling en preventie van diverse darm aandoeningen, waaronder allergische 
ziekten en diarree. Echter, de precieze moleculaire werkingsmechanismen en de bac-
terie stam afhankelijke factoren die daarbij betrokken zijn, zijn nog niet geheel bekend. 
In dit proefschrift zijn in vitro moleculaire studies en in vivo mechanistische studies in 
verschillende muismodellen gecombineerd, om nieuwe inzichten krijgen in de positieve 
mechanismen van geselecteerde lactobacillen en om nieuwe bacteriële genen die in-
vloed op de immuunrespons hebben te identificeren. Hiernaast is onderzocht of in vitro 
immuun testen een voorspellende waarde voor de effecten van probiotica in vivo.
Hoofdstuk 1 en hoofdstuk 2 geven een overzicht van de huidige kennis en de wer-
king van de immunomodulerende effecten van verschillende probiotische soorten en 
stammen op het mucosale immuunsysteem, dendritische cellen (DCs) en het adaptieve 
immuunsysteem. Daarnaast worden de relevantie en de implicaties van in vitro studies 
voor mechanistisch onderzoek in dierlijke modellen en in klinische studies besproken.
Hoofdstuk 3 en hoofdstuk 4 tonen nieuwe inzichten aan verkregen uit onderzoek naar 
de stam-afhankelijke factoren die betrokken zijn bij probiotische immuunmodulatie. 
De inductie van de immuunrespons varieerde aanzienlijk tussen de 42 verschillende L. 
plantarum stammen. Deze resultaten werden gebruikt om genetische loci te identifi-
ceren die correleerden met de hoeveelheid geïnduceerde cytokines (zoals IL-10 of IL-
12) na co-kweek met DCs (hoofdstuk 3) of perifere mononucleaire bloedcellen (PBMCs) 
(hoofdstuk 4). Deze in silico 'gen-eigenschap matching’ aanpak heeft geleid tot de iden-
tificatie van een aantal kandidaat-genen in het genoom van L. plantarum, die cytokine 
respons van het immuunsysteem op L. plantarum zouden kunnen moduleren. Selec-
tieve gen deletie mutanten werden gemaakt voor de kandidaat-genen in L. plantarum 
WCFS1 en vergeleken met de wild-type stam in immuun assays met PBMCs en DCs. De 
voorspelde fenotypes van de genetische deletie mutanten werden bevestigd voor de 
meeste van de kandidaat-loci, waaronder genen waren die coderen voor een N-acetyl-
glucosamine/galactosamine fosfotransferase systeem, de LamBDCA quorum sensing-
systeem, een geannoteerde transcriptionele regulator gen (lp_2991) en onderdelen van 
de plantaricin (bacteriocine) biosynthese en transport route. Transcriptoom analyse en 
qPCR data laten zien dat transcript niveau van gtcA3, waarvan voorspeld wordt dat deze 
betrokken is bij de glycosylering van celwand teichoine zuren, aanzienlijk toegenomen 
is in de lp_2991 deletie mutant (44 - en 29-voud respectievelijk). 
In vitro testen voor het pre-screenen van kandidaat-probiotica zouden gebaat kunnen 
zijn bij gestandaardiseerde methoden en technieken voor cryopreservatie van    
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ongerijpte DCs (iDCs) of precursor monocyten. Literatuur over de effecten van cryo-
preservatie en ontdooiing van monocyten of monocyt-afgeleide iDCs suggereren dat 
deze strategie nuttig zou kunnen zijn, hoewel bacteriën nog niet eerder gebruikt zijn 
als een stimulans. Daarom hebben we in hoofdstuk 5 de effecten van cryopreservatie 
en ontdooiing van de voorloper van monocyten en iDCs op de rijping en immuunre-
spons van de DCs onderzocht met potentiële probiotische stammen en bacteriële TLR-
agonisten. Een vergelijkbare expressie in de oppervlakte markers CD83 en CD86 werd 
gemeten bij iDCs gegenereerd uit gecryopreserveerde of vers geïsoleerde monocyten. 
Cryopreservatie van iDCs leidde tot een verhoging van de expressie van CD86 en CD83 
in vergelijking met vers gegenereerd iDCs, maar dit had geen invloed op de capaciteit 
van de DCs om kenmerken te verwerven van volledig gerijpte cellen na stimulatie. In 
tegenstelling hier op was de cytokine respons tegen lipoteichoïnezuur en bacteriële 
stimulatie wel veranderd door cryopreservatie van monocyten of iDCs, met name voor 
IL-12 secretie dat 250-voud verminderd was of zelfs helemaal niet gedetecteerd kon 
worden. Cryopreservatie verminderde ook TNF-α en IL-1β productie in gestimuleerde 
iDCs, maar in mindere mate dan voor IL-12, en afhankelijk van de gebruikte rijpings-
factoren. De hoeveelheden IL-10 geproduceerd door gestimuleerde iDCs werden tot 
3,6 keer verhoogd wanneer iDCs waren ingevroren, maar daalde 90-voudig wanneer 
zij gegenereerd waren uit gecryopreserveerd monocyten. Onrijpe DCs worden vaak ge-
bruikt om de immunomodulerende eigenschappen van probiotica te onderzoeken, en 
hier hebben we voor de eerste keer laten zien dat gecryopreserveerde monocyten en 
gecryopreserveerde iDCs een veranderde cytokine respons tegen microbiële stimulatie 
geven. Daarom zijn wij van mening dat de standaardisatie van probiotische screeningst-
esten door het gebruik van cryopreservatie methodes momenteel nog niet gebruikt kan 
worden. De beschreven gedetailleerde methode voor het genereren van DC uit menseli-
jke monocyten beschreven in hoofdstuk 5 kan echter nuttig zijn voor het ontwikkelen 
van gestandaardiseerde immuun assays.
In hoofdstuk 6 zijn de immunomodulerende eigenschappen van 28 commercieel 
beschikbare bacteriestammen in vitro bepaald, gebruikmakend van menselijke PB-
MCs. Daaruit zijn stammen geselecteerd en onderzocht voor hun in vivo immunomo-
dulerende potentieel in een geoptimaliseerd pinda-allergie model in de muis. De 28 
probiotische stammen induceerden zeer variabele cytokine profielen in PBMCs. De 
stammen L. salivarius HMI001 (HMI001), L. casei Shirota (LCS) en L. plantarum WCFS1 
(WCFS1) werden geselecteerd voor nader onderzoek op basis van hun verschillende pa-
tronen van IL-10, IL-12 en IFN-γ inductie. Profylactische behandeling met zowel HMI001 
en LCS verzwakten het Th2-fenotype in het muis model (minder mestcel degranulatie 
en verminderde ex vivo pinda geinduceerde IL-4 en / of IL-5 productie). In tegenstelling 
daartoe verhoogde WCFS1 het Th2-fenotype (verhoogde mestcel  degranulatie en pin-
da specifiek antilichaam reacties, en verhoogde ex vivo pinda geïnduceerde productie 
van IL-4). In vitro PBMC screening was nuttig bij het selecteren van stammen met anti-
inflammatoire en Th1 sturende eigenschappen. In het geval van HMI001 (inductie van 
een hoge IL-10/IL-12-ratio) en LCS (inductie van grote hoeveelheden van IFN-γ en IL-
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12) behandeling werd gedeeltelijke bescherming aangetoond in het muis pinda-allergie 
model. Echter sommige stammen kunnen de allergische reactie verergeren, zoals in het 
geval van de stam WCFS1. Dit hoofdstuk laat zien dat de pre-selectie van kandidaat-
probiotica met behulp van in vitro immuun assays bruikbaar is voor het selecteren van 
stammen voor translationeel onderzoek bij de mens.
Van probiotica is aangetoond dat deze de effectiviteit van verschillende vaccins kunnen 
verhogen. Aangezien probiotica eenvoudig geconsumeerd kunnen worden in voeding, 
kunnen ze nuttig zijn in de verbetering van de huidige mucosale vaccins. In hoofdstuk 7 
hebben we onderzoek gedaan naar de mechanismen achter het effect van lactobacillen 
op de humorale reacties met een intranasaal vaccin. Naast L. rhamnosus GG, hebben we 
zes stammen van Lactobacillus plantarum geselecteerd, die verschillende immunomod-
ulerende eigenschappen hadden in vitro en in hun TLR-2/6 activerende eigenschap-
pen. Deze selectie was gebaseerd op de data verkregen in hoofdstuk 3 en hoofdstuk 
4 waarin respectievelijk de in vitro immuunrespons van DCs afgeleid van menselijke 
monocyten en PBMCs tegen 42 verschillende L. plantarum stammen werden getest. 
Allereerst hebben we een griep vaccinatie model opgezet in Balb/ c muizen die  gevoelig 
genoeg moest zijn voor immunomodulatie door lactobacillen. Het model moest gevoe-
lig zijn voor zowel de potentiële op- als de neer-regulatie van het immuun systeem 
door de geselecteerd lactobacillen. Behandeling met stam WCFS1, die de laagste IL-10/ 
IL-12 ratio ïnduceerde in een DC co-kweek, leidde tot een sterk toegenomen vaccin-
specifiek antilichaam reactie tegen het intranasale vaccin in vergelijking met de con-
trole vaccin groep. Verschillende Lactobacillus stammen verhoogden de vertraagd-type 
overgevoeligheids respons na de vaccinatie ten opzichte van de controle vaccin groep, 
wat aangeeft dat in deze gevallen de Th1-gemedieerde vaccin-reacties waren verhoogd. 
Voor stam LMG18021 kwam dit ook tot uiting in de aanzienlijk hogere vaccin-specifieke 
IgG2a tot IgG1 antilichaam verhouding. LMG18021, CIP104448 en CIP104450, die de 
hoogste IL-10/ IL-12 ratios hadden van de geteste stammen, verbeterden aanzienlijk de 
ex vivo vaccin-specifieke inductie van IL-10, IL-17A, IL-6 en IL-4 in mesenteriale lymphe-
klier cellen. B1839 werd meegenomen als negatieve controle, aangezien deze stam een 
lage cytokine induceerder was. Deze stam liet geen verbetering van de vaccin-specifieke 
antilichaam reactie en de vaccin-specifieke immuunrespons zien. Dit toont aan dat im-
muun-stimulerende eigenschappen van stammen belangrijk zijn in het mediëren van de 
probiotische effecten op de vaccin reactie. Er is echter meer onderzoek nodig om aan 
te tonen of deze effecten ook leidt tot betere bescherming tegen influenza blootstelling 
en om de betrokken immunomodulerende mechanismen te valideren.
Hoofdstuk 8 sluit dit proefschrift af met een overzicht van de belangrijkste bevindingen 
van dit proefschrift, en bediscusseerd de mogelijke onderzoeks-beperkingen en toe-
komstige onderzoek perspectieven. Wij benadrukken het belang van een goede stam 
selectie met behulp van in vitro testen, en het gebruik van strategieën om nieuwe im-
munomodulerende factoren te identificeren. De resultaten beschreven in dit proef-
schrift ondersteunen het gebruik van in vitro co-cultuur assays voor de selectie van 
kandidaat-probiotica voor in vivo dierproeven en klinische studies.
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